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ABSTRAKT 
 
Savčí organismus je plně závislý na systému oxidativní fosforylace (OXPHOS) 
jako hlavním zdroji produkce energie (ATP) v buňce. Poruchy OXPHOS mohou být 
způsobeny mutacemi v genech kódovaných mitochondriální DNA nebo jadernou DNA. 
Část výzkumné práce je zaměřena na roli raně a pozdně se asemblujících, jaderně 
kódovaných, strukturních podjednotek cytochrom c oxidasy (CcO) a Oxa1l, lidského 
homologu kvasinkové mitochondriální Oxa1 translokasy, v biogenezi cytochrom c 
oxidasy a její funkci s využitím stabilní RNA interference COX4, COX5A, COX6A1 a 
OXA1L a ektopické exprese epitopově značených podjednotek Cox6a, Cox7a a Cox7b 
v buněčné linii HEK (lidské embryonální ledviny)-293. Naše výsledky ukazují, že 
zatímco podjednotky Cox4 a Cox5a jsou nezbytné pro asemblaci funkčního komplexu 
CcO, Cox6a podjednotka je důležitá pro její stabilitu. V buňkách se sníženou expresí 
OXA1L byla překvapivě zjištěna normální aktivita i hladina holoenzymu CcO, přestože 
inaktivace OXA1 u kvasinek vyvolá kompletní ztrátu aktivity CcO. 
Při studiu poruch OXPHOS v izolovaných mitochondriích kosterního svalu, srdce, 
jater a frontálního kortexu získaných od pacientů s Leigh syndromem (mtDNA mutace 
8363G>A), MERRF syndromem (mtDNA mutace 8344A>G) a MELAS syndromem 
(mtDNA mutace 3243A>G) jsme nalezli tkáňově specifické rozdíly v dopadu mt-tRNA 
mutací na OXPHOS mozku, které se významně lišily od dopadu těchto mutací v 
ostatních tkáních. Navíc jsme ukázali, že v případě mtDNA mikrodelece 9205ΔTA v 
ATP6 genu je výrazně omezena syntéza podjednotky a komplexu ATPasy a postižena 
biogeneze CcO.  
 
Klíčová slova: mitochondrie, cytochrome c oxidasa, ATP synthasa (ATPasa), tkáňová 
specifita, asemblace proteinů, biogeneze, RNA interference (RNAi) 
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ABSTRACT 
 
The mammalian organism fully depends on the oxidative phosphorylation system 
(OXPHOS) as the major energy (ATP) producer of the cell. Disturbances of OXPHOS 
may be caused by mutations in either mitochondrial DNA (mtDNA) or nuclear DNA.  
One part of the thesis is focused on the role of early and late assembled nuclear-
encoded structural subunits of cytochrome c oxidase (CcO) as well as Oxa1l, the human 
homologue of the yeast mitochondrial Oxa1 translocase, in the biogenesis and function 
of the human CcO complex using stable RNA interference of COX4, COX5A, 
COX6A1 and OXA1L, as well as expression of epitope-tagged Cox6a, Cox7a and 
Cox7b, in HEK (human embryonic kidney)-293 cells. Our results indicate that, whereas 
nuclear- encoded CcO subunits Cox4 and Cox5a are required for the assembly of the 
functional CcO complex, the Cox6a subunit is required for the overall stability of the 
holoenzyme. In OXA1L knockdown HEK-293 cells, intriguingly, CcO activity and 
holoenzyme content were unaffected, although the inactivation of OXA1 in yeast was 
shown to cause complete absence of CcO activity.  
In addition, we compared OXPHOS protein deficiency patterns in mitochondria 
from skeletal muscle, heart, liver and frontal cortex of patients with Leigh (mtDNA 
mutation 8363G>A), MERRF (mtDNA mutation 8344A>G), and MELAS (mtDNA 
mutation 3243A>G) syndromes. Our data show new effects of mt-tRNA mutations on 
the brain which differ substantially from those described for other tissues. Furthermore, 
we found that mtDNA 9205ΔTA microdeletion in the ATP6 gene prevents the synthesis 
of ATPase subunit a and also affects the biogenesis of CcO. 
 
Key words: mitochondria, cytochrome c oxidase, ATP synthase (ATPase), tissue 
specificity, protein assembly, biogenesis, RNA interference (RNAi) 
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1     INTRODUCTION 
 
Mitochondria hold a central position in cellular bioenergetics. The most important 
mitochondrial energy-yielding reaction is performed by the oxidative phosphorylation 
system (OXPHOS) which is mainly composed of five large multi-subunit complexes 
(CI-CV) embedded in the inner mitochondrial membrane. The importance of 
mitochondria for cell viability is most dramatically apparent from diseases resulting 
from its malfunction. OXPHOS disorders, first recognized 50 years ago (Luft et al. 
1962), have been found to be the most frequent cause of metabolic abnormality in 
pediatric neurology (DiMauro and Schon 2008; Zeviani et al. 1996) but often present 
with nonneurological symptoms (e. g. hepatic, cardiac, renal, gastrointestinal, 
endocrine, hematological symptoms, failure to thrive) (Di Donato 2009; Munnich et al. 
1996) or can contribute to severe diseases of adulthood (e. g. Parkinson’s disease, 
Alzheimer’s disease, Type 2 diabetes mellitus) (Civitarese and Ravussin 2008; Lin and 
Beal 2006; Zeviani and Carelli 2007). The clinical and genetic variability of OXPHOS 
disorders makes it extremely difficult to estimate prevalence accurately; however, the 
general incidence of mitochondrial disease is approximately 1:5000 (Schaefer et al. 
2004; Thorburn 2004). Since the OXPHOS is composed of 13 structural subunits 
encoded by mitochondrial DNA (mtDNA) and more than 70 structural polypeptides 
encoded by nuclear DNA (nDNA), primary OXPHOS disorders can be classified 
genetically according to whether the primary defect is in the nuclear or mitochondrial 
genome. Furthermore, 24 additional mtDNA-encoded genes are involved in 
mitochondrial translational apparatus and numerous nDNA-encoded genes are 
necessary for synthesis of prosthetic groups and assembly of OXPHOS complexes, 
stability of mtDNA and mitochondrial biogenesis (Fig. 1). Therefore, inheritance of 
these mutations may be autosomal recessive or dominant, X-linked or maternal 
(Smeitink et al. 2001b). MtDNA mutations, as it currently is believed, account for 
mitochondrial encephalopathy in 20% to 30% of pediatric patients and a higher 
proportion of adult patients with mitochondrial disorders (Lebon et al. 2003; Thorburn 
2004). 
At the metabolic level, the impact of OXPHOS disease can be classified as 
systemic consequences (e. g. pathological increase in concentration of the lactic acid, 
alanin or higher ketone body ratio) or consequences at the tissue and cellular level (bio-
energy deficiency, redox or metabolite imbalance or elevated or disturbed production of 
reactive oxygen species (ROS)) (Smeitink et al. 2006). Although often assumed to be 
the primary effect of mitochondrial disease, sufficient supply of ATP to meet cellular 
needs is not necessarily the only factor or in some cases even the main factor in 
OXPHOS disease (Smeitink et al. 2006).  
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Biochemically, OXPHOS defects are classified based on the affected enzyme as 
isolated (only one OXPHOS enzyme is deficient) or combined (more than one complex 
deficiency is observed). Due to high complexity of genes which are involved in optional 
functioning of OXPHOS, some of which very likely remain to be identified, most 
patients are still classified clinically or biochemically, simply because the genetic defect 
has not yet been established. Moreover, very common and severe pathogenic 
manifestation of OXPHOS dysfunction - Leigh syndrome (see Chapter 3.3.1.1 for 
clinical details), for example, may be caused by mutations in more than 25 different 
genes (Kirby and Thorburn 2008), thus in many cases there is  no clear candidate gene 
to investigate and many potential candidates may need to be analyzed (Tucker et al. 
2010). Therefore, there is a great need to better understand the genetics of mitochondrial 
disease as well as biogenesis of OXPHOS, which will enable prenatal diagnoses and 
will deliver deeper understanding of mitochondrial function necessary for development 
of effective therapies (Koene and Smeitink 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1   Genes associated with mitochondrial disease (Tucker et al. 2010). Mutations have been 
identified in genes encoding CI, CII, CIII, CIV, and CV subunits and assembly factors; genes involved in 
mitochondrial DNA (mtDNA) maintenance (via nucleotide metabolism), mtDNA replication, and mtDNA 
expression; genes affecting the electron carriers coenzyme Q (CoQ) and cytochrome c (CytC); genes 
affecting Fe-S assembly; and genes involved in protein import, toxicity/apoptosis, and membrane function. 
Recently identified genes are highlighted in red. Genes affecting oxidative phosphorylation for which 
mutations are not reported to cause neuropathology are underlined.  
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2     AIMS OF THE STUDY 
 
Our laboratory for study of mitochondrial disorders specializes in biochemical and 
molecular diagnostics of OXPHOS deficiencies in the patients predominantly coming 
from Czech and Slovak Republics. One part of this thesis is based on the study of 
selected deleterious mutations of mtDNA in terms of their impact on OXPHOS steady-
state levels and functioning in various patients´ tissues. All analyzed mutations, 
especially those in genes coding for mt-tRNAs, usually affects more than one OXPHOS 
complex, thus they manifest as combined OXPHOS defects. We were interested in 
differences in OXPHOS deficiency patterns among various tissues.  
Second part of this thesis is aimed at biogenesis of cytochrome c oxidase (CcO), 
the complex IV of OXPHOS, which plays central role in oxidative metabolism. 
Defective CcO functionality results in heterogeneous group of diseases predominantly 
affecting tissues with high-energy demands. For its medical relevance, CcO biogenesis 
has received significant attention and has been intensively studied by biochemical, 
genetic, spectroscopic and crystallographic means. Data from medical records of 180 
CcO-deficient children identified in Poland, Czech and Slovak Republics, that means 
from area accounting for more than 50 million inhabitants, revealed fairly high 
mortality of CcO deficiency, relatively early onset of the diseases resulting from CcO 
deficiency and pretty severe clinical symptoms, encephalopathy to be the most common 
(Bohm et al. 2006). In this group, molecular basis of CcO deficiency, which is 
fundamental e. g. for prenatal diagnostics in affected families, still remains to be 
elucidated approximately in the half of cases. Therefore, the study of CcO assembly 
also became an important interest in our laboratory and of my thesis. 
 
The specific aims of this thesis have been: 
 
1)  to study new aspects of the CcO assembly pathway 
 
a) Characterization of the assembly and function of human nuclear-encoded CcO 
subunits 4, 5a, 6a, 7a and 7b. 
 
b) Characterization of the biochemical properties of OXA1L, the human 
homologue of the yeast mitochondrial Oxa1 translocase, and study of its role for 
CcO biogenesis.  
 
2)  to study the molecular basis of selected mtDNA-encoded mutations and their 
impact on OXPHOS function 
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a) Analysis of the tissue-specific effects of mt-tRNA point mutations in patients 
affected by Leigh syndrome (8363G>A), MERRF syndrome (8344A>G), and 
MELAS syndrome (3243A>G) on the steady-state levels and activity of 
OXPHOS complexes. 
 
b) Study of molecular and biochemical impact of mtDNA mutation in the ATP6 
gene (9205ΔTA) on the biosynthesis of ATPase subunit a and its structural and 
functional consequences.  
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3     REVIEW   OF  THE  LITERATURE 
 
3.1. Evolutionary trends in mitochondria 
 
Mitochondria are the endosymbiotic semiautonomous ATP-generating organelles 
of eukaryotes. The divergence of mitochondria from bacteria and aerobic respiration in 
eukaryotes are conventionally associated with a global disaster about 2.0 billion years 
ago (Sicheritz-Ponten et al. 1998), when atmospheric oxygen levels increased rapidly, 
presumably from the accumulated activity of oceanic photosynthetic cyanobacteria 
(Andersson et al. 2003). A continuous presence of oxygen during the entire history of 
the biosphere, albeit primary at very low levels (Holland 1990), matches the ancient 
origins of the terminal oxidases characteristic of mitochondria as well as represented in 
the archaea and bacteria. Thus, the oxidative respiratory system was at the time of 
mitochondrial origin an ancient enzymatic system (Kurland and Andersson 2000). 
Phylogenetic reconstructions have by now provided convincing evidence that the 
various mitochondrial genomes have a single monophyletic origin in α-proteobacterial 
subdivision (Gray et al. 1999). A studying of mitochondrially encoded, chaperone and 
ribosomal proteins points specifically towards the Rickettsiaceaea family (Andersson et 
al. 2003; Andersson et al. 1998; Viale and Arakaki 1994).  A weakness of all current 
theories of mitochondrial origins is the uncertain identity of the host of the ancestral 
endosymbiont (Andersson et al. 2003; Lang et al. 1999). Phylogenomic reconstructions 
show that the characteristic eukaryotic complexity arose without any intermediate 
grades seen between the prokaryotic and eukaryotic levels of organization (Koonin 
2010). 
ATP production in eukaryotes from glucose and oxygen normally consists of two 
catabolic processes (Voet et al. 2006). First, the glycolytic system of the eukaryotes, 
which seems not to trace its origin back to the α-proteobacteria (Andersson et al. 2003), 
supply mitochondria (as well as the obligate parasites of the genus Rickettsia) with 
pyruvate. Second, pyruvate dehydrogenase complex and Krebs cycle catalyze oxidative 
conversion of pyruvate to H2O and CO2. Substrates of Krebs cycle do not come only 
from glycolysis, but also from beta-oxidation of fatty acids and proteolysis. 
Concomitantly to these catabolic processes, electrons are transferred via coenzymes 
NAD+ and FAD to pass into the mitochondrial electron-transport chain which produces 
a proton gradient across the mitochondrial membrane. The free energy stored in this 
electrochemical gradient drives the synthesis of ATP from ADP and phosphate through 
oxidative phosphorylation (Voet et al. 2006). The mechanistic principle of oxidative 
phosphorylation was first proposed by Peter Mitchell (Mitchell 1961) who received for 
chemiosmotic hypothesis Nobel prize in 1978.  
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The processes transforming the ancestral α-proteobacterium into the modern 
mitochondrion were obviously incremental and presumably spread over millions of 
years. Many ancestral mitochondrial genes have been lost, a smaller number of 
mitochondrial proteins have been transferred from the mitochondrial to the nuclear 
genome and the minimum of mitochondrial genes remained to be encoded by 
mitochondrial DNA (mtDNA). The tendency to transfer the vast majority of residual 
ancestral mitochondrial genes to the nuclear genome might have been favored for its 
well-developed sexual mechanisms compared to the asexual character of mitochondrial 
lineages which suggests that they might be particularly vulnerable to Muller’s ratchet1 
(Kurland and Andersson 2000). Like a typical bacterial genome, many mtDNAs map as 
circular molecules, although linear mtDNA exist as well (Nosek et al. 1998). Although 
the genetic role of mtDNA appears to be universally conserved, this genome exhibits 
remarkable variation in conformation and size, which ranges from <6kbp in 
Plasmodium falciparum (the human malaria parasite) to >200kbp in land plants, as well 
as in actual gene content, arrangement and expression. The contrast between the 
expansive plant and condensed animal mitochondrial genomes in virtually every 
parameter (e. g. proportion of coding to noncoding sequence, rate of primary sequence 
divergence, conservation of gene order) suggests that these mtDNAs exhibit entirely 
opposite evolutionary trends (Gray et al. 1999). 
The largest number of mitochondrial proteins, which have no bacterial or archaeal 
orthologues, constituted a novel “eukaryotic” group of mitochondrial proteins, which 
evidently evolved from the nuclear genome by duplication and functional divergence of 
sequences that predate the arrival of the endosymbiont ancestor of mitochondria 
(Karlberg et al. 2000). The phylogenetic clustering of the mitochondrial proteins into α-
proteobacterial and eukaryotic homologues goes hand in hand with the functional 
profiles of the clusters (Kurland and Andersson 2000). Thus, the bacterial homologues 
seem to be mainly involved in translation and energy metabolism. In contrast, the 
eukaryotic proteins are typically associated with transport and regulatory functions. An 
important group of eukaryotic proteins, which originated subsequent to the integration 
of the endosymbiont into the eukaryotic cell, involves protein and ATP transport 
machinery (Andersson et al. 2003). Transport of mitochondrial precursor proteins to 
mitochondria is posttranslational process subsequent to their synthesis by cytosolic 
ribosomes. A recognition, import and sorting of mitochondrial precursor proteins based 
on their targeting sequence signals is mediated by translocases in the outer and inner 
membrane of mitochondria (Neupert and Herrmann 2007). The evolution of 
mitochondrial targeting system gave a possibility to the host cell to decorate the 
                                                 
1  Muller´s ratchet is the process by which the genomes of an asexual population accumulate deleterious 
mutations in an irreversible manner. 
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mitochondrial core complexes with a variety of new proteins, e. g. participating in the 
assembly of complexes or functioning in regulation. It is assumed, that the coevolution 
of the core α-proteobacterial components and the complementary eukaryotic nuclear 
components transformed the endosymbiont into an organelle (Kurland and Andersson 
2000). The presence of ATP/ADP transporter systems made it possible for the 
mitochondriate cell to fully exploit the benefits of the high ATP yields obtained by 
aerobic respiration and may even have been critical for the transition from single cells 
to early, undifferentiated forms of multicellular eukaryotes (Pfeiffer et al. 2001). 
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3.2. The main characteristic features of mitochondria  
 
Mitochondria display striking interspecies and inter-tissue variations in shape, 
connectivity, and inner membrane morphology (Mannella 2008). The general structure 
of mitochondrion is defined by its two membranes (Frey and Mannella 2000; Logan 
2006). A topologically simple and limiting outer membrane enwraps the energy-
transducing inner membrane whose surface area is considerably larger and which in 
turn encloses a protein-rich matrix. To accommodate the volume constraint imposed by 
the outer membrane, the inner membrane has numerous invaginations, the cristae, each 
of which can have one or more tubular connections to the membrane periphery 
(Mannella 2006b). In addition to the scaffold function of the inner membrane for the 
assembly and operation of the respiratory chain complexes, this highly pleomorphic 
structure provides the permeability barrier across which the respiratory machinery 
generates its chemiosmotic gradient. Electron tomographic analyses of various 
mitochondria provided overwhelming evidence that cristae are not simply random folds 
in the inner membrane but rather internal compartments formed by invaginations of the 
membrane, which originates at narrow neck-like segments referred as crista junctions. 
In other words, crista junctions delimit an intercristal space, thereby presumably 
functionally restricting diffusion between intercristal compartments and the peripheral 
intermembrane space (Mannella 2006a; Mannella 2006b; Mannella et al. 1997). The 
number of crista junctions and the morphology of the intercristal space have been 
shown to change with the metabolic state of the mitochondria (Hackenbrock 1968; 
Mannella et al. 1997; Mannella et al. 1994) and can only be achieved by the inner 
membrane undergoing fusion and fission (Mannella et al. 2001). The relative activities 
of proteins involved in mitochondrial fusion and fission determine an overall 
morphology, integrity and turnover of the mitochondrial population as well as 
segregation and protection of mitochondrial DNA (Berman et al. 2008; Cerveny et al. 
2007; Chen and Chan 2005; Scott et al. 2003). In many cases, mitochondria form a 
complex reticulum that interacts with other cellular components, in particular the 
cytoskeleton and endoplasmic reticulum (Mannella 2000; Rutter and Rizzuto 2000). 
Interaction of mitochondrial and endoplasmic reticulum networks and the connectivity 
state of mitochondria controls metabolic flow, production of ROS,  protein transport, 
intracellular Ca2+ signaling and cell death (Csordas et al. 2006; de Brito and Scorrano 
2008; Giorgi et al. 2009; Kakkar and Singh 2007; Szabadkai and Rizzuto 2007). 
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3.3. System of oxidative phosphorylation 
 
Mitochondria comprise the site of most ATP production in eukaryotic cells by a 
process known as oxidative phosphorylation (Saraste 1999). This remarkably complex 
process, which is performed by system of oxidative phosphorylation (OXPHOS) 
(Fig. 2), requires four major events, electron transport (CI-CIV) and generation of a 
proton gradient (CI, CIII and CIV), transport of Pi and ADP and finally coupling the 
proton gradient to ATP synthesis (CV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2   The complexes of OXPHOS (Eng et al. 2003). The diagram shows the five complexes of 
OXPHOS (CI – CV). Complexes I–IV are the electron-transport complexes, whereas complex V 
synthesizes ATP. Electrons are passed down the four complexes (black and red arrows) to molecular 
oxygen and then complex V generates ATP from ADP and Pi. The blue arrows show where the protons 
are pumped to the cytosolic side of the inter-membrane to generate an electrochemical gradient, and 
where proton movement back across complex V (the ATP synthase) is used to drive ATP synthesis. 
 
 
3.3.1. Electron-transport chain 
 
Oxidation of NADH and FADH2 and transfer of electrons to O2 is carried out by 
the electron transport chain also known as respiratory chain. Electrons travel through 
this chain from lower to higher standard reduction potentials through series of redox 
centers, so that the overall process is exergonic. Some of these redox centers are mobile, 
and others are components of integral membrane protein complexes (Fig. 2). The 
released energy is used at three locations within the chain (CI, CIII and CIV) to expel 
protons from the matrix into the IMS, resulting in a potential difference (ΔΨ) and 
proton gradient (ΔpH) across the IMM (Voet et al. 2006). The energy stored in this 
electrochemical proton gradient, generally referred to as proton motive force (PMF) can 
be used for chemical, osmotic and mechanical work. The PMF is dominated by ΔΨ, 
with ΔpH contributing ∼15% to its total magnitude (Koopman et al. 2008; Nicholls and 
Ferguson 2002). In addition to crucial role of PMF in ATP synthesis, it is also used for a 
variety of other energy-dependent processes, which are (indirectly) driven by either ΔΨ 
or ΔpH (Fig. 3). 
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Figure 3   Processes driven by proton motive force (PMF) (Koopman et al. 2010). In addition to CV-
mediated ATP generation, the PMF also is required for transport processes across the IMM. These 
processes are (indirectly) driven by either ΔΨ or ΔpH. For instance, mitochondrial Ca2+ uptake, ATP/ADP 
exchange by the adenine-nucleotide translocator (AAC), trans-IMM Na+ and K+ fluxes (important in 
mitochondria volume regulation), and import of nDNA-encoded preproteins are ΔΨ dependent, whereas 
several mitochondrial antiporters (aspartate/glutamate, H+/K+, H+/Na+, 2H+/Ca2+) and symporters 
(H+/pyruvate and Pi/ADP) are ΔpH dependent. In this panel, indirect dependencies on ΔpH are marked by 
dotted lines. 
 
 
3.3.1.1. Complex I 
 
Complex I, NADH:ubiquinone oxidoreductase, is a very large integral membrane 
protein complex which oxidizes NADH, produced predominantly by the tricarboxylic 
acid cycle (Krebs cycle) and the β-oxidation of fatty acids, to regenerate the NAD+ pool 
in the mitochondrial matrix. The transfer of two electrons from NADH which reduce 
ubiquinone (oxidized CoQ) to ubiquinol (reduced CoQ) in the membrane is coupled to 
the vectorial translocation of four protons across both the inner mitochondrial 
membrane and the plasma membrane of many bacteria thus contributing to generation 
of the proton motive force across the membrane. The ubiquinol is subsequently 
reoxidized by complex III (Hirst 2010).  
Complex I has an unusual L-shaped structure, with one arm in the plane of the 
mitochondrial inner membrane, and one arm protruding into the matrix, both arms being 
of approximately equal length (Zickermann et al. 2009). The L-shaped structure of 
complex I, observed by electron microscopy, is conserved among species (Guenebaut et 
al. 1998; Radermacher et al. 2006), although the protein composition of the eukaryotic 
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and prokaryotic enzymes varies significantly. The 14 central subunits are conserved in 
prokaryotes and eukaryotes and harbor all bioenergetic core functions sufficient for 
energy transduction (Weidner et al. 1993).  These core subunits consist of seven highly 
hydrophobic (in eukaryotes mtDNA-encoded) subunits (ND1, ND2, ND3, ND4, ND4L, 
ND5 and ND6; human nomenclature) and seven hydrophilic (in eukaryotes nDNA-
encoded) subunits (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7 and 
NDUFS8; human nomenclature). The eukaryotic enzyme, which accounts for a total 
mass in the range of 1MDa, contains numerous accessory subunits which vary between 
species and augment both enzyme domains. The function of these subunits is largely 
unknown, but they are very unlikely to participate directly in energy transduction 
(Koopman et al. 2010). In man and cow, there is 31 accessory subunits (Carroll et al. 
2006). The conserved cofactors of complex I are a non-covalently bound FMN (flavin 
mononucleotide) and eight iron-sulfur clusters (Fe-S) with the iron coordinated with 
two to four cysteine side chains from the polypeptide. FMN accepts electrons from 
NADH (Gostimskaya et al. 2007; Grivennikova and Vinogradov 2006), Fe-S clusters 
transport electrons through the enzyme to ubiquinone. All Fe-S clusters are bound by 
the hydrophilic domain. Evidence was provided that mitochondrial complex I can 
undergo a so called active/deactive transition (Vinogradov 1998). To facilitate the 
proper buildup and stability of complex I protein, several assembly chaperones are 
required (Vogel et al. 2007). 
The prokaryotic minimal form of complex I has been characterized e. g. from 
Escherichia coli (Weidner et al. 1993) or Paracoccus denitrificans (Usui et al. 1990). 
To establish a yeast genetic approach to complex I, obligate aerobic yeast Yarrowia 
lipolytica has been extensively used (Kerscher et al. 2002), since this enzyme is absent 
in fermentative yeasts like Saccharomyces cerevisiae (Buschges et al. 1994). Further 
eukaryotic model organisms are e. g. Bos taurus (Carroll et al. 2003), fungi Neurospora 
crassa (Marques et al. 2005) or plant Arabidopsis thaliana (Perales et al. 2005). 
Nevertheless, no high resolution structure of the whole complex I holoenzyme is 
available to date.   
Isolated complex I deficiency is the most common cause of OXPHOS dysfunction 
(Smeitink et al. 2001a; Smeitink et al. 2001b). Clinical phenotypes of complex I 
deficiency can result from mutations in nuclear-encoded subunits, generally presenting 
in infancy and early childhood. Mutations in mtDNA-encoded subunits are more 
common in the late childhood or adolescence. Disease causing mutations have been 
described in all seven mtDNA-encoded structural subunits, twelve of the nDNA-
encoded structural subunits and nDNA-encoded assembly factors NDUFAF2, 
NDUFAF1, C6orf66, C8orf38 and C20orf7 (Distelmaier et al. 2009; Janssen et al. 
2006). MtDNA mutation-based diseases are inherited maternally, while nDNA 
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mutation-based diseases are mostly inherited in an autosomal recessive manner, 
although also X-linked inheritance has been described (Fernandez-Moreira et al. 2007). 
The most common and devastating clinical phenotype associated with early-onset 
complex I deficiency is Leigh syndrome, first described as subacute necrotizing 
encephalomyelopathy (Leigh 1951). Leigh syndrome is an early-onset, progressive 
neurological disorder characterized by motor and intellectual developmental delay, 
signs of brainstem and basal ganglia involvement, and increased lactate levels in blood 
and/or cerebrospinal fluid (Rahman et al. 1996). 
 
3.3.1.2. Complex II 
 
Complex II, succinate dehydrogenase (SDH) or succinate:ubiquinone 
oxidoreductase is a functional member of both the Krebs cycle (tricarboxylic acid cycle) 
and respiratory electron transfer chain. Within the Krebs cycle, SDH oxidizes succinate 
to fumarate in the mitochondrial matrix (or cytoplasm in bacteria) which is coupled to 
the reduction of ubiquinone in the membrane. SDH is the only OXPHOS complex to 
lack subunits encoded by the mitochondrial genome and the only respiratory complex 
not to pump protons across the membrane during its catalytic cycle. The physiological 
form of the mitochondrial SDH is most likely to be a monomer (Sun et al. 2005), unlike 
that for Escherichia coli, which is believed to be a trimer (Yankovskaya et al. 2003). 
Eukaryotic holoenzyme of SDH consists of equimolar amounts of four subunits, two of 
which, subunit A with a covalently bound FAD cofactor and subunit B containing three 
iron-sulfur clusters, form a hydrophilic catalytic head. This heterodimer is anchored in 
the inner membrane by hydrophobic tail composed of subunits C and D, which contain 
one heme b at the subunit interface each providing one of the two axial His ligands. The 
heme moiety is present in mammalian, yeast and Escherichia coli SDHs, but diverse 
SDH species vary in the number of heme groups as well as in the number of their 
hydrophobic subunits (Lemos et al. 2002; Sun et al. 2005). The electron transfer 
pathway in the oxidation of succinate by SDH involves initial reduction of a FAD 
cofactor followed by electron transfer through three Fe-S centers to ubiquinone 
(Hagerhall 1997). Two ubiquinone binding sites have been identified in SDH 
complexes in mammals and Escherichia coli (Sun et al. 2005; Yankovskaya et al. 
2003). The high affinity ubiquinone site lies on the matrix side of the inner membrane 
and is formed by residues in subunits B, C and D. The second, low affinity ubiquinone 
site resides in the membrane closer to the intermembrane space. SDH is closely related 
to fumarate reductase (manaquinol:fumarate oxidoreductase), which catalyzes the 
opposite reaction to that of SDH during anaerobic respiration in bacteria (Kroger et al. 
1992). Both enzymes are suggested to have evolved from a common ancestor. 
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Mutations of SDH genes can manifest themselves with a wide variety of clinical 
phenotypes in humans (Rustin and Rotig 2002). A mutation in SDHA gene for 
subunit A was described, first by Bourgeron et al (1995), to contribute to complex II 
deficiency and Leigh syndrome (Bourgeron et al. 1995; Parfait et al. 2000) or late-onset 
optic atrophy, ataxia and myopathy (Birch-Machin et al. 2000). Mutations in genes 
coding for subunits B, C and D (SDHB, SDHC and SDHD respectively) have never 
been described in any of these progressive neurodegenerative syndromes related to 
mitochondrial complex II deficiencies, however, they cause the tumors observed in 
hereditary paraganglioma and/or pheochromocytoma (Baysal et al. 2000; Niemann and 
Muller 2000; Pasini and Stratakis 2009). Very recently, mutations in SDHAF1, 
encoding a new LYR-motif protein, were described to manifest as defective SDH and 
infantile leukoencephalopathy in patients (Ghezzi et al. 2009). Being a soluble protein, 
the authors concluded that SDHAF1 is not a stable component of the SDH complex and, 
therefore, must be an assembly factor.  
 
3.3.1.3. Complex III 
 
Complex III, ubiquinol:cytochrome c oxidoreductase (QCR) or bc1 complex, is a 
component of the eukaryotic or bacterial respiratory chain and of the photosynthetic 
apparatus in purple bacteria. Every bc1 complex (bacterial as well as mitochondrial) 
contains three common subunits with active redox centers. These catalytic core 
components are cytochrome b with two noncovalently attached b-type hemes bL (also 
called b565) and bH (b562), cytochrome c1 with covalently attached heme c group and the 
“Rieske” iron-sulfur protein (ISP) with an [2Fe-2S] iron-sulfur cluster. The 
mitochondrial system contains additional nonredox subunits absent in the bacterial 
complexes (Hunte et al. 2000; Iwata et al. 1998; Schagger et al. 1986; Zhang et al. 
1998), seven in yeast and eight in mammalian enzymes (Zara et al. 2009). The redox 
subunit b is encoded by mtDNA in these systems. In mitochondria, more than half of 
the total molecular mass of this structurally dimeric transmembrane protein complex 
protrudes into the matrix region, including two core proteins (Leonard et al. 1981; Xia 
et al. 1997). Both these subunits, Core1 and Core2, have been shown to be members of 
the mitochondrial processing peptidase family of proteins, suggesting that the QCR may 
be a bifunctional protein also involved in mitochondrial import protein processing 
(Braun et al. 1992; Braun and Schmitz 1995).  
In respiratory chain, QCR functions to enable one molecule of ubiquinol, a two-
electron carrier, to reduce two molecules of cytochrome c, a one-electron carrier (Voet 
et al. 2006). This occurs by a modified version of the “proton-motive Q cycle” of 
Mitchell (Mitchell 1976), that permits QCR to pump protons from the matrix to the 
intermembrane space and explains the main features of the enzyme activity (Brandt and 
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Trumpower 1994; Crofts et al. 1999a; Crofts et al. 1999b). The key trait of the model is 
that there are two separate binding sites for ubiquinone and ubiquinol. Ubiquinol is 
oxidized at the Qo site of the complex in a bifurcated reaction, in which one electron is 
transferred to a high-potential chain and the other to a low-potential chain. The high-
potential chain, consisting of the ISP, cytochrome c1 and CytC, transfers one electron 
from ubiquinol to an acceptor (cytochrome c oxidase, Compolex IV), what leaves a 
ubisemiquinone at the Qo site. The low potential chain consists of two cytochrome b 
hemes (bL and bH, for low- and high-potential hemes), which serve as a pathway 
through which electrons are transferred across the coupling membrane from 
ubisemiquinone at the Qo site to the Qi site, at which ubiquinone binds and is reduced to 
ubiquinol. The two electrons at the Qi site required for reduction of ubiquinone are 
provided in successive turnovers. The first electron at the Qi site generates a relatively 
stable ubisemiquinone that is reduced to ubiquinol by the second electron. Thus, for 
every two ubiquinols that enter the Q cycle, one ubiquinol is regenerated. Proton 
translocation is the result of deprotonation of ubiquinol at the Qo site (near the P side of 
the IMM) and protonation of the reduced ubiquinone at the Qi site (near the N side of 
the IMM). The circuitous route of electron transfer in complex III is tied to the ability of 
CoQ to diffuse within the hydrophobic core of the membrane in order to bind to both 
the Qo and Qi sites. Binding of mobile CytC to subunit cytochrome c1 of the enzyme is 
mainly mediated by nonpolar interactions (Lange and Hunte 2002). The exclusive 
reduction of heme bL from Qo-bound ubisemiquinone rather than the Rieske Fe-S 
cluster of the ISP protein, despite the greater reduction potential difference favoring the 
latter reaction, is secured by mechanic movement of the extrinsic domain of the Fe-S 
component after its reduction by ubiquinol from Qo site to the proximity of heme c1 
group. Merely after oxidation of the Fe-S protein by the cytochrome, the subunit can 
move back to the docking interface on cytochrome b, close to the Qo site to undergo 
further reduction by the ubiquinol (Zhang et al. 1998).  
Complex III deficiency was first described by Spiro et al. (1970) in a 46-year-old 
man and his 16-year-old son with progressive ataxia, predominantly proximal muscle 
weakness, areflexia, extensor plantar responses and dementia. Studies of muscle 
mitochondria showed very loose coupling of oxidative phosphorylation and marked 
reduction in cytochrome b content, representing a defect in complex III (Spiro et al. 
1970). Disorders related to complex III deficiency are clinically heterogeneous and 
relatively rare. Interestingly, absence of complex III was described to be associated with 
combined I-III deficiency, possibly due to structural importance of complex III for 
stability of complex I in the form of supercomplexes (see Chapter 3.4.1). Most of the 
cases of complex III deficiency are caused by mutations in the mtDNA-encoded 
cytochrome b subunit. Patients with these mutations usually present with an isolated 
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myopathy with ragged red fibers, characterized by exercise intolerance, weakness and 
myoglobinuria (Fernandez-Vizarra et al. 2009). Only one mutation in nDNA-encoded 
structural subunit has been described so far (Haut et al. 2003), a homozygous 4-bp 
deletion in the UQCRB gene, encoding the ubuquinone-binding protein presented with 
hypoglycemia and liver dysfunction. More than 20 pathogenic mutations have been 
reported in the complex III assembly factor BCS1L, dysfunction of which is associated 
with a wide variety of phenotypic manifestations, e. g. GRACILE syndrome (growth 
retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis and early death), 
encephalopathy or Björnstad syndrome (sensorineural hearing loss and pili torti) 
(Fernandez-Vizarra et al. 2009).  
 
3.3.1.4. Complex IV 
 
Complex IV, cytochrome c oxidase (CcO), is the terminal enzyme complex of the 
mitochondrial electron-transport chain, which couples the electron transfer from 
reduced cytochrome c to molecular oxygen with vectorial proton translocation across 
the inner membrane. The mammalian CcO complex is composed of 13 different 
polypeptide subunits, encoded by both the nuclear and mitochondrial genomes. 
Mitochondrially encoded Cox1 and Cox2 form the redox site involved in electron 
transfer. Electrons enter the CcO complex at the binuclear copper site (CuA) in the Cox2 
subunit, which also mediates electrostatic binding of cytochrome c (Zhen et al. 1999). 
From CuA, electrons pass to other metal centers in the Cox1 subunit, first to heme a and 
then to a heterobimetallic heme a3/CuB center (Stiburek et al. 2006). Together with 
Cox3, mitochondrially encoded subunits constitute the evolutionarily conserved 
structural core of the enzyme. The remaining ten subunits (Cox4, Cox5a, Cox5b, 
Cox6a, Cox6b, Cox6c, Cox7a, Cox7b, Cox7c and Cox8), which are encoded by nuclear 
DNA, are associated with the surface of the complex core. These small polypeptides are 
required for the assembly and stability of the holoenzyme and are thought to function in 
the regulation of its activity (Fontanesi et al. 2008; Helling et al. 2008; Huttemann et al. 
2008). Tissue-specific isoforms of subunits Cox4, Cox6a, Cox6b, Cox7a and Cox8 have 
been identified in mammals (Huttemann et al. 2001; Kadenbach et al. 2000). Most CcO 
subunits have one or more transmembrane domains, with the exception of Cox5a and 
Cox5b, which are located at the matrix side, and Cox6b, which is associated with the 
surface of the complex in the intermembrane space (Tsukihara et al. 1996).  
Subunit Cox4 is the largest nuclear-encoded subunit of the complex. It was shown 
to be involved in the allosteric inhibition of CcO activity by ATP, which binds to the 
matrix portion of the subunit (Arnold and Kadenbach 1997). Isoforms 1 and 2 of Cox4 
are encoded by two separate genes and are likely to differ with respect to ATP-induced 
inhibition of CcO activity (Horvat et al. 2006). In mammalian cells, the first step of 
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CcO assembly is the membrane integration of Cox1, followed by the association of the 
Cox4–Cox5a heterodimer (Stiburek et al. 2005) (Fig. 4B, C). Subunit Cox5a binds 
indirectly to subunit Cox1 via the matrix domain of subunit Cox4 and the 
extramembrane segment of Cox6c. Knockdown (KD) of both early-assembled subunits 
Cox4 and Cox5a, which we performed, resulted in accumulation of four subcomplexes 
consisting merely of subunit Cox1. The absence of Cox1–Cox4/Cox5a heterodimers 
confirmed further the interdependence of the assembly of Cox4 and Cox5a (Barrientos 
et al. 2009; Stiburek et al. 2005). Together with the lack of accumulation of higher-
molecular-mass intermediates, our findings suggest that the assembly of the Cox4–
Cox5a heterodimer with Cox1 is necessary for the subsequent association of Cox2, and 
thus for the rest of the assembly to proceed (Fornuskova et al. 2010). 
Either under mild detergent conditions or when crystallized or reconstituted in 
phospholipids vesicles, the majority of mammalian CcO exists as a homodimer. 
Subunits involved in the stabilization of the dimeric state of CcO are Cox6a and Cox6b. 
Subunit Cox6a may also contribute to the formation of an interaction site for 
cytochrome c (Tsukihara et al. 1996). Subunit Cox6a (Nijtmans et al. 1998) and very 
likely also subunit Cox6b (Massa et al. 2008) were shown to associate with the 
complex, together with subunits Cox7a or Cox7b, at a very late stage of CcO assembly 
(Nijtmans et al. 1998) (Fig. 4A). The expression of FLAG-tagged versions of Cox7a2, 
Cox7b and Cox6a2 in both wild-type and Cox6a1-deficient backgrounds allowed us to 
elucidate for the first time the very late events in human CcO assembly (Fornuskova et 
al. 2010). We identified the particular entry points of these three subunits and 
demonstrated the significance of the CcO holoenzyme bands a1 and a2; detected e. g. by 
(Massa et al. 2008). According to our results, band a1 probably represents the 
13-subunit CcO holoenzyme (S4). In contrast, band a2 lacks subunit Cox6a, which 
appears to be added as the last assembled structural subunit. Band a2 (S4*) is formed by 
the addition of Cox7a2 and probably Cox6b1 (Massa et al. 2008) to the assembly 
intermediate S3. Finally, subunit Cox7b was found to join the assembling complex 
during or at the end of the formation of the assembly intermediate S3 (Fig. 4C). 
Furthermore, unlike COX4- and COX5A-KD mitochondria, in which the reduction in 
the holoenzyme band a1 was accompanied by a more pronounced decrease in band a2, 
Cox6a-deficient mitochondria retained significantly higher levels of the latter species. 
These results indicate that band a2 represents another rate limiting step in human CcO 
assembly (Fornuskova et al. 2010). 
The biogenesis of CcO is a complicated, sequential process that necessitates 
sophisticated coordination. Studies in yeast revealed that the CcO assembly requires 
more than 30 auxiliary proteins, encoded in the nuclear genome, that are essential for 
proper biogenesis of the CcO complex but are not part of the mature enzyme 
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(Barrientos et al. 2002; Winge and Tzagoloff 2009). These nonstructural factors 
(assembly factors), accomplish diverse functions at all the levels of the assembly 
process which include transcription and mRNA maturation, translation of CcO 
mitochondrial genes, as well as import into mitochondria of nuclear nDNA-encoded 
subunits and insertion of transmembrane subunits into the inner mitochondrial 
membrane. Essential additional roles involve heme a biosynthesis, copper homeostasis 
and insertion into the apoenzyme and formation of assembly intermediates (Fontanesi et 
al. 2008). A number of these factors were shown to have human homologues some of 
which were studied at the protein level (Stiburek et al. 2006). These include copper 
metallochaperones Sco1, Sco2, Cox11 and Cox17, which are involved in 
trafficking/insertion of copper ions into CuA and CuB centers in Cox2 and Cox1 
subunits, respectively; inner membrane proteins Cox10, Cox15 and Surf1, which are 
required for synthesis and incorporation of heme a moieties into Cox1; and Oxa1 and 
Cox18 translocases, which are involved in the export/translocation of transmembrane 
segments of integral inner membrane proteins, including CcO subunits (Stiburek and 
Zeman 2010). In our laboratory, we addressed the role of human Oxa1l, the human 
orthologue of the yeast Oxa1, in the biogenesis of OXPHOS. Oxa1 protein is a member 
of the evolutionarily conserved Oxa1/Alb3/YidC protein family, which is involved in 
the biogenesis of membrane proteins in mitochondria, chloroplasts and bacteria 
(Herrmann and Neupert 2003; Yi and Dalbey 2005). The predicted human Oxa1l shares 
33% sequence identity with the corresponding yeast polypeptide. The inactivation of 
OXA1 in yeast was shown to cause pleiotropic OXPHOS defects, characterized mainly 
by the complete absence of CcO activity (Altamura et al. 1996), pointing to Oxa1 as 
essential factor for CcO biogenesis. Oxa1l-depleted cells showed markedly decreased 
protein levels and ATP hydrolytic activity of the complex V and moderately reduced 
levels and activity of complex I. Intriguingly, the cytochrome oxidase activity and 
content of CcO, as well as the ascorbate/TMPD fuelled, sodium azide-sensitive oxygen 
uptake, were either unaffected or even increased when compared to negative controls 
(Stiburek et al. 2007). Since the yeast Oxa1 is strictly required for the N-terminal export 
of Cox2 precursor, it is possible that the complete absence of the N-terminal leader 
peptide in nascent human Cox2 might be responsible for the observed Oxa1-
independent assembly of human CcO. The fact that human Oxa1l is able to partially 
restore the respiratory growth of yeast oxa1 cells suggests that both proteins share at 
least basic functional features.  
CcO deficiency, in addition to complex I deficiency, is frequent cause of 
mitochondrial encephalomyopathies. Although several pathogenic mutations in each of 
the three mitochondrially encoded CcO subunits (Shoubridge 2001) and two mutations 
in nDNA-encoded genes for structural subunits Cox4i2 (Shteyer et al. 2009) and Cox6b 
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(Massa et al. 2008) have been reported, the majority of fatal infantile CcO deficiencies 
identified so far result from autosomal recessive mutations in genes encoding CcO 
assembly factors (e. g. (Barrientos et al. 2009; Diaz 2010)). Indeed, two of the human 
CcO assembly factors, LRPPRC (leucine-rich pentatricopeptide repeat cassette)  and 
TACO1 (translational activator of Cox1), both of which are involved in mitochondrial 
CcO mRNA translation, were identified primarily on the basis of their mutant 
phenotypes in human patients (Mootha et al. 2003; Weraarpachai et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4   Models of the mammalian CcO assembly pathway according to Nijtmans et al. (1998) (A), Stiburek 
et al. (2005) (B) and Fornuskova et al. (2010) (C). Prosthetic groups and assembly factors are indicated. Roman 
(A) or Arabic (B, C) numerals denote CcO subunits within subcomplexes. S2 and S3 indicate assembly 
intermediates. S4 represents the 13-subunit CcO holoenzyme, and S4* indicates the late assembly intermediate that 
immediately precedes the formation of the holoenzyme. 
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3.3.2. Complex V 
 
Complex V,  F1Fo-ATP synthase or F-type ATPase is multisubunit enzyme nearly 
ubiquitous in the cell membranes of eubacteria, inner membranes of mitochondria and 
tylakoid membranes of chloroplasts (Boyer 1998). Under oxidative conditions, ATP 
synthase is a critically important for synthesis of ATP from ADP and Pi driven by a 
proton or sodium motive force (Meier et al. 2009; Meier et al. 2005; Pogoryelov et al. 
2009; Preiss et al. 2010), thereby providing the vast majority of ATP in the cell. Under 
anaerobic conditions, eubacterial enzymes catalyze the reverse reaction and generate the 
proton motive force using energy liberated by hydrolysis of ATP produced by 
fermentation, whereas specific inhibitory mechanisms prevent the chloroplast and 
mitochondrial enzymes from carrying out the reverse reaction. Inhibition of the ATP 
hydrolysis activity of F1 under certain conditions was shown in context of IF1 
regulatory polypeptide (ATPase inhibitory factor 1) in mammals and Inh1p, Stf1p and 
Stf2p in yeast (Hong and Pedersen 2002; Walker 1994). 
F1Fo-ATP synthase contains an extramembranous cytoplasmic F1 part (α3β3γδε in 
bacteria) and a membrane-embedded Fo part (ab2c10-12 in bacterial F1Fo) (Fig. 5A). Both 
parts are linked by a peripheral and a central stalk. Overall, this large complex has eight 
different subunits in prokaryotes and 16-18 in mammals (Meyer et al. 2007), where the 
additional subunits are mostly in the stalk region. The central stalk, containing F1-
subunits γ and ε, is associated with a ring of Fo-subunits c. This central stalk/subunit c 
assembly constitutes the rotor in the fully assembled ATP synthase. In mitochondria 
(Fig. 5B), there is an additional subunit in the rotor, which is inconveniently called „ε“ 
and has no equivalent in bacteria or chloroplasts. The mitochondrial „δ“ subunit is the 
equivalent of the bacterial „ε“ (Nakamoto et al. 2008). Peripheral stalk extends from the 
top (membrane distal) region of F1, along the external surface of the α3β3 domain, and 
then reaches down into and across the membrane, where it is associated with subunit a 
(Walker and Dickson 2006). Its role is to act as stator which connects catalytic α3β3 
complex to the transport mediating subunit a. In most bacteria is made up of two copies 
of the helical b subunits (b2) and the single δ subunit (the homologue of the bovine 
OSCP subunit). In some photosynthetic bacteria and chloroplasts, the two b subunits are 
similar but are the products of two genes (bb´) (Nakamoto et al. 2008). In the 
mitochondrial complex, there is only one subunit b with two additional subunits in the 
peripheral stalk, d and F6 (known as subunit h in Saccharomyces cerevisiae (Rubinstein 
et al. 2005)) and four additional membranous subunits e, f, g and A6L are associated 
with subunit a (Dickson et al. 2006). Unlike the situation in bovine heart where are 
subunits e and g tightly bound as the part of monomeric ATP synthase, yeast subunits e 
and g as well as k were proposed to be a dimer-specific (Arnold et al. 1998). Subunit a 
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(ATP6 gene) and A6L (ATP8) are encoded by mammalian mtDNA, whereas yeast 
mitochondrial genome codes also for the ATP synthase subunit c, (ATP9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5   Schematic representation of the bacterial and mitochondrial F1FO-ATP synthases (Kucharczyk et 
al. 2009). The enzyme of Escherichia coli (A), with a subunit stoichiometry of α3β3γδεab2c10-12, is organized in 
four subdomains, i.e. the catalytic headpiece (α3β3), the central rotor stalk (γε), the stator stalk (b2δ), and the 
proton channel (ac10-12). The human mitochondrial enzyme (B) contains the additional subunit ε in the central stalk 
(γδε); the stator stalk is composed of one subunit b, subunits d, F6, f and OSCP; subunit c is present in 10 copies 
and subunits e and g mediate enzyme dimerization.  
 
 
The F1 part contains three catalytic sites, which lie mainly in β-subunits at 
interfaces with α-subunits. The study of these catalytic sites (Weber and Senior 2000) 
indicated that F1 part is effectively a trimeric complex of three α and three β subunits 
that displays string negative cooperativity of substrate binding and, at the same time, 
string positive cooperativity of enzymatic activity. To explain these unusual properties, 
Paul Boyer proposed mechanism named as binding change hypothesis (or also 
alternating site hypothesis) (Boyer 1993). The key feature of this hypothesis is that three 
interacting catalytic αβ-protomers are each in a different conformational state at any 
one time. One binds substrates and products loosely, one binds them tightly and one 
does not bind them at all. The cyclic nature of the binding change mechanism led Boyer 
to propose that the binding changes are driven by the rotation of the catalytic assembly 
(α3β3) with respect to other portions of the F1Fo ATPase (Boyer 1993; Boyer 2000). We 
know now that C-terminal region of the γ-subunit penetrates α3β3 domain in asymmetric 
manner and as it rotates, it brings about a series of conformational changes given by this 
asymmetry of the central stalk (Walker and Dickson 2006). Each 360° rotation of the 
central stalk in a clockwise manner (as viewed from the membrane) inside the F1 
domain generates three ATP molecules, and the rotation of the central stalk proceeds, to 
a first approximation, in 120° steps. If each c subunit translocates one proton, and if it 
takes the energy for translocation of three or four protons to synthesize one ATP 
molecule, then three or four small rotations (each through an angle that depends on the 
number of c subunits in the ring) are required to drive a 120° rotation of γε relative to 
the α3β3 domain. During the rotation of the central stalk, energy is stored transiently, 
31 
presumably in an elastic element, and then released in a quantum to drive each 120° 
step (Beke-Somfai et al. 2010; Capaldi and Aggeler 2002; Nakamoto et al. 2008; 
Tsunoda et al. 2001). The two most obvious candidates for such elastic element are the 
α-helical region of the γ-subunit in the central stalk and the peripheral stalk (Walker and 
Dickson 2006). 
In humans, the most common cause of ATPase defects are missense heteroplasmic 
mtDNA mutations in the ATP6 gene for subunit a, which affect the protonophoric 
function of ATPase (Hutcheon et al. 2001; Stock et al. 1999). Higher prevalence show 
8993T>G(C) mutations (Ciafaloni et al. 1993; Holt et al. 1990; Puddu et al. 1993; 
Shoffner et al. 1992; Tatuch et al. 1994) which change Leu156 to Arg or Pro. At a lower 
mutation load, they manifest as neurogenic muscle weakness, ataxia, and retinitis 
pigmentosa (NARP syndrome); at heteroplasmy exceeding 90% they present as 
maternally inherited Leigh syndrome (severe and fatal encephalopathy). Less common 
are 9176T>G(C) mutations, which change Leu217 (Carrozzo et al. 2001; Dionisi-Vici et 
al. 1998; Thyagarajan et al. 1995), or a 8851T>G mutation (De Meirleir et al. 1995) 
that changes Trp109, all manifesting also as striatal necrosis syndromes (Schon et al. 
2001). Impairment of the ATPase H+ channel results often, but not always, in decreased 
ATP production, whereas the ATPase hydrolytic activity remains largely unchanged 
(Houstek et al. 1995b; Tatuch and Robinson 1993). Otherwise, a mutation in which 
A8527G changes the ATPase 6 initiation codon AUG into GUG (Met > Val), has been 
found in an adult patient with neuropathy, mental retardation, myopathy and retinopathy 
(Dubot et al. 2004). More rarely, ATP synthase dysfunction can be caused by a 
mutation in the ATP8 gene (Jonckheere et al. 2008). A homoplasmic nonsense mutation 
in overlapping region of ATP6 and ATP8 gene, which results in truncated A6L protein 
without the last 14 amino acids, has been detected in a 16-year-old patient with 
hypertrophic cardiomyopathy and neuropathy. A different type of pathogenic 
mechanism represents mtDNA 2bp microdeletion 9205delTA, which was found in a 
newborn with transient lactic acidosis (Seneca et al. 1996) and also in our patient, a 
child with encephalopathy and severe psychomotor retardation (Jesina et al. 2004). A 
9205delTA mutation removes the stop codon of the ATP6 gene and affects the cleavage 
site between the ATP6 and COX3 transcripts.  
Our study on fibroblasts with primary defects in mitochondrial ATP synthase due 
to heteroplasmic mtDNA mutations in the ATP6 gene, affecting protonophoric function 
or synthesis of subunit a, show that at high mutation loads, mitochondrial membrane 
potential ΔΨm at state 4 is normal, but ADP-induced discharge of ΔΨm is impaired and 
ATP synthesis at state 3-ADP is decreased. Increased ΔΨm and low ATP synthesis is 
also found when the ATPase content is diminished by altered biogenesis of the enzyme 
complex. Irrespective of the different pathogenic mechanisms, elevated ΔΨm in primary 
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ATPase disorders could increase mitochondrial production of ROS and decrease an 
energy provision (Vojtiskova et al. 2004). 
A distinct group of inborn defects of ATP synthase is represented by the enzyme 
deficiency due to nuclear genome mutations which are very rare and characterized by a 
selective inhibition of ATP synthase biogenesis. ATPase deficiency of possible 
nonmitochondrial origin was first described in a child with 3-methylglutaconic aciduria 
and severe lactic acidosis (Holme et al. 1992). Extremely low ATPase activity and low, 
tightly coupled respiration rates were observed in muscle mitochondria, but no mutation 
was found in mtDNA genes encoding ATPase subunits. A nuclear origin of ATP 
synthase deficiency was demonstrated for the first time in 1999 (Houstek et al. 1999) in 
a new type of fatal mitochondrial disorder: a child with severe lactic acidosis, 
cardiomegaly, and hepatomegaly died 2 days after birth. 70 to 80% decrease in ATPase 
activity and ATP production was associated with a corresponding selective decrease in 
the ATPase complex, which had normal size and subunit composition. Increased 
biosynthesis of the β subunit with a very short half-life contrasted with decreased 
biosynthesis of the assembled ATPase and indicated assembly defect at the level of F1-
ATPase. Cybrid cells made of patient fibroblasts fully complemented the ATPase defect 
and confirmed the nuclear origin of impaired biogenesis of the enzyme complex 
(Houstek et al. 1999). In 2004, the search for the diseased-causing gene resulted in the 
identification of a homozygous missense mutation in the third exon of the ATP12 
(ATPAF2) gene which replaced tryptophan 94 with arginine.  The mutation was found 
in a patient with severe encephalopathy and it was confirmed that the primary defect 
was in the assembly of the F1 catalytic part of ATP synthase (De Meirleir et al. 2004). 
In 2008, the expression profiling and homozygosity mapping identified a mutation in 
the second intron of TMEM70 encoding a 30kDa mitochondrial protein of unknown 
function. The mutation leading to aberrant splicing and loss of TMEM70 transcript was 
found in 24 patients (Cizkova et al. 2008). This protein turned out to be a novel 
ancillary factor of ATP synthase biogenesis, interestingly, the first one specific for 
higher eukaryotes. The first case of a mitochondrial disease due to a mutation in a 
nuclear encoded structural subunit of ATP synthase was described most recently. 
Missense mutation in ATP5E gene coding for ε subunit replaced tyrosine 12 with 
cysteine in patient with neonatal onset, lactic acidosis, 3-methylglutaconic aciduria, 
mild mental retardation and developed peripheral neuropathy (Mayr et al. 2010).  
 
3.3.3. Transporters of ATP synthase substrates 
 
The net efflux of phosphate across the inner mitochondrial membrane occurs to a 
great extent as γ-phosphate of ATP via the adenine nucleotide carrier, which catalyses 
efflux of ATP in exchange for ADP.  Moreover, ADP as well as inorganic phosphate 
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(Pi) must be transported into the mitochondrial matrix to be utilized for oxidative 
phosphorylation.  
 
3.3.3.1. Transport of ADP 
 
The protein, which mediates link between the mitochondrial and cytosolic 
compartments of all aerobic eukaryotic cells by catalysis of the transmembrane 
exchange between ATP from oxidative phosphorylation generated inside mitochondria 
and cytosolic ADP, is ADP/ATP carrier (AAC) or translocase. The popular term 
adenine nucleotide transporter (ANT) is misleading since this term also implies 
transport of AMP which is explicitly excluded by the AAC (Klingenberg 2008). The 
transported substrates are large, hydrophilic, highly charged molecules, averse to low 
dielectric membrane environment, thus their transport through biomembranes requires a 
carrier with highly efficient catalytic qualities. Paradoxically to this point, transport by 
AAC requires adenine nucleotides with their full charge as ATP4- and ADP3- and the 
less charged AMP is excluded from both uptake and efflux. dADP and dATP are 
transported at 10-15% the rates of their ribose homologues. Concerning the base 
moiety, a stringent specificity for adenine is maintained, excluding most other bases 
(Duee and Vignais 1969; Pfaff and Klingenberg 1968). With AAC reconstituted 
vesicles, also a 1:1 exchange of pyrophosphate (PPi) against ADP was characterized 
(Kramer and Klingenberg 1985). Although a fractional charge, corresponding to a 
partial ADP3- - ATPH3- transport cannot be ruled out and may serve to adjust the energy 
share used in the exchange in dependence on Δψ and ΔpH, various studies substantiate a 
fully electric ATP4- - ADP3- exchange (LaNoue et al. 1978; Villiers et al. 1979; Wulf et 
al. 1978). Under in vivo conditions, ADP and ATP are offered simultaneously at 
varying proportions. In the energized state, ATP is released preferably to ADP but in 
the uncoupled state ADP leaves the mitochondria more rapidly than ATP (Klingenberg 
1980), although equal rates should be expected, just as observed for uptake 
(Klingenberg 2008). This can be explained by considering that in the mitochondria the 
nucleotides are present mostly as the Mg2+ complexes which are not transported and 
thus the concentration of free ATP which binds Mg2+ about 5-times tighter than ADP 
(Heldt et al. 1972) is decreased more than of ADP (Klingenberg 2008). Without 
membrane potential the AAC can catalyze the four exchange combinations of ADP and 
ATP, two homoexchange modes (ATP-ATP, ADP-ADP) and two heteroexchange 
modes (ATP-ADP, ADP-ATP) at nearly equal rates. Only the ADP-ATP mode (ADP 
uptake, ATP release) is productive for the ATP delivery whereas the ATP-ADP mode is 
counter-productive. The homo-modes are diverting exchange capacity. The membrane 
potential skews this distribution in favor of the ADP-ATP mode and suppresses the 
ATP-ADP mode (Klingenberg 2008). The central role of the AAC in oxidative 
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metabolism requires high expression levels in most eukaryotic cells exceeding other 
transporters.  
The amino acid sequence of the AAC was first established in the bovine heart 
(Aquila et al. 1982). The sequence comprising 297 amino acids is likely to be 
segmented into three similar domains, each featuring two helices with a total of six 
transmembrane helices (Saraste and Walker 1982). It closely resembles the typical 
structure of members of the mitochondrial carrier protein family. The striking sequence 
RRRMMM regarded as an AAC signature was present in all forthcoming AAC 
sequences, such as of Neurospora crassa (Arends and Sebald 1984) and Saccharomyces 
cerevisiae (Adrian et al. 1986). By using cross-linking and analytical ultracentrifuge 
techniques it was shown that the AAC as well as the mitochondrial uncoupling protein, 
at least in the solubilized state, forms a homodimer (Hackenberg and Klingenberg 1980; 
Lin et al. 1980). A dimer state of yeast yAAC2 was demonstrated using native gel 
electrophoresis of mitochondria (Ryan et al. 1999). 
First in yeast and then in other organisms, particularly in mammals, genes of AAC 
isoform were identified. Saccharomyces cerevisiae contains three genes (AAC1, AAC2 
also known as PET9, AAC3) for AAC isoforms. yAAC2 is the principal AAC in 
aerobic yeast. The study of involved promoters and transcription factors showed the N-
terminal extension of yAAC2 which is instrumental for the high expression level 
(Betina et al. 1995). yAAC1 is barely expressed (Lawson et al. 1990). yAAC3 is 
obligatory for anaerobic growth (Drgon et al. 1991; Kolarov et al. 1990) and is 
suggested to act in reversed order, supplying ATP from glycolysis to the mitochondria. 
Notably, in the obligate aerob Neurospora crassa only one ncAAC gene has been found 
(Arends and Sebald 1984). In man as well as in cow, four tissue-specific isoforms were 
described. h- and bAAC1 is predominantly expressed in skeletal and cardiac muscles 
(Stepien et al. 1992). hAAC2 expression is strongly stimulated by growth factor in 
fibroblasts (Ku et al. 1990) and also increased in neoplastic cells (Torroni et al. 1990) as 
well in early myoblasts (Stepien et al. 1992) indicating that this isoform is related to 
enhanced glycolysis in the proliferating cells and has the role of supplying glycolytic 
ATP into the mitochondria, similarly as suggested for yAAC3 in yeast. At very low 
level, hAAC3 is expressed in brain, liver, kidney, heart and skeletal muscle (Stepien et 
al. 1992) and hAAC4 in liver and testis, marginally in brain (Dolce et al. 2005). 
Overall, the sequence differences in AAC isoforms are small, as compared to those in 
the yeast, retaining about 85% identity, with the exception of h- and bAAC4 with only 
66-68% identity to the other isoforms (Dolce et al. 2005).  
Mutations in hAAC1 gene (SLC25A4) have been shown predominantly to result 
in autosomal dominant progressive external ophthalmoplegia and familial hypertrophic 
cardiomyopathy. Kaukonen et al. (2000) identified a missense mutation in the AAC1 
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gene (A114P) in 5 families with autosomal dominant progressive external 
ophthalmoplegia (PEOA2). The analogous mutation in yeast caused a respiratory 
defect. The authors also identified mutations in the AAC1 gene (V289M) in a sporadic 
case of PEO (Kaukonen et al. 2000). Chen (2002) determined that the A128P mutation 
of the Saccharomyces cerevisiae yAAC2 protein, equivalent to A114P in human AAC1, 
does not always affect respiratory growth. Rather, expression of A128P resulted in 
depolarization, structural swelling, disintegration of mitochondria and ultimately an 
arrest of cell growth in a dominant-negative manner. The author proposed that the 
A128P mutation may induce an unregulated channel, allowing free passage of solutes 
across the inner membrane, rather than interfere specifically with ATP/ADP exchange 
(Chen 2002).  Fontanesi et al. (2004) introduced dominant-acting missense mutations 
associated with PEO into yAAC2, the yeast ortholog of human AAC1. Expression of 
the equivalent mutations in aac2-defective haploid strains of Saccharomyces cerevisiae 
resulted in a marked growth defect on nonfermentable carbon sources and a concurrent 
reduction of the amount of mitochondrial cytochromes, cytochrome c oxidase activity 
and cellular respiration. The AAC2 pathogenic mutants showed a significant defect in 
ADP versus ATP transport compared with wildtype AAC2. The aac2 mutant alleles 
were also inserted in combination with the endogenous wildtype AAC2 gene. The 
heteroallelic strains behaved as recessive for oxidative growth and petite-negative 
phenotype. In contrast, reduction in cytochrome content and increased mtDNA 
instability appeared to behave as dominant traits in heteroallelic strains (Fontanesi et al. 
2004). Palmieri et al. (2005) first reported a recessive mutation in the AAC1 gene in a 
sporadic patient who presented with hypertrophic cardiomyopathy, exercise intolerance 
and lactic acidosis but without ophthalmoplegia. A muscle biopsy showed numerous 
ragged-red fibers and Southern blot analysis disclosed multiple mtDNA deletions. 
Homozygous mutation 368C>A in AAC1 gene converting a highly conserved alanine 
into an aspartic acid at codon 123 was found. The equivalent mutation in AAC2, the 
yeast ortholog of human AAC1, resulted in a complete loss of transport activity and in 
the inability to rescue the severe OXPHOS phenotype displayed by WB-12, an 
AAC1/AAC2 defective strain. Interestingly, exposure to ROS scavengers dramatically 
increased the viability of the WB-12 transformant, suggesting that increased redox 
stress is involved in the pathogenesis of the disease (Palmieri et al. 2005). 
In mouse, two AAC isoforms, mAAC1 and mAAC2, were described (Levy et al. 
2000). A knockout of heart/muscle specific isoform (mAAC1) (Graham et al. 1997) 
revealed ragged-red fibers in skeletal muscle and cardiac hypertrophy accompanied by 
dramatic proliferation of mitochondria. In mutant adults, a lactic acidosis and severe 
exercise intolerance were observed. Muscle specific AAC1 isoform with low expression 
in myoblasts, is settled to be predominantly expressed by muscle development (Stepien 
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et al. 1992). Surprisingly, the absence of mAAC1 in knockout mouse was not 
compensated by an increase in the other AAC isoform. Interestingly, comparable 
observations were characterized in context of cytochrome c oxidase isoforms of 
structural subunit Cox6a. Liver-type subunit Cox6a (Cox6a1/Cox6aL) is found in all 
non-muscle tissues, whereas heart/muscle-type subunit Cox6a (Cox6a2/Cox6aH), 
encoded by a different gene, is expressed only in striated muscles (Schlerf et al. 1988). 
Mature Cox6a1 and Cox6a2 subunits share lower intra-species (approx. 60%) than 
inter-species (80–88%) amino acid sequence identity in humans, rats and cows (Fabrizi 
et al. 1992). The tissue-specific pattern of these isoforms is also (similarly to AAC 
isoforms) established during tissue differentiation (Bonne et al. 1993; Kim et al. 1995; 
Taanman et al. 1992). A switch from COX6A1 to COX6A2 isoforms was described to 
occur during mammalian postnatal development in skeletal muscle and heart as well as 
during differentiation of myogenic cells in vitro, and is assumed to be essential for 
normal function of tissues with high aerobic metabolic demands (Kim et al. 1995; 
Taanman et al. 1992). In the heart of mice lacking the COX6A2 gene, the content of 
CcO comprising Cox6a1 appeared to be unchanged; in other words, without apparent 
compensation by induction of the expression of subunit Cox6a1 in the knockout heart 
(Radford et al. 2002). In our study (Fornuskova et al. 2010), used HEK-293 cells are 
derived from embryonic kidney tissue, which is specific by almost exclusive (both 
prenatal and postnatal) expression of the COX6A1 isoform (Bonne et al. 1993; Kim et 
al. 1995; Taanman et al. 1992). Indeed, the vast majority of the COX6A transcripts in 
HEK-293 cells is represented by the COX6A1 isoform. Similar to the results from 
mCOX6A2-KO and mAAC1-KO, the decrease in the major isoform in our COX6A1-
KD cells was not accompanied by up-regulation of the minor isoform (COX6A2). 
However, ectopic expression of Cox6a2 in COX6A1-KD cells tends to complement the 
CcO defect (Fornuskova et al. 2010). It appears that the mechanisms responsible for 
maintenance of tissue-specific patterns of COX6A as well as AAC isoforms cannot 
react in response to actual cellular state. In contrast, it is also possible that the 
pronounced biochemical defect still did not provoke sufficient physiological 
impairment, which would otherwise trigger the expression of the minor subunit. 
 
3.3.3.2. Transport of Pi  
 
A smaller fraction of phosphate may be transported by the dicarboxylate carrier, 
which catalyzes a Pi/dicarboxylate or Pi/Pi exchange (Wohlrab 1986). Furthermore, the 
protein, which is mainly responsible for phosphate transport, is the mitochondrial 
phosphate carrier (PIC) also named as phosphate transport protein (PTP) (Fig. 3). Three 
different modes of PIC action were elucidated. Homologous phosphate/phosphate (Pi–
/Pi–) antiport, heterologous phosphate/hydroxyl (Pi–/OH–) antiport or phosphate/proton 
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(Pi–/H+) symport represents the physiological transport mode of unidirectional 
phosphate uptake. In the functionally active catalytic complex, two binding sites have to 
be simultaneously occupied in the transport cycle thus forming a ternary complex. The 
lack of any dependence on the electrical potential confirmed the electroneutrality of the 
transport reaction (Wohlrab 1986), which is, however, dependent on the membrane pH 
gradient as driving force of the mitochondrial phosphate carrier (Wohlrab and Flowers 
1982). Kinetic modeling of the pH dependence of the unidirectional phosphate transport 
reaction favors the Pi-/OH- antiport rather than Pi–/H+ symport (Stappen and Kramer 
1994). In addition to the physiological transport mode, PIC can undergo a functional 
shift from coupled antiport to uncoupled uniport after modification of cysteine residues 
by mercurial reagents (Stappen and Kramer 1993). A similar shift has been observed for 
the ATP/ADP and the carnitine carrier from mitochondria (Kramer 1998).  
The amino acid sequence of the phosphate carrier from several species including 
bovine (Runswick et al. 1987) or human (Dolce et al. 1991) heart and yeast (Phelps et 
al. 1991) has been determined. It closely resembles the typical structure of members of 
the mitochondrial carrier protein family with subunits of six transmembrane segments 
and a molecular mass of ∼32 kDa (Aquila et al. 1985; Kuan et al. 1995). Similarly to 
many mitochondrial transport proteins (Wohlrab 2009; Wohlrab 2010), PIC appears to 
function as homodimer (Phelps and Wohlrab 2004; Schroers et al. 1998; Wohlrab 
2004). Among the family members, the mammalian, but not the yeast, PIC is 
exceptional in having a processed N-terminal sequence that helps to target the protein 
into mitochondria (Zara et al. 1992). Only one gene for the PIC has been detected in 
human (SLC25A3) and cow (Dolce et al. 1994), in both, with two closely related exons 
named 3A and 3B which appear to be alternatively spliced (Dolce et al. 1994). At 
transcript and protein levels, two PIC isoforms (A and B) has been demonstrated. PIC-A 
is present only in heart and skeletal muscles, whereas PIC-B is ubiquitous (Fiermonte et 
al. 1998). The recombinant, reconstituted isoforms exhibit similar substrate specificity 
and inhibitor sensitivity, but they differ in kinetic parameters. 
Mayr et al. (2007) described the first patients with mitochondrial phosphate carrier 
deficiency caused by a homozygous mutation in the SLC25A3 gene, i. e. 215G>A 
transition in alternatively spliced exon 3A, resulting in an amino acid substitution of  
Gly72 to Glu. Two siblings showed lactic acidosis, hypertrophic cardiomyopathy, and 
muscular hypotonia and died within the first year of life. Functional investigation of 
intact mitochondria showed a deficiency of ATP syntase in muscle but not in 
fibroblasts, which correlated with the tissue-specific expression of exon 3A in muscle 
versus exon 3B in fibroblasts (Mayr et al. 2007).  
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3.4. Organization of OXPHOS, functional and structural relevance 
 
The molar ratios of the respiratory components of mitochondria from different 
species as well as from different organs of the same species vary significantly (Lenaz 
and Genova 2007). These different stoichiometries could reflect the adaptability of the 
tissues to a variable energy demand. In bovine heart, the main components of OXPHOS 
best fit unit stoichiometry of 1 complex I : 1.3 complex II : 3 complex III : 6.7 complex 
IV (Schagger and Pfeiffer 2001). For each complex IV are 0.5 unit of ATP synthase and 
3-5 units of the ADP/ATP translocase (Capaldi 1982). The amount of CoQ is in 
considerable molar excess to complex III and CytC is usually in slight molar excess to 
complex IV (Lenaz and Genova 2009).  
 
3.4.1. Random diffusion vs. solid-state assembly of electron transfer 
enzymes 
 
In the prevalent view, the large enzymatic complexes are randomly distributed in 
the lipid bilayer of the inner membrane and functionally connected by lateral diffusion 
of small redox molecules, i. e., coenzyme Q and cytochrome c. All these components 
undergo independent lateral diffusion in the plane of the membrane, however, diffusion 
rates of mobile electron carriers are faster than those of the bulkier macromolecular 
complexes. The diffusion-coupled collision frequencies may be either higher or lower 
than any given reaction step within the complexes, and consequently electron transfer 
would be either reaction limited or diffusion limited. Such a random liquid-state 
organization is usually referred as fluid mosaic model, random diffusion model or 
random collision model of electron transfer (Lenaz and Genova 2007; Lenaz and 
Genova 2009) and was essentially based on the isolation of functional individual 
complexes (Hatefi 1985), on the failure of electron microscopic and liposomal fusion 
studies to identify associations of complexes (Capaldi 1982), and on the pool behavior 
of  CoQ and CytC in bovine mitochondria (Gupte and Hackenbrock 1988; Kroger and 
Klingenberg 1973).  
Alternatively, the components of the chain form aggregates ranging from small 
clusters of few complexes to the extreme of a solid-state assembly. The aggregates may 
be either permanent or transient, but their duration in time must be larger than any 
electron transfer turnover to show kinetic differences from the previous model (Lenaz 
and Genova 2007; Lenaz and Genova 2009). The evidence that the respiratory chain 
complexes are associated to form specific stoichiometric supramolecular units with well 
defined structure provided the electrophoretic analyses by both BN-PAGE and colorless 
native PAGE (CN-PAGE) supporting the idea of highly ordered associations of the 
respiratory supercomplexes and discarding most doubts on artificial interactions. The 
interactions may be  species- or kingdom- specific (Schagger and Pfeiffer 2000; Vonck 
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and Schafer 2009) presumably within the plane of the membrane, whereas the matrix-
exposed protein domains are in close vicinity but probably do not substantially interact 
(Dudkina et al. 2005).  
In bovine heart mitochondria, complexes I-III interactions were apparent from the 
presence of about 17% of total complex I in the form of I1III2 supercomplex that was 
found further assembled into two major supercomplexes (respirasomes) comprising 
different copy numbers of complex IV (I1III2IV1 and I1III2IV2 contain 54% and 9% of 
total complex I, respectively). Only 14-16% of total complex I, 40-42% of complex III 
and majority of complex IV (>85%) was found in free form in the presence of digitonin 
(Schagger and Pfeiffer 2001). Associations of complex II with other complexes of the 
OXPHOS system could not be identified under the conditions of BN-PAGE (Lenaz and 
Genova 2009). However, Acin-Perez and colleagues demonstrated recently that some of 
the previously identified mammalian supercomplexes contain also complex II, and 
complex V, as well as electron carriers CoQ and CytC (Acin-Perez et al. 2008).  
In Saccharomyces cerevisiae, complex I is absent and replaced by three NADH 
dehydrogenases. Compared to bovine heart mitochondria, yeast complex IV does not 
occur significantly in free form. It is quantitatively associated with complex III, and the 
amount of the supercomplexes formed depends on the amount of complex IV available 
at different growth conditions. The amount of supercomplexes seems to reflect the 
demand of the cell for energy supply via the OXPHOS system (Schagger and Pfeiffer 
2000). Stable supercomplexes of complexes III and IV were isolated also from several 
bacteria, e. g. from Paracoccus denitrificans (Berry and Trumpower 1985), the 
thermophilic Bacillus PS3 (Sone et al. 1987), the thermoacidophilic archaeon 
Sulfolobus sp. strain 7 (Iwasaki et al. 1995a; Iwasaki et al. 1995b) and Corynebacterium 
glutamicum (Niebisch and Bott 2003). 
Supercomplexes are stabilized by cardiolipin (Claypool et al. 2008; McKenzie et 
al. 2006; Pfeiffer et al. 2003), an anionic phospholipid consisting of two phosphatidyl 
residues that are linked by a glycerol moiety (Lecocq and Ballou 1964; Macfarlane 
1964). Cardiolipin is exclusively found in bacterial and mitochondrial membranes, 
which are designed to generate an electrochemical potential for substrate transport and 
ATP synthesis (Schlame et al. 2000). It is buried within the protein complexes having 
important structural and catalytic role (Lange et al. 2001; Sedlak and Robinson 1999). 
Although, from a structural point of view, little doubt exists that respiratory chain 
complexes are organized, at least in part, as supramolecular aggregates, characterization 
of the supercomplexes by biochemical functional analysis is still poor. The close 
proximity of the enzymes catalyzing consecutive reactions enables increased metabolic 
flow in the pathway by ensuring the substrate channeling of quinones and/or CytC and 
sequestration of reactive intermediates like ubisemiquinone, which can react with 
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oxygen to generate superoxide anion radical (Grivennikova and Vinogradov 2006; 
Schagger and Pfeiffer 2000). Kinetic testing using metabolic flux control analysis (see 
Chapter 3.4.3) can discriminate whether the enzyme complexes are independently 
embedded in the lipid bilayer of the inner membrane and connected by randomly 
diffusing mobile electron carriers or functions as the part of multicomplex units with 
direct electron channeling between complexes. The former model implies that each 
enzyme may be rate-controlling to a different extent, whereas in the latter, the whole 
metabolic pathway would behave as a single supercomplex and inhibition of any one of 
its components would elicit the same flux control. In bovine heart mitochondria 
particles and submitochondrial particles, both complexes I and III were found to be 
highly rate-controlling over NADH oxidation, a strong kinetic evidence suggesting the 
existence of functionally relevant association between the two complexes, whereas 
complex IV appears randomly distributed, indicating that electron transfer occurs via a 
random pool of CytC molecules. Moreover, complex II is fully rate-limiting for 
succinate oxidation, clearly indicating the absence of substrate channeling toward 
complexes III and IV (Bianchi et al. 2004). The presence of a large excess of free 
complex IV (Schagger and Pfeiffer 2001) is in line with this conclusion, however, this 
fact also prevents, using this approach, to exclude substrate channeling within those 
complex IV units that are bound in a respirasome. Interestingly, in yeast, where the 
majority of complexes III and IV is associated in form of III-IV supercomplex, overall 
quinol oxidase rate (rate of complexes III-IV) was significantly decreased after DDM 
treatment of digitonin-solubilized yeast mitochondria. Indeed, the decrease in quinol 
oxidase activity was observed in the same range of DDM as dissociation of 
supercomplexes III-IV was detected by BN-PAGE (Schagger and Pfeiffer 2000). Taken 
together, substrate channeling of electrons in bovine heart mitochondria, which was 
confirmed between complexes I and III, may occur also between complexes III and IV 
but is not required for electron transfer (Genova et al. 2008).  
In addition, the supercomplex assembly appears to play role in structural 
stabilization of individual complexes. Analysis of the structural integrity of human 
respirasomes in patients with defined defects of individual respiratory chain complexes 
(Schagger et al. 2004) provided evidence that a loss of complex III prevented 
respirasome formation and led to secondary loss of complex I, therefore primary 
complex III assembly deficiencies presented as combined complex III/I defects. 
Conversely, absence of complex I did not influenced stability of complex III. Also 
several other studies in mutants and patients suggested that complex III is involved in 
the assembly and stabilization of complex I (Acin-Perez et al. 2004; Blakely et al. 2005; 
Stroh et al. 2004). Moreover, Marques et al. (2007) studied biogenesis of complex I in 
Neurospora crassa using a collection of deletion mutants that can survive for the 
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presence of alternative NADH dehydrogenases. They found that the biogenesis of 
complex I is obligatorily linked with its assembly in supercomplexes. Furthermore, 
complex I of nuo51 mutant, that lacks the NADH-binding 51kDa subunit and is 
enzymatically inactive, is assembled into supercomplexes like those found in wild-type 
mitochondria, showing that a major function of supercomplex organization might be 
non-catalytic, but rather to direct assembly of the respiratory complexes (Marques et al. 
2007).  
Regarding structural relevance of complex IV for stability of complex I, the recent 
evidence is not so straightforward. In the study of Schagger et al. (2004), complex IV 
deficiency led to normal steady-state levels of complexes I and III (Schagger et al. 
2004). However, similar authors observed reduced stability of complex I under the 
conditions of BN-PAGE and substantial decrease in NADH-ubiquinone oxidoreductase 
activity in the mutant strain of Paracoccus denitrificans lacking complex IV (Stroh et 
al. 2004). Similarly, the total loss of CcO in a mouse COX10-knockout model (Diaz et 
al. 2006) as well as substantial decrease of CcO due to RNAi KD of Cox4 in murine 
cultured cells (Li et al. 2007) resulted in decreased stability and activity of complex I. 
Nevertheless, the knockdown of Cox4 and Cox5a in Caenorhabditis elegans led to 
enzymatic defect of complex I with otherwise normal amount of the assembled complex 
(Suthammarak et al. 2009). In contrast, the CcO deficiency in our COX4-, COX5A- and 
COX6A-KD cells did not lead to any significant changes in the amount and/or activity 
of other OXPHOS complexes, including complex I (Fornuskova et al. 2010). Similarly, 
normal levels and activity of complex I were also found in murine COX5BKD cells 
with severe CcO deficiency (Galati et al. 2009).  
Another aspect of supercomplex assembly concerns at what stage of biogenesis of 
respiratory complexes are the supercomplexes organized. In four Neurospora crassa 
deletion mutants of complex I membrane arm subunits nuo9.8, nuo11.5 and nuo20.8, 
2D BN-SDS immunoblots of digitonin-solubilized mitochondria detected that 
subcomplexes of peripheral arm containing at least the 30.4kDa subunit and 
accumulating in these samples comigrate with III/IV supercomplexes and/or the 
prohibitin complex, thus pointing to them as putative candidates for interaction partners 
(Marques et al. 2007). In another study, Mick et al. (2007) investigated the role of 
Shy1, the yeast homolog of human Surf1, in the assembly of complex IV from 
Saccharomyces cerevisiae by analyzing the nature of intermediate subcomplexes by gel 
electrophoresis. They found that complex IV associates with complex III already in the 
form of incomplete subcomplexes, and that some of the late assembled subunits are 
probably added directly to the III/IV supercomplex (Mick et al. 2007). An example of 
such a subunit is Cox13, the yeast homologue of human Cox6a (Brandner et al. 2005). 
We performed BN/BN-PAGE immunoblots in our CcO deficient samples with 
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knockdown of selected structural CcO subunits, including subunit Cox6a. In all 
samples, including controls, additional spots that migrated at the level of 
supercomplexes in the first dimension, but with apparent molecular masses lower than 
that of the CcO holoenzyme were detected. These spots were most apparent in COX5A-
KD mitochondria, which exhibited the most severe CcO holoenzyme defect and the 
highest accumulation of incomplete CcO assemblies (Fornuskova et al. 2010). Although 
we cannot exclude the removal of some of the peripheral subunits because of detergent 
treatment, these spots might represent incomplete CcO assemblies that are already 
present in supercomplexes. Collectively, subcomplexes resulting from pathological 
conditions as well as those accumulating in the mitochondria under physiological 
conditions seem to be capable, at least to some extent, to assemble into supercomplexes.  
 
3.4.2. Supramolecular organization of ATP synthase and pleiotropic 
effects of its dysfunction 
 
While prokaryotic ATP synthase is thought to occur exclusively as a monomer, 
mitochondrial ATP synthase adopts supramolecular structures that have been found in a 
large range of organisms. Originally, ATP synthases arrangements were observed by 
electron microscopy of deep-etched Paramecium mitochondria as a double row of 
particles, which form a zipper-like array along the outer curved margin of the helically 
shaped tubular cristae (Allen et al. 1989), however, the same approach failed to reveal a 
similar arrangement in mammalian specimens (Allen et al. 1989). Therefore, it was 
unclear whether or not the dimer ribbons were a special feature of ciliate mitochondria. 
Ten years later, rows of F1 parts were also seen by cryo-electron tomography of 
Neurospora crassa mitochondria (Nicastro et al. 2000) and then by atomic force 
microscopy in yeast (Buzhynskyy et al. 2007) and by cryo-tomography in rat and 
bovine mitochondria (Strauss et al. 2008) indicating that the ribbons of ATP synthase 
dimers are rather common to all eukaryotes. Furthermore, dimeric and occasionally 
higher oligomeric forms of ATP synthase were isolated with high yield by native gel 
electrophoresis after mild detergent treatment of mitochondrial membranes, first in 
yeast (Arnold et al. 1998) and later in mammalian (Schagger and Pfeiffer 2000) and 
plant (Eubel et al. 2003) mitochondria. A gentle separation by CN-PAGE, without the 
use of Coomassie stain, promotes the retention of even-numbered oligomers like 
tetramers, hexamers and octamers suggesting that oligomeric ATP synthase is formed 
from dimeric building blocks (Wittig and Schagger 2005). A higher digitonin/protein 
ratio, used for membrane solubilization, induces breakdown of the oligomers into 
dimers and monomers.  
Association between the two ATP synthases in a dimer occurs via the Fo parts 
which are linked together so that the dimer adopts a V-like structure. The dimer ribbons 
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seem to assemble from two dimer types assigned as “true dimer” and “pseudo dimer” 
(Dudkina et al. 2006). The former appears to be characterized by large angle (70-90°) 
between the ATP synthase monomers across both rows and the latter is characteristic by 
rather small angle (20-35°) made up of neighbors within a row (Vonck and Schafer 
2009; Wittig and Schagger 2009). In Saccharomyces cerevisiae, it has been shown that 
subunits e and g that are not involved in the ATPase or ATP synthase activity are 
essential actors for dimerization (Arnold et al. 1998) and oligomerization (Fronzes et al. 
2006). Both subunits are Fo components with a single transmembrane span (Belogrudov 
et al. 1996). Other components such as subunit 4, the homologous subunit to the b-
subunit of beef ATP synthase, and other proteins of the peripheral stalk are involved in 
vivo in the interactions between monomers (Fronzes et al. 2006; Gavin et al. 2005; 
Wittig and Schagger 2008).  
Deletion mutants of e and g not only lacked ATP synthase dimers but also had 
altered inner membrane morphology with the inner membranes forming onion-like 
structures. Thus, the association of ATP synthase dimers was strongly suggested to be 
involved in the control of the biogenesis of the inner mitochondrial membrane (Giraud 
et al. 2002; Paumard et al. 2002).  Strauss et al (2008) further characterized in bovine 
and rat mitochondria, that the dimer ribbons are associated with a sharp bend (∼ 60°) in 
the lipid bilayer implying that the ATP synthase arrays are a key factor in shaping 
cristae morphology (Strauss et al. 2008). Cristae are perhaps the most notable 
ultrastructural feature of active mitochondria. Numerical simulation indicates that, 
although the electrochemical potential must be the same along the entire inner 
membrane surface under equilibrium conditions, the local pH gradient, and hence the 
ΔpH contribution to the proton motive force is significantly higher in regions of high 
membrane curvature (Strauss et al. 2008). As the ΔpH contribution seems to be more 
effective than ΔΨ in driving ATP synthesis (Kaim and Dimroth 1999), this would 
suggest that a position of the ATP synthase at the apex of mitochondrial cristae is 
optimal for ATP production.  
ATP synthase is fundamentally dependent on the phosphate (PIC) and adenine 
nucleotide (AAC) carriers (Kaplan 2001), which are responsible for transport of Pi and 
ADP, the substrates for ATP synthesis, to the mitochondrial matrix (see Chapter 3.3.3). 
Each carrier consists of a single polypeptide chain in dimeric form and both were found 
to sub-fractionate under the mild conditions in complex with ATP synthase as ATP 
synthase/PIC/AAC supercomplex of 1:1:1 stoichiometry named also as “ATP 
synthasome” (Ko et al. 2003). A likely location of PIC and AAC is adjacent to one 
another and although they are near the more centrally located subunit c ring of ATP 
synthase Fo part, do not overlap with it (Chen et al. 2004).  
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In some yeast mutants of complex V subunits, combined deficiencies in 
complexes IV and V were found. The complex IV was affected more than the other 
respiratory enzymes in strains with mutation in ATP4 (Paul et al. 1989), ATP6 (Choo et 
al. 1985), ATP8 (Marzuki et al. 1989), ATP9 (Hadikusumo et al. 1988) or ATP17 
(Spannagel et al. 1997), however, high level of petite production, i. e. cells bearing 
large deletions in the mtDNA or totally lacking mtDNA, rendered the interpretation 
difficult. More recently, Δatp6 (Rak et al. 2007), Δatp1 and Δatp2 (Marsy et al. 2008) 
mutant strains with minimal petite production also showed substantial decrease in the 
accumulation of complex IV. Interestingly, no decrease in complex IV levels was 
observed in uncoupled complex V mutants of ATP3, ATP16 or ATP15 genes (coding 
for subunits γ, δ and ε, respectively) where maintenance of a mitochondrial potential 
was found to be severely compromised by massive proton leaks through the Fo 
(Duvezin-Caubet et al. 2003; Guelin et al. 1993; Xiao et al. 2000). Therefore, it was 
hypothesized that reduction of the amount of complex IV would be observed only in 
complex V mutants unable to dissipate the proton gradient. Indeed, blocking proton 
translocation in wild-type yeast cells with use of oligomycin also induced a strong 
quantitative deficit in complex IV, which was reversible when the cells were returned to 
an oligomycin-free medium (Marsy et al. 2008).  
In tightly coupled mitochondria, the oxygen consumption rate and ATP synthesis 
activity depend on each other (Kadenbach 2003). The first mechanism of respiratory 
control suggest that an uptake of ADP into mitochondria stimulates the ATP synthase, 
thereby decreasing proton motive force, which in consequence stimulates the activity of 
the three proton pumps and thus mitochondrial respiration (Nicholls and Ferguson 
2002); the proton pumps are inhibited at high membrane potential (150-200 mV). The 
second mechanism of respiratory control, however, involves allosteric inhibition of 
cytochrome c oxidase by ATP at high intramitochondrial ATP/ADP ratios (Arnold and 
Kadenbach 1997; Kadenbach and Arnold 1999) which is suggested to keep in vivo the 
mitochondrial membrane potential at low values (Lee et al. 2001), close to optimal 
values for the synthesis of ATP by the ATP synthase (100-140mV) (Kaim and Dimroth 
1999). Thus in the system with minimal or no activity of ATP synthase, low energy 
provision (low ATP) can presumably stimulate cytochrome c oxidase activity, which in 
turn increases membrane potential without its dissipation by ATP synthase. At high 
mitochondrial membrane potentials (>140 mV), an exponential increase of 
mitochondrial ROS production occurs (Korshunov et al. 1997; Liu 1999), which could 
be prevented by an uncoupler treatment (Houstek et al. 2004). High membrane potential 
across the inner membrane would also hamper import of glycolytic ATP into 
mitochondria unable to perform oxidative phosphorylation (Brustovetsky et al. 1996), 
since this is an electrogenic reaction exchanging four against three negative charges by 
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reversal of the ADP/ATP translocase (see Chapter 3.3.3.1). Defective OXPHOS 
presumably tends to lower the respiratory chain in attempt to prevent either a too high 
membrane potential or the accumulation of reduced intermediary components of the 
respiratory chain. In accordance with the second mechanism of respiratory control, the 
pleiotropic effects of severe complex V deficiency are mainly striking for complex IV. 
In human skin fibroblasts from Leigh patients with ATP synthase deficiency due 
to mtDNA 8993T>C heteroplasmic mutation (>95%) in ATP6 gene, the pleiotropic 
effects similar to those observed in yeast mutants with ATP synthase deficiency (Rak et 
al. 2007) were absent (Marsy et al. 2008). In our study, we investigated impact of 
mitochondrial tRNA mutations on the amount and stability of OXPHOS in various 
tissues including skeletal muscle, heart, frontal cortex and liver (Fornuskova et al. 
2008). In skeletal muscle and heart, the patterns of OXPHOS deficiencies were typical 
for mutations affecting mt-tRNALeu(UUR) and mt-tRNALys with respect to abundance of 
respective codons in mitochondrially-translated subunits of OXPHOS, i. e. isolated 
defect of complex I in the patient with a mutation in mt-tRNALeu(UUR) and combined 
severe deficiency of complexes I and IV in patients with mutations in mt-tRNALys 
(complex V was also significantly decreased, albeit less than complexes I and IV). 
Accordingly, immunoblotting of BN/SDS/PAGE in skeletal muscle of patient with 
dysfunctional mt-tRNALys detected the level of free S1 subcomplex (related to free 
mtDNA-encoded subunit Cox1 of complex IV with most abundant AAR codons 
specific for Lys) to be below the detection limit of the method what very likely reflected 
the limiting character of this subunit in the holoenzyme assembly and clearly 
demonstrated aberrant CcO assembly due to dysfunction of mt-tRNALys. However, in 
frontal cortex mitochondria of both types (with affected mt-tRNALeu(UUR) as well as mt-
tRNALys), the patterns of OXPHOS deficiencies differed substantially from those 
observed in other tissues, what was particularly striking for ATP synthase. Surprisingly, 
in the frontal cortex of the patient with mutation in mt-tRNALeu(UUR), whose ATP 
synthase level was below the detection limit, the assembly of complex IV appeared to 
be hindered by some factor other than the availability of mtDNA-encoded subunits, 
based on the massive accumulation of all three mitochondrially encoded subunits, either 
free or partially assembled. Although the Cox1 subunit was shown to be a key 
regulatory target for CcO reduction in yeast cells (Rak et al. 2007), hindered CcO 
assembly in frontal cortex of our patient (Fornuskova et al. 2008) employing other 
mechanism might be comparable to pleiotropic (presumably protective) effects of very 
severe ATP synthase deficiencies observed in yeast mutants (Marsy et al. 2008; Rak et 
al. 2007).  
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3.4.3. Tissue-specific physiological diversity of OXPHOS  
 
Mitochondria of various tissues exhibit large diversity in mitochondrial shape and 
organization with an important variability of organellar section profile, intracellular 
localization and heterogeneity (Benard et al. 2006). Accordingly, the different tissues 
present with large differences in the composition of the OXPHOS machinery and the 
organization of mitochondria, which could reflect their variable physiological activity.  
The tissue specific nature of mitochondria was proposed to contribute to the observed 
tissue variation in the control of oxidative phosphorylation, which was studied by 
metabolic flux control analysis (MCA). MCA is usually performed by titrating the 
whole respiratory chain activity (global flux) and its single steps with inhibitors of the 
individual complexes thus quantitatively expressing the effect of a pertubation of a step 
on a flux. It allows determination of control coefficients or threshold curves. The 
control coefficients are calculated from the measured per cent changes in the enzyme 
activities upon the addition of a small concentration of specific inhibitors (Groen et al. 
1982; Rossignol et al. 2000). In the case of the threshold curves, each point represents 
the respiratory rate inhibition percentage as a function of inhibition percentage of the 
isolated step activity for the same inhibitor concentration. The threshold curves exhibit 
two types according to their profile (Mazat et al. 2000). Type I threshold curves present 
a large plateau phase followed by a steep breakage allowing a precise determination of 
the threshold value, whereas in type II, a plateau is no longer apparent and the threshold 
value is hardly defined. Threshold curve profiles can be explained by an excess of 
enzyme activity that accounts for the plateau phase of type I threshold curves. 
Conversely, in the case of no excess of enzyme activity, the isolated step inhibition will 
have a direct effect on the flux (type II profile), so the threshold curve will no longer 
have a plateau phase. Type I threshold curves for complexes I and III and type II 
threshold curves for oxidative phosphorylation network (ATP synthase, AAC, PIC) 
were observed in mitochondria originated from various rat tissues (muscle, heart, brain, 
liver and kidney). Complex IV presented the two profiles according to the tissue with a 
type I in the liver, the brain and the kidney and a type II in the muscle and the heart 
(Rossignol et al. 1999). The authors proposed two tissue groups, each characterized by 
similar threshold values (determined from threshold curves). The first group included 
the muscle and the heart and the second group encompassed the kidney and the brain. 
The liver could be associated to either one or the other of these two groups according to 
the complex considered. Based on the control coefficient distribution, two slightly 
different tissue groups were obtained by the same authors (Rossignol et al. 2000). The 
muscle and the heart on the one hand, controlled essentially at the level of the 
respiratory chain and the liver, the kidney and the brain on the other hand, controlled 
mainly at the phosphorylation level by ATP synthase and the phosphate carrier. Indeed, 
47 
when we studied tissue-specific impact of mt-tRNA mutations with comparable tissue 
heteroplasmy on OXPHOS deficiency patterns using Western immunoblotting, the 
observed steady-state levels of OXPHOS complexes suggested that the brain ATP 
synthase is most sensitive to disturbances of the mitochondrial translational system, 
however, in the skeletal muscle and the heart, steady-state levels of respiratory chain 
complexes I (and IV) were most severely affected. In skeletal muscle and heart, the 
preferential deficiency of complex I and also IV is in line with the particular abundance 
and distribution of codons for affected mt-tRNAs in mitochondrially-translated subunits 
of these complexes (Fornuskova et al. 2008). 
Finally, when the tissue diversity of OXPHOS was considered also based on 
mitochondrial morphology, overall mitochondrial content, relative and absolute content 
of respiratory chain complexes II, III an IV, their kinetics and stoichiometry with 
respective substrate as well as global functioning of the respiratory chain, three groups 
of tissues were obtained. The first group, skeletal muscle and heart, presented with the 
highest OXPHOS capacity and a low resistance against the occurrence of respiratory 
chain perturbation. The second group, liver and kidney, was characterized by a lower 
OXPHOS capacity and a lower sensitivity to OXPHOS defects. The third group, which 
contained solely the brain, was between the first and the second group regarding the 
OXPHOS capacity and flux response (Benard et al. 2006).  
Taken together, oxidative phosphorylation capacity is highly variable and diverse 
in tissues. It appaers to be determined by different combinations of the mitochondrial 
content, the amount of respiratory chain complexes and their intrinsic activity. Tissue 
specificity of these parameters can partly explain the tissue specificity of mitochondrial 
deficiencies.   
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4     MATERIAL  AND  METHODS  
 
4.1. Tissues and cell lines 
Human samples for analyses were obtained from patients with mtDNA 
microdeletion 9205ΔTA, from three patients harboring two mutations in mt-tRNALys 
(8363G>A and 8344A>G) or one mutation in mt-tRNALeu(UUR) (3243A>G), as well as 
from age-related controls. Open muscle biopsies from the tibialis anterior muscle were 
frozen at -80°C. Post-mortem tissue specimens obtained at autopsy of patients with 
mtDNA mutations 8363G>A and 3243A>G, and controls were frozen less than 2 h after 
death. The studies were performed in available stored material from the muscle (tibialis 
anterior), heart, liver, and brain (frontal cortex). Fibroblast cultures were established 
from skin biopsies. HEK-293 cells (CRL-1573) were obtained from A.T.C.C. 
(Manassas VA, U.S.A.). 
 
4.2. Ethics 
All studies were carried out in accordance with the Declaration of Helsinki of the 
World Medical Association and were approved by the Committees of Medical Ethics at 
all collaborating institutions. Informed consent was obtained from investigated 
individuals or their parents. 
 
4.3. Plasmid construction 
The nucleotide sequences of 33 different candidate miR-30-based shRNAs 
[shRNAmirs (microRNA-adapted shRNAs)] targeted to COX4I1, COX5A and 
COX6A1 mRNAs were designed with shRNA Retriever (http://katahdin.cshl.org/ 
siRNA/RNAi.cgi?type=shRNA). The nucleotide sequences of eight different 
shRNAmirs targeted to the coding sequence of human OXA1L were downloaded from 
the publicly accessible RNAi Codex database (Olson et al. 2006). The corresponding 
97-mer oligonucleotides were synthesized (Invitrogen) and used as template sequences 
for PCR amplification to produce clonable double-stranded products. The 
corresponding XhoI/EcoRI restriction fragments were inserted downstream of the 
CMV-GFP-IRESNeo expression cassette of the lentiviral pCMV-GIN-Zeo vector 
(Open Biosystems). The negative control (non-silencing) shRNAmir pCMV-GIN-Zeo 
derivative was obtained from Open Biosystems. The coding sequences of COX7A2 
(IMAGE ID: 40002220) and COX7B (IMAGE ID: 3861730) were amplified from the 
respective full-length cDNA clones (ImaGenes), fused to the C-terminal FLAG epitope 
and cloned (EcoRI/NotI) into the modified pmaxFP-Red-N plasmid (Amaxa). The full 
length human OXA1L coding sequence (IMAGE ID: 40017377) was amplified and 
inserted into the C-FLAG fusion mammalian expression vector pCMV-Tag4a 
(Stratagene). The fidelity of all constructs was confirmed by automated DNA 
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sequencing. Plasmids pReceiver-M02 (EXC0224) and pReceiver-M13 (EX-C0224) 
(GeneCopoeia) were used to express Cox6a2 and Cox6a2–FLAG respectively. 
 
4.4. Cell culture, transfections and flow cytometry 
Fibroblast cultures were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% (v/v) fetal calf serum (Sigma) at 37°C in 5% CO2. Cells were 
grown to ∼90% confluence and harvested using 0.05% (w/v) trypsin and 0.02% (w/v) 
EDTA. Detached cells were diluted with an ice-cold culture medium, sedimented by 
centrifugation and washed twice in PBS (Sigma). 
HEK-293 cells were grown at 37°C in a 5% (v/v) CO2 atmosphere in high-glucose 
Dulbecco’s modified Eagle’s medium (PAA) supplemented with 10% (v/v) fetal bovine 
serum Gold (PAA). Cell lines stably expressing shRNAmir were prepared using the 
NucleofectorTM device (Amaxa) and the HEK-293 cell-specific transfection kit. At 48 h 
after the transfection the cells were split into culture medium containing 720 μg/ml of 
G418 sulfate (Clontech) and antibiotic-resistant colonies were selected over a period of 
three weeks. The cells were further maintained in the presence of 720 μg/ml G418. 
The GFP fluorescence of stable G418-resistant HEK-293 cells was measured with 
a FACSCalibur flow cytometer and analyzed using the Cell Quest 3.3 application 
(Becton Dickinson). 
The transient expression of Oxa1l or selected CcO subunits in HEK-293 cells was 
accomplished using the Lipofectamine 2000 reagent (Invitrogen) or the Express-In 
Transfection Reagent (Open Biosystems). To obtain optimal accumulation of the CcO 
subunit polypeptides, the cells were transfected twice consecutively, leading to 
transgene expression for a total of 4 days. 
To assess the efficiency of the shRNAmir constructs interfering with OXA1 
transcripts, HEK-293 cells were co-transfected using a Nucleofector™ device with 
either one of the eight OXA1L-targeted shRNA constructs or the negative control (non-
silencing) shRNA construct and with the OXA1L-FLAG expression construct. At 48 h 
after the transfection, the cells were lysed and the expression level of the Oxa1l-FLAG 
fusion protein was examined by immunoblot analysis. The three OXA1L-targeted 
constructs that contained shRNA 1 (mp_id 433861, 5′-CAAGTTAGCAGGAGACCAT-
3′), shRNA 2 (mp_id 19616, 5′-CCTACAACCTGGAAAGGAT-3′) and shRNA 3 
(mp_id 19615, 5′- GAGACCATATTGAGTATTA-3′) (RNAi Codex) showed the 
highest potential to interfere with the expression of Oxa1l-FLAG protein in the transient 
assay. For the generation of stable transfectants, HEK-293 cells (106) were transfected 
using a Nucleofector™ device with the three functionally validated OXA1L-targeted 
shRNA constructs, the negative control (non-silencing) shRNA construct and with the 
empty vector. 
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4.5. Isolation of mitochondria 
Mitochondria were isolated from fibroblasts by a hypo-osmotic shock method 
(Bentlage et al. 1996). The freshly harvested cells were disrupted in 10 mM Tris buffer 
(pH 7.4) and quickly homogenized in a Teflon/glass homogenizer at 4°C. Sucrose was 
added to a final concentration of 0.25 M immediately after homogenization. The nuclei 
were removed by centrifugation for 10 min at 4°C and 600 g and the mitochondrial 
fraction was isolated from the postnuclear supernatant by centrifugation for 10 min at 
4°C and 10 000 g. The mitochondrial pellet was washed and finally resuspended in 
0.25 M sucrose, 2 mM EGTA, 40 mM KCl and 20 mM Tris, pH 7.4, and stored at 
-70°C. Mitoplasts were prepared from fibroblasts as described previously (Klement et 
al. 1995). In brief, trypsinized cells suspended in isotonic STE medium [0.25 M 
sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, 1% (w/v) Protease inhibitor cocktail 
(Sigma)] were treated with digitonin (0.4 mg/mg of protein; Fluka) on ice for 15 min. 
The suspension was diluted 10-fold with STE and centrifuged for 10 min at 4°C and 
12 000 g. The pellet was washed by centrifugation and resuspended in STE to a final 
concentration of 1–2 mg of protein/ml. Based on immunodetection and enzyme activity 
measurements, >95% of the mitochondrial inner membrane proteins were recovered in 
this fraction.  
To isolate mitochondria from HEK-293 cells, collected and thawed cells were 
resuspended in STE buffer, homogenized in a glass/glass homogenizer at 4°C. 
Unbroken cells and nuclei were removed by centrifugation for 15 min at 4°C and 600 g 
and the mitochondrial fraction was isolated from the postnuclear supernatant by 
centrifugation for 25 min at 4°C and 10 000 g. The mitochondrial pellet was washed, 
resuspended in STE buffer (2.5 volume of the mitochondrial pellet) and stored at -80°C. 
Muscle mitochondria were isolated according to (Schagger and von Jagow 1991), 
but without use of protease. Tissue samples were homogenized at 4°C in a KCl medium 
(100 mM KCl, 50 mM Tris, 2 mM EDTA, 10 mg/ml aprotinin, pH 7.5). The 
homogenate was centrifuged for 10 min at 4°C and 600 g, the supernatant was filtered 
through a 100 μm nylon screen, and mitochondria were sedimented by centrifugation 
for 10 min at 4°C and 10 000 g. The mitochondrial pellet was washed by centrifugation 
and resuspended to a final protein concentration of 20-25 mg/ml. 
 
4.6. Immunofluorescence 
HEK-293 cells (1.5×105) grown on 70 mm2 glass chamber slides (BD Falcon) 
were transfected with an OXA1L–FLAG expression construct using the Lipofectamine 
2000 reagent. At 24 h after the transfection, the cells were incubated with 200 nM 
MitoTracker Red CMX Ros (Molecular Probes) for 15 min, and then fixed and 
permeabilized with PBS, 4% (v/v) paraformaldehyde and 0.1% (v/v) Triton X-100 
solutions, respectively. Subsequently, the cells were incubated in PBS containing 
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10% (w/v) BSA for 1 h at 37°C to block non-specific binding. Immunocytochemical 
detection was then performed with a monoclonal M2 anti-FLAG antibody (1:1000) and 
with an anti-mouse IgG1 Alexa Fluor® 488 antibody (1:500). 
 
4.7. Laser scanning confocal microscopy 
xyz images sampled according to the Nyquist criterion were acquired using a 
Nikon Eclipse TE2000 microscope equipped with a C1si confocal scanning head and an 
Apo TIRF 60× (N.A. 1.49) objective. The 488 nm and 543 nm laser lines and 
appropriate 515±15 and 590±15 nm band pass filter sets were used for excitation and 
fluorescence detection, respectively. Individual channel images were acquired 
separately. Images were restored using the measured point spread function (PSF) and 
the classic maximum likelihood deconvolution algorithm in Huygens Professional 
Software (SVI). 
 
4.8. Sub-cellular and submitochondrial fractionation 
The postnuclear supernatant from 107 HEK-293 cells (see Chapter 4.5) was 
centrifuged at 10 000 g for 25 min to pellet the mitochondria. The resulting supernatant 
corresponding to the cytoplasmic fraction was collected, and the mitochondrial pellet 
was washed once with STE buffer. For sonical disruption, isolated mitochondria were 
adjusted to a protein concentration of 2.5 mg/ml, sonicated and centrifuged at 100 000 g 
for 30 min. Alkaline sodium carbonate extraction of mitochondrial membranes was 
performed essentially as described (Fujiki et al. 1982). 
 
4.9. Preparation of a polyclonal antibody to human Oxa1l 
An Oxa1l-specific antibody was prepared by Open Biosystems. An Oxa1l-specific 
antiserum was generated by immunizing chicken with a synthetic peptide (KLH-
coupled) corresponding to the C-terminal part of human Oxa1l (CKPKSKYPWHDT). 
The polyclonal antibody to human Oxa1l was affinity-purified from the total IgY with 
the respective peptide-packed column. The specificity of the produced antibody was 
tested by immunodetection of the Oxa1l-FLAG fusion protein. 
 
4.10. Electrophoresis and Western blot analysis 
In cultured skin fibroblasts, BN-PAGE (Schagger and von Jagow 1991) was used 
for the separation of native mitochondrial OXPHOS complexes on 6–15% (w/v) 
polyacrylamide gradient minigels (Mini Protean system; Bio-Rad) as described 
previously (Klement et al. 1995). Mitoplasts were pelleted by centrifugation for 10 min 
at 4°C and 10 000 g, and solubilized using 1 g of DDM/g of protein for 20 min on ice in 
a buffer containing 1.75 M aminocaproic acid, 2 mM EDTA and 75 mM Bis-Tris (pH 
7.0). Samples were centrifuged for 20 min at 20 000 g and Serva Blue G dye was added 
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to collected supernatants at a concentration of 0.1 g/g of detergent. Electrophoresis was 
performed at 50 V for 30 min and then at 90 V. SDS/PAGE (Schagger and von Jagow 
1987) was performed on 10% (w/v) polyacrylamide slab minigels, and analysis of 
[35S] methionine-labelled proteins was performed on a 16 cm long 15-20% (w/v) 
gradient polyacrylamide slab gels (Protean system; Bio-Rad). The samples were boiled 
for 3 min in sample lysis buffer [2% (v/v) mercaptoethanol, 4% (w/v) SDS, 10 mM 
Tris/HCl, 10% (v/v) glycerol]. For 2D analysis, strips of the first-dimension BN-PAGE 
gel were incubated for 1 h in 1% (w/v) SDS and 1% (v/v) mercaptoethanol and then 
subjected to SDS/PAGE (10% polyacrylamide) for separation in the second dimension 
(Schagger and von Jagow 1987). Gels were blotted onto Hybond C-extra nitrocellulose 
membranes (Amersham) by semi-dry electrotransfer for 1 h at 0.8 mA/cm2 and the 
membrane was blocked in PBS containing 0.2% (v/v) Tween 20. The membranes were 
used whole or were cut according to molecular mass markers into portions containing 
individual OXPHOS complexes or their subunits. Membranes were incubated for 3 h 
with primary antibodies diluted in PBS containing 2% (w/v) BSA. Previously 
characterized polyclonal antibodies were used at the indicated titres: those against the 
Foc subunit of ATPase (1:900) (Houstek et al. 1995a) and those against the Foa (ATP6) 
subunit of ATPase (1:500) (Dubot et al. 2004). In addition, we used monoclonal 
antibodies against complex IV subunits Cox1 (1:330), Cox4 (1:670) and Cox6c (1:200), 
complex I subunit NADH39 (1:250) and the 70 kDa flavoprotein subunit of SDH 
(SDHA) (1:2000), all obtained from Molecular Probes, as well as subunit F1-α of 
ATPase (1:200 000 (Moradi-Ameli and Godinot 1983). Incubation with peroxidase-
labelled secondary antibodies in PBS with 2% (w/v) BSA was performed for 1 h using 
either goat anti-mouse IgG (1:1000; Sigma A8924) or goat anti-rabbit IgG (1:1000; 
Sigma F0382). The chemiluminescence reaction with an ECL® kit (Amersham) was 
detected on an LAS 1000 instrument (Fuji) and the signal was quantified using Aida 
2.11 Image Analyzer software. 
In bioptic or autoptic tissues, proteins were electroblotted from the gels onto 
Immobilon™-P PVDF membranes (Millipore) using semi-dry transfer for 60-90 min at 
a constant current of 0.6-0.8 mA/cm2. Membranes were air-dried overnight, rinsed twice 
with 100% (v/v) methanol, and blocked in TBS and 10% (w/v) non-fat dried milk for 
1-2 h. Primary detection of BN/PAGE-blots was performed with mouse monoclonal 
antibodies raised against the complex I subunit NDUFA9 (2 μg/ml), ATP synthase 
subunit F1-α (2-3 μg/ml), complex III subunit Core2 (0.5 μg/ml), complex IV subunit 
Cox2 (0.5–1 μg/ml), and complex II subunit 70 kDa protein (1 μg/ ml) (Mitosciences), 
at indicated dilutions. Primary detection of two-dimensional BN/SDS/PAGE-blots for 
the CcO assembly was performed as described previously (Stiburek et al. 2005). Blots 
were incubated with primary antibodies in TBS, 0.3% (v/v) Tween 20 and 2% non-fat 
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dried milk for 2 h. Secondary detection was carried out with a goat anti-mouse IgG-
horseradish peroxidase conjugate (1:1000–1:4000; Sigma A8924) in TBS, 0.1% 
Tween 20 and 2% non-fat dried milk, for 1 h. The immunoblots were developed with 
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Signal acquisition 
was performed using either a VersaDoc 4000 imaging system (Bio-Rad Laboratories) or 
Kodak BioMax Light films (Eastman Kodak Co.). Digital images were analyzed using 
the Quantity One application (Bio-Rad Laboratories). All blotting experiments were 
repeated with independently isolated mitochondrial samples. Duplicate experiments 
yielded consistent results. 
In HEK-293 cells, protein sample preparations, electrophoresis, immunoblot 
analysis and signal acquisition for SDS, BN (blue native) and BN/SDS/PAGE 
immunoblot analysis were performed essentially as described above for bioptic and 
autoptic tissues.  Monoclonal antibodies against the mitochondrial outer membrane 
protein porin, CcO subunits Cox1, Cox2, Cox4, Cox5a, Cox6a1 and Cox6c, the 70 kDa 
flavoprotein subunit of SDH (SDHA), complex III subunit Core2, complex I subunits 
NDUFA9 and NDUFB6, complex V subunits F1-α, F1-β, subunit d and OSCP, and 
pyruvate dehydrogenase (PDH) subunit E2 were obtained from Mitosciences. The 
mouse monoclonal antibody to mtHSP70 was from Alexis Biochemicals. Polyclonal 
antibodies to α-tubulin and eIF2α were from Cell Signaling Technology, and the 
monoclonal anti-FLAG antibody was from Sigma. For analysis of respiratory 
supercomplexes by BN/SDS/PAGE and BN/BN/PAGE, isolated mitochondria were 
extracted using digitonin (detergent/protein ratio of 6). Primary detection of 
BN/SDS/PAGE and BN/BN/PAGE immunoblots was performed with mouse 
monoclonal antibodies (Mitosciences) raised against the complex I subunit NDUFB6, 
complex III subunit Core1 and complex IV subunit Cox1. The first dimension gel strips 
for BN/BN/PAGE immunodetection were soaked in cathode buffer containing 0.1% 
DDM for 15 min and then in cathode buffer containing 0.02% DDM for another 15 min. 
The second dimension of BN-PAGE separation was performed in the presence of 0.02% 
DDM as described in (Wittig et al. 2006). 
 
4.11. Immunoprecipitation of Oxa1l–FLAG protein 
HEK-293 cells (∼106) were transiently (48 h) transfected with the Oxa1l–FLAG 
expression construct, lysed with a buffer containing 1% Triton X-100, 150 mM NaCl, 
1 mM EDTA and 50 mM Tris/HCl (pH 7.4), and the lysate was incubated for 6 h at 4°C 
with previously washed 50 μl of an ANTI-FLAG® M2 affinity agarose resin (flagipt-1; 
Sigma). Subsequently, the resin was washed five times with a buffer containing 
150 mM NaCl, 50 mM Tris/HCl (pH 7.4), and the bound protein was eluted by 
competition with 3× FLAG peptide. Finally, the eluted immunoprecipitate was 
combined with SDS sample buffer and resolved using SDS/PAGE. 
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4.12. Spectrophotometric assays 
The activities of respiratory chain complexes were measured 
spectrophotometrically with a UV-2401PC instrument (Shimadzu). The activities of the 
mitochondrial enzymes NADH:coenzyme Q10 reductase (NQR, complex I), 
succinate:coenzyme Q10 reductase (SQR, complex II), succinate:cytochrome c reductase 
(SCCR, complex II+III), NADH:cytochrome c reductase (NCCR, complex I+III), 
coenzyme Q10:cytochrome c reductase (QCCR, complex III), and cytochrome c oxidase 
(COX, CcO, complex IV) were measured spectrophotometrically by standard methods 
at 37°C in muscle homogenate and isolated muscle mitochondria (Fischer et al. 1986; 
Makinen and Lee 1968) or in cultured fibroblasts (Chowdhury et al. 2000). In HEK-293 
cells, rotenone-sensitive complex I activity (NADH:ubiquinone oxidoreductase) was 
measured by incubating 45 μg of mitochondrial protein in 1 ml of assay medium 
(50 mMTris/HCl, pH 8.1, 2.5 mg/ml BSA, 50 μM decylubiquinone, 0.3 mM KCN and 
0.1 mM NADH without or with 3 μM rotenone). The decrease in absorbance at 340 nm 
due to the NADH oxidation was followed. Complex II activity (succinate:2,6-
dichloroindophenol oxidoreductase) was measured by incubating 20 μg of 
mitochondrial extract in 1 ml of assay medium (10 mM potassium phosphate, pH 7.8, 
2 mM EDTA, 1 mg/ml BSA, 0.3 mM KCN, 10 mM succinate, 3 μM rotenone, 0.2 mM 
ATP, 80 μM 2,6-dichloroindophenol, 1 μM antimycin and 50 μM decylubiquinone). 
The decrease in absorbance at 600 nm due to the reduction of 2,6-dichloroindophenol 
was monitored. CcO activity was measured by incubating 15–18 μg of mitochondrial 
protein in 1 ml of assay medium (40 mM potassium phosphate, pH 7.0, 1 mg/ml BSA, 
25 μM reduced cytochrome c and 2.5 mM DDM) and the oxidation of cytochrome c (II) 
at 550 nm was monitored. All assays were performed at 37°C. The total protein was 
determined using the method of Lowry (Lowry et al. 1951). 
Aurovertin-sensitive ATP hydrolytic activity was measured in a ATP-regenerating 
system as described in (Baracca et al. 1989). Mitochondria (8-22 μg of protein/ml) were 
incubated in a medium containing 40 mM Tris (pH 7.4), 5 mM MgCl2, 10 mM KCl, 
2 mM phosphoenolpyruvate, 0.2 mM NADH, 1 μg/ml rotenone, 0.1% (w/v) BSA, 
5 units of pyruvate kinase and 5 units of lactate dehydrogenase for 2 min. The reaction 
was started by the addition of 1 mM ATP and the rate of NADH oxidation, equimolar to 
ATP hydrolysis, was monitored as the decrease in absorbance at 340 nm. Sensitivity to 
aurovertin was determined by parallel measurements in the presence of 2 μM inhibitor. 
 
4.13. High-resolution oxygraphy 
Oxygen consumption in cultured fibroblasts was determined at 30°C as described 
in (Chowdhury et al. 2000; Pecina et al. 2003) using an Oxygraph-2k (Oroboros). 
Freshly harvested fibroblasts were suspended in a KCl medium (80 mM KCl, 10 mM 
Tris/HCl, 3 mM MgCl2 , 1 mM EDTA, 5 mM potassium phosphate, pH 7.4) and cells 
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were permeabilized by digitonin (0.1 mg of detergent/mg of protein). Respiratory 
substrates and inhibitors were used at the concentrations indicated. Oxygen 
consumption was expressed in pmol of oxygen/s per mg of protein. CcO activity was 
measured with 5 mM ascorbate and 1 mM TMPD, and was corrected for substrate 
autooxidation (determined as oxygen uptake insensitive to 0.33 mM KCN). 
Muscle fibers were separated mechanically according to (Kunz et al. 1993), and 
oxygen consumption by saponin-skinned muscle fibers was determined using multiple 
substrate inhibitor titrations as described (Wenchich et al. 2003). 
The oxygen consumption of digitonin-permeabilized HEK-293 cells was 
measured at 30°C using an OROBOROS Oxygraph (Anton Paar) in a medium 
containing 0.5 mM EGTA, 3 mM MgCl2, 60 mM potassium lactobionate, 20 mM 
taurine, 10 mM KH2PO4, 110 mM sucrose, 1 g/l BSA, 20 mM Hepes (pH 7.1). The 
measurements were carried out in the presence of 30-75 μg/ml of digitonin, 2.5 μM 
antimycin A, 2 mM ascorbate, 500 μM TMPD and 0.5-1.5 μM FCCP. Respiration was 
inhibited by the addition of sodium azide to a final concentration of 10 mM. The P50 
(partial pressure of oxygen at the half-maximal respiration rate) value was measured in 
the presence of 0.5 μM FCCP and 10 mM succinate essentially as described in (Pecina 
et al. 2004). All measurements were performed independently three to six times for 
each cell line. 
 
4.14. Cytofluorimetric analysis of mitochondrial membrane potential 
Freshly harvested fibroblasts were resuspended in 80 mM KCl, 10 mM Tris/HCl 
(pH 7.4), 3 mM MgCl2, 1 mM EDTA, 5 mM potassium phosphate and 10 mM succinate 
at a protein concentration of 1 mg/ml. Cells (∼104 per each measurement) were 
permeabilized by 0.1 mg digitonin per mg protein (Sigma) and stained with 20 nM 
TMRM (Molecular Probes) for 15 min at room temperature.  ADP, inhibitors, or both 
were added at indicated concentrations 1 min before cytofluorometric measurements, 
which were performed as described elsewhere (Floryk and Houstek 1999) on a FACSort 
flow cytometer (Becton Dickinson) equipped with an argon laser, 488 nm. The TMRM 
signal was analyzed in the FL2 channel, equipped with a band pass filter 585±21 nm; 
the photomultiplier value of the detector was at 631 V in FL2. Data were acquired in log 
scale using CellQuest (Becton Dickinson) and analyzed with WinMDI 2.8 software 
(TSRI). Arithmetic mean values of the fluorescence signal in arbitrary units were 
determined for each sample for the purpose of subsequent graphic representation. 
 
4.15. ATP synthesis 
The rate of ATP synthesis was measured at 37°C in 150 mM KCl, 25 mM 
Tris/HCl, 10 mM potassium phosphate, 2 mM EDTA and 1% (w/v) BSA, pH 7.2, using 
0.5 mM ADP and 10 mM succinate or 10 mM pyruvate + 10 mM malate (or 
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ketoglutarate + malate) as substrate, as described previously (Wanders et al. 1996). 
Protein concentration was 1 mg/ml. For permeabilization of fibroblasts and cybrids, 0.1 
and 0.03 mg of digitonin/mg of protein, respectively, was used. The reaction was started 
by addition of the cells and performed for the indicated time intervals. Reaction mixture 
aliquots of 200 μl were added to 200 μl of DMSO, and ATP content was determined in 
DMSO-quenched samples by a luciferase assay according to (Ouhabi et al. 1998). ATP 
production was expressed in nmol of ATP/min per mg of protein. 
 
4.16. Biosynthesis of mitochondrial proteins 
Growth medium was removed from cultured fibroblasts, and the cells were rinsed 
with methionine-free medium without serum (Gibco medium 21013; 1 mM pyruvate, 
2 mM glutamine and 30 mg/l cysteine) and incubated in the same medium containing 
10% (v/v) dialysed fetal calf serum and 100 μg/ml emetine for 10 min. The cells were 
labelled for 3 h with 300 μCi/ml L-[35S] methionine, as described in (Chomyn 1996). 
The products were separated by 15-20% (w/v) polyacrylamide gradient SDS-PAGE. A 
small aliquot of the samples prepared for electrophoresis was used to measure the total 
incorporation of radioactivity in the mitochondrial fraction as trichloroacetic acid-
precipitable counts. The radioactivity of proteins was quantified in dried gels using a 
BAS-5000 system (Fuji). Labelled proteins were identified according to their molecular 
mass as reported previously in ex vivo translation assays (Chomyn 1996). 
 
4.17. Protein determination 
The protein content was measured by the Bradford or Micro BCA protein kit 
assays (Bio-Rad Laboratories), using BSA as a standard. Samples were sonicated for 
20 s prior to protein determination.  
 
4.18. DNA analysis and sequencing 
Total genomic DNA from muscle and cultured fibroblasts was isolated by phenol 
extraction. The entire mtDNA was amplified in six overlapping fragments by PCR 
(7-3148, 2073-5719, 5645-8815, 8403-11 132, 11 005-14 684 and 13 863-136). Purified 
fragments were sequenced on the automatic sequencer ALF Express II (Amersham 
Biosciences) using cycle sequencing with 41 Cy5-labelled internal sequencing primers 
or on an AbiPrism 3100 Avant Genetic Analyzer (Applied Biosystems).  
 
4.19. Restriction analysis 
To determine the amount of mtDNA mutations, PCR/RFLP (restriction fragment 
length polymorphism) analysis method was performed. 9205delTA microdeletion was 
quentified according to (Chrzanowska-Lightowlers et al. 2004) using the mismatched 
(bold) primers 5´-CCT CTA CCT GCA CGA CAA TGC A-3´ (forward) and 5´-CGT 
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TATGCATTGGAAGTGAAATCA C-3´ (reverse), which introduce two novel NsiI 
restriction sites in the case of the wild-type mtDNA and one NsiI restriction site in the 
case of mutant mtDNA. PCR products were radioactively labelled with [α-32P]dCTP in 
the final cycle of PCR and run on a non-denaturing 13% (w/v) polyacrylamide gel after 
complete digestion. To quantify 8363G>A mutation, PCR products (8279–8485) were 
radioactively labelled with [α-32P]dCTP in the final cycle of PCR, and run on a non-
denaturing 10% (w/v) polyacrylamide gel after complete digestion with TspRI (New 
England BioLabs). The mutation abolishes one of two TspRI restriction sites on the 
fragment. The levels of heteroplasmy of the prevalent 3243A>G and 8344A>G 
mutations were determined as described elsewhere (Brantova et al. 2006). The 
proportions of wild-type to mutant mtDNA were measured using PhosphorImager and 
ImageQuant software (Molecular Dynamics).  
 
4.20. Northern blot analysis 
Total RNA was isolated from cultured fibroblasts by phenol/guanidium 
thiocyanate/chloroform extraction (Sambrook and Russell 2001). ∼20 μg of total RNA 
per lane was separated through a 1.2% (w/v) agarose/formaldehyde gel and transferred 
to a Hybond-N nylon membrane (Amersham) in 20×SSC (1×SSC is 0.15 M NaCl/ 
0.015 M sodium citrate). The membrane was prehybridized for 2 h at 45°C in 5×SSC, 
Denhardt’s solution, 0.5% SDS and 100 μg/ml sonicated herring sperm. The membranes 
were hybridized overnight at 45°C with [α-32P]dCTP-labelled probes corresponding to 
regions of the genes ATP6 (8361–9060), COX3 (9269–9912), ND1 (3313–4252) and 
COX1 (6120–6960). The radioactivity was detected by PhosphorImager and 
ImageQuant software (Molecular Dynamics). 
 
4.21. Quantitative RT-PCR (reverse transcription–PCR) analysis 
Total RNA was isolated from cultured fibroblasts using RNA Blue reagent (Top-
Bio, Prague, Czech Republic). Following DNase I treatment (Invitrogen), first-strand 
cDNA was synthesized from 1 μg RNA aliquots with 200 units SuperScript II reverse 
transcriptase using either 200 ng of random hexamer primers or 500 ng of 
oligo(dT)12−18 (all Invitrogen) according to the manufacturer’s instructions. Real-time 
quantitative RT-PCR was performed on a LightCycler instrument (Roche Diagnostics) 
using a QuantiTect SYBR Green PCR kit (Qiagen). PCR reactions were performed  on 
cDNAs using primer pairs specific for the ATP6 gene transcript (forward, 5´-CCT TAT 
GAG CGG GCA CAG T-3´; reverse, 5´- CAG GGC TAT TGG AA-3´; nt 8846–8994), 
for the COX3 gene transcript (forward, 5´-GCC CTC TCA GCC CTC CTA ATG-3´; 
reverse, 5´-GTG GCC TTG GTA TGT GCT TTC TCG-3´; nt 9267–9416), for the 
ATP6–COX3 gene transcript (forward, 5´- AAT CCA AGC CTA CGT TTT CAC 
ACT-3´; reverse, 5´-TAG GCC GGA GGT CAT TAG G-3´; nt 9150–9299), for the 
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CYTB gene transcript (forward, 5´-GACCTCCCCACCCCATCCA-3´; reverse, 5´-
AAA GGC GGT TGA GGC GTC TG-3´; nt 14 804– 14 935) and for the ND1 gene 
transcript (forward, 5´-CAA CCT CAA CCT AGG CCT CCT-3´; reverse, 5´-ACG 
GCT AGG CTA GAG GTG GC-3´; nt 3595–3644). The primer pair for ATP6–COX3 
was designed to flank the splice site of the ATP6–COX3 transcript. Amplified regions 
of the ATP6 or COX3 transcript were present in both processed and unprocessed RNAs. 
All reactions were run at an annealing temperature of 60°C. The PCR mixture contained 
5 μl of 2×SYBR Green PCR Master Mix, 2 μl of 100×diluted reverse transcription 
product and 200 nM of each primer in a total volume of 10 μl. All reactions were 
performed in triplicate. For each primer pair, non-template controls were included to 
check for the absence of contaminants and primerdimers that would interfere with 
quantification when SYBR Green is used. The external standard curve was generated in 
parallel for all reactions using serial dilutions of cDNA synthesized from control RNA. 
For each sample, the relative amounts of ATP6, COX3, CYTB, ND1 and unprocessed 
ATP6–COX3 transcripts were determined from the standard curves. Each sample was 
analyzed in two separate experiments. 
Total RNA from HEK-293 cells was isolated using TriReagent solution (MRC). 
First-strand cDNA was synthesized from 4 μg of total RNA with the use of 
Superscript III reverse transcriptase (Invitrogen) and Oligo-dT primers (Promega). Pre-
amplification and relative quantification was performed according to the manufacturer’s 
instructions (Applied Biosystems). Ten pre-amplification cycles were run with 12.5 μl 
of cDNA and a 0.05×pooled mixture of eight TaqMan Gene Expression Assays 
[Hs00971639_m1, COX4I1; Hs00261747_m1, COX4I2; Hs01924685_g1, COX6A1; 
Hs00193226_g1, COX6A2; Hs00427620_m1, TBP (TATA-box-binding protein); 
Hs00173304_m1, PPARGC1A (peroxisome-proliferator-activated receptor γ co-
activator 1α); Hs00188166_m1, SDHA (succinate dehydrogenase complex subunit A; 
Hs01082775_m1, TFAM (transcription factor A, mitochondrial)]. Relative 
quantification was performed in duplicates twice on the 7300 Real-Time PCR System 
(Applied Biosystems). The transcript levels of all mRNAs were normalized to the level 
of TBP mRNA. Because the amplification efficiency of the reference and target genes 
was the same, the comparative ΔΔCt method was used for relative quantification. 
 
4.22. Statistical analysis 
A Student's t test was performed using Microsoft Excel. Results are expressed as 
mean±S.D. A P value of less than 0.05 was considered as statistically significant, and 
asterisks are used to denote significance as follows: *P<0.05; ** P <0.01; *** P <0.001. 
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5     RESULTS  AND  DISCUSSION 
 
5.1. Characterization of the assembly and function of human nDNA-
encoded CcO subunits 4, 5a, 6a, 7a and 7b (specific aim 1a) 
 
 
Fornuskova D, Stiburek L, Wenchich L, Vinsova K, Hansikova H and Zeman J 
 
Novel insights into the assembly and function of human nuclear-encoded cytochrome c 
oxidase subunits 4, 5a, 6a, 7a and 7b. 
 
Biochem J 2010; 428: 363-374. 
 
 
To study the role of nuclear-encoded cytochrome c oxidase (CcO) structural 
subunits Cox4, Cox5a and Cox6a as well as the sequence of late events in the CcO 
assembly pathway, we prepared stable HEK-293 knockdown lines using microRNA-
adopted design evoking RNA interference of COX4, COX5A and COX6A1. 
Furthermore, we used ectopic expression of C-end epitope-tagged Cox6a, Cox7a and 
Cox7b in wild-type HEK-293 cells and COX6A knockdowns to elucidate entry points 
of these subunits into the CcO assembly pathway. To estimate functionality and 
integrity of OXPHOS in context of CcO deficiency, we employed quantitative real-time 
RT-PCR, isolation of crude mitochondrial fraction by cellular fractionation and 
differential centrifugation, spectrophotometric enzyme activity assays, high-resolution 
respirometry and blue-native (BN), denaturing (SDS) and two-dimensional (BN/SDS or 
BN/BN) PAGE with downstream immunoblot detections using monoclonal antibodies 
against various mitochondrial proteins. 
Knockdown of Cox4, Cox5a and Cox6a resulted in reduced CcO activity, 
diminished affinity of the residual enzyme for oxygen, decreased CcO holoenzyme and 
CcO dimer levels, increased accumulation of CcO subcomplexes and gave rise to an 
altered pattern of respiratory supercomplexes. An analysis of the patterns of CcO 
subcomplexes found in both knockdown and overexpressing cells identified a novel 
CcO assembly intermediate, identified the entry points of three late-assembled subunits 
and demonstrated directly the essential character as well as the interdependence of the 
assembly of Cox4 and Cox5a. The ectopic expression of the heart/muscle-specific 
isoform of the Cox6 subunit (COX6A2) resulted in restoration of both CcO holoenzyme 
and activity in COX6A1-knockdown cells. This was in sharp contrast with the unaltered 
levels of COX6A2 mRNA in these cells suggesting the existence of a fixed expression 
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programme. The normal amount and function of respiratory complex I in all of our 
CcO-deficient knockdown cell lines suggest that, unlike non-human CcO-deficient 
models, even relatively small amounts of CcO can maintain the normal biogenesis of 
respiratory complex I in cultured human cells. 
I contributed fundamentally to this study by designing the research, cloning of 
pCMV-GIN-ZEO plasmid derivatives coding for candidate shRNAs to achieve the most 
efficient knockdown, maintaining the HEK-293 cell culture, carrying out expression 
cloning, preparation of knockdown cell lines and transiently transfected cellular 
materials, performing mitochondrial isolations and all Western blot analyses and by 
writing the paper. 
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Novel insights into the assembly and function of human nuclear-encoded
cytochrome c oxidase subunits 4, 5a, 6a, 7a and 7b
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Department of Pediatrics, First Faculty of Medicine, Charles University in Prague, Ke Karlovu 2, Prague 2, 128 08, Czech Republic
Mammalian CcO (cytochrome c oxidase) is a hetero-oligomeric
protein complex composed of 13 structural subunits encoded
by both the mitochondrial and nuclear genomes. To study the
role of nuclear-encoded CcO subunits in the assembly and
function of the human complex, we used stable RNA interference
of COX4, COX5A and COX6A1, as well as expression of
epitope-tagged Cox6a, Cox7a and Cox7b, in HEK (human
embryonic kidney)-293 cells. Knockdown of Cox4, Cox5a and
Cox6a resulted in reduced CcO activity, diminished affinity of
the residual enzyme for oxygen, decreased holoCcO and CcO
dimer levels, increased accumulation of CcO subcomplexes and
gave rise to an altered pattern of respiratory supercomplexes.
An analysis of the patterns of CcO subcomplexes found in
both knockdown and overexpressing cells identified a novel
CcO assembly intermediate, identified the entry points of three
late-assembled subunits and demonstrated directly the essential
character as well as the interdependence of the assembly of Cox4
and Cox5a. The ectopic expression of the heart/muscle-specific
isoform of the Cox6 subunit (COX6A2) resulted in restoration
of both CcO holoenzyme and activity in COX6A1-knockdown
cells. This was in sharp contrast with the unaltered levels of
COX6A2 mRNA in these cells, suggesting the existence of a
fixed expression programme. The normal amount and function
of respiratory complex I in all of our CcO-deficient knockdown
cell lines suggest that, unlike non-human CcO-deficient models,
even relatively small amounts of CcO can maintain the normal
biogenesis of this respiratory complex in cultured human cells.
Key words: cytochrome c oxidase, protein assembly, respiratory
supercomplex, RNA interference (RNAi).
INTRODUCTION
Cytochrome c oxidase (CcO), the terminal enzyme complex of
the mitochondrial electron-transport chain couples the electron
transfer from reduced cytochrome c to molecular oxygen
with vectorial proton translocation across the inner membrane.
The mammalian CcO complex is composed of 13 different
polypeptide subunits, which are encoded by both the nuclear
and mitochondrial genomes. Mitochondrially encoded Cox1 and
Cox2 form the redox site involved in electron transfer. Electrons
enter the CcO complex at the binuclear copper site (CuA) in
the Cox2 subunit, which also mediates electrostatic binding of
cytochrome c [1]. From CuA, electrons pass to other metal
centres in the Cox1 subunit, first to haem a and then to a
heterobimetallic haem a3/CuB centre [2]. Together with Cox3,
mitochondrially encoded subunits constitute the evolutionarily
conserved structural core of the enzyme. The remaining ten
subunits, which are encoded by nuclear DNA, are associated with
the surface of the complex core. These small polypeptides are
required for the assembly and stability of the holoenzyme and are
thought to function in the regulation of its activity [3–5]. Tissue-
specific isoforms of subunits Cox4, Cox6a, Cox6b, Cox7a and
Cox8 have been identified in mammals [6,7]. Most CcO subunits
have one or more transmembrane domains, with the exception
of Cox5a and Cox5b, which are located at the matrix side, and
Cox6b, which is associated with the surface of the complex in the
intermembrane space [8].
Subunit Cox4 is the largest nuclear-encoded subunit of the
complex. It was shown to be involved in the allosteric inhibition
of CcO activity by ATP, which binds to the matrix portion of
the subunit [9]. Isoforms 1 and 2 of Cox4 are encoded by two
separate genes and are likely to differ with respect to ATP-induced
inhibition of CcO activity [10]. In mammalian cells, the first step
of CcO assembly is the membrane integration of Cox1, followed
by the association of the Cox4–Cox5a heterodimer [11]. Subunit
Cox5a binds indirectly to subunit Cox1 via the matrix domain of
subunit Cox4 and the extramembrane segment of Cox6c. Subunit
Cox6a is involved in the stabilization of the dimeric state of CcO
and may contribute to the formation of an interaction site for
cytochrome c [8]. Liver-type subunit Cox6a (Cox6a1/Cox6aL)
is found in all non-muscle tissues, whereas heart/muscle-type
subunit Cox6a (Cox6a2/Cox6aH), which is encoded by a different
gene, is expressed only in striated muscles [12]. Subunit Cox6a
was shown to associate with the complex, together with subunits
Cox7a or Cox7b, at a very late stage of CcO assembly [13].
In the present study, we generated HEK (human embryonic
kidney)-293 cell lines with stably [shRNA (short hairpin RNA)]
down-regulated levels of CcO subunits Cox4, Cox5a and Cox6a.
We analysed the steady-state levels of the CcO holoenzyme
and the presence and composition of CcO subcomplexes. We
have demonstrated directly that depletion of each of the selected
subunits results in decreased levels of CcO with a parallel
accumulation of CcO subcomplexes and unassembled subunits.
These changes were accompanied by a reduction in the activity
of CcO and a decreased affinity of CcO for oxygen. The subunit
composition of CcO subcomplexes in Cox6a-depleted cells, along
with analyses of the ectopic expression of subunits Cox7a2 and
Cox7b in these cells, provided novel insights into the late stages
Abbreviations used: BN, blue native; CcO, cytochrome c oxidase; DDM, n-dodecyl-β-D-maltoside; FCCP, carbonyl cyanide p-trifluoro-
methoxyphenylhydrazone; HEK, human embryonic kidney; KD, knockdown; NDUFB6, NADH dehydrogenase (ubiquinone) 1β subcomplex 6; P50, partial
pressure of oxygen at half-maximal respiration rate; qRT-PCR, quantitative real-time PCR; RNAi, RNA interference; SDHA, succinate dehydrogenase
complex subunit A; shRNA, short hairpin RNA; shRNAmir, microRNA-adapted shRNA; SQR, succinate:coenzyme Q10 reductase, complex II; TBP, TATA-
box-binding protein; TMPD, N,N,N′,N′-tetramethyl-p-phenylenediamine; UTR, untranslated region.
1 To whom correspondence should be addressed (email jzem@lf1.cuni.cz).
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of human CcO assembly. Moreover, CcO deficiency in COX6A1-
KD (knockdown) cells was complemented by ectopic expression
of the Cox6a2 isoform. We have demonstrated further that CcO
deficiency in COX5A- and COX6A-KD cells affects the formation
of respiratory supercomplexes containing the dimeric form of
CcO.
EXPERIMENTAL
Plasmid construction
The nucleotide sequences of 33 different candidate miR-30-
based shRNAs [shRNAmirs (microRNA-adapted shRNAs)]
targeted to COX4I1, COX5A and COX6A1 mRNAs were
designed with shRNA Retriever (http://katahdin.cshl.org/
siRNA/RNAi.cgi?type=shRNA), synthesized and cloned into
the pCMV-GIN-ZEO plasmid (Open Biosystems) as described
previously [14]. A pCMV-GIN-ZEO derivative that expresses
negative control (non-silencing) shRNAmir was obtained from
Open Biosystems. The coding sequences of COX7A2 (GenBank®
accession number BC100852; IMAGE ID: 40002220) and
COX7B (GenBank® accession number BC018386; IMAGE ID:
3861730) were amplified from the respective full-length cDNA
clones (ImaGenes), fused to the C-terminal FLAG epitope
and cloned (EcoRI/NotI) into the modified pmaxFP-Red-N
plasmid (Amaxa). The fidelity of all constructs was confirmed
by automated DNA sequencing. Plasmids pReceiver-M02 (EX-
C0224) and pReceiver-M13 (EX-C0224) (GeneCopoeia) were
used to express Cox6a2 and Cox6a2–FLAG respectively.
Cell culture and transfection
HEK-293 cells (CRL-1573) were obtained from A.T.C.C.
(Manassas, VA, U.S.A.) and grown at 37 ◦C in a 5% (v/v)
CO2 atmosphere in high-glucose Dulbecco’s modified Eagle’s
medium (PAA) supplemented with 10% (v/v) fetal bovine
serum Gold (PAA). Cell lines stably expressing shRNAmir were
prepared using the NucleofectorTM device (Amaxa) essentially as
described previously [14]. The transient expression of selected
CcO subunits in HEK-293 cells was accomplished using the
Express-In Transfection Reagent (Open Biosystems).
Reverse transcription and qRT-PCR (quantitative real-time PCR)
Total RNA was isolated from HEK-293 cells using TriReagent
solution (MRC). First-strand cDNA was synthesized from
4 μg of total RNA with the use of Superscript III reverse
transcriptase (Invitrogen) and Oligo-dT primers (Promega).
Pre-amplification and relative quantification was per-
formed according to the manufacturer’s instructions
(Applied Biosystems). Ten pre-amplification cycles were
run with 12.5 μl of cDNA and a 0.05× pooled mixture of
eight TaqMan Gene Expression Assays [Hs00971639_m1,
COX4I1; Hs00261747_m1, COX4I2; Hs01924685_g1,
COX6A1; Hs00193226_g1, COX6A2; Hs00427620_m1, TBP
(TATA-box-binding protein); Hs00173304_m1, PPARGC1A
(peroxisome-proliferator-activated receptor γ co-activator 1α);
Hs00188166_m1, SDHA (succinate dehydrogenase complex
subunit A; Hs01082775_m1, TFAM (transcription factor A,
mitochondrial)]. Relative quantification was performed in
duplicates twice on the 7300 Real-Time PCR System (Applied
Biosystems). The transcript levels of all mRNAs were normalized
to the level of TBP mRNA. Because the amplification efficiency
of the reference and target genes was the same, the comparative
Ct method was used for relative quantification.
Immunoblot analysis
Protein sample preparation and signal acquisition for SDS,
BN (blue native) and BN-SDS/PAGE immunoblot analysis
were performed essentially as described in [11,14]. The
immunoblots were developed with SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific). For analysis
of respiratory supercomplexes by BN-SDS/PAGE and BN/BN-
PAGE, isolated mitochondria were extracted using digitonin
(detergent/protein ratio of 6). Primary detection of BN-
SDS/PAGE and BN/BN-PAGE immunoblots was performed with
mouse monoclonal antibodies (Mitosciences) raised against the
complex I subunit NDUFB6 [NADH dehydrogenase (ubiquinone)
1β subcomplex 6], complex III subunit Core1 and complex IV
subunit Cox1. The first dimension gel strips for BN/BN-PAGE
immunodetection were soaked in cathode buffer containing 0.1%
DDM (n-dodecyl-β-D-maltoside) for 15 min and then in cathode
buffer containing 0.02% DDM for another 15 min. The second
dimension of BN-PAGE separation was performed in the presence
of 0.02% DDM as described in [15].
Spectrophotometric assays
The activities of respiratory chain complexes were measured spec-
trophotometrically with a UV-2401PC instrument (Shimadzu).
Rotenone-sensitive complex I activity (NADH:ubiquinone
oxidoreductase) was measured by incubating 45 μg of
mitochondrial protein in 1 ml of assay medium (50 mM Tris/HCl,
pH 8.1, 2.5 mg/ml BSA, 50 μM decylubiquinone, 0.3 mM
KCN and 0.1 mM NADH without or with 3 μM rotenone).
The decrease in absorbance at 340 nm due to the NADH
oxidation was followed. Complex II activity (succinate:2,6-
dichloroindophenol oxidoreductase) was measured by incubating
20 μg of mitochondrial extract in 1 ml of assay medium (10 mM
potassium phosphate, pH 7.8, 2 mM EDTA, 1 mg/ml BSA,
0.3 mM KCN, 10 mM succinate, 3 μM rotenone, 0.2 mM ATP,
80 μM 2,6-dichloroindophenol, 1 μM antimycin and 50 μM
decylubiquinone). The decrease in absorbance at 600 nm due
to the reduction of 2,6-dichloroindophenol was monitored. CcO
activity was measured by incubating 15–18 μg of mitochondrial
protein in 1 ml of assay medium (40 mM potassium phosphate,
pH 7.0, 1 mg/ml BSA, 25 μM reduced cytochrome c and 2.5 mM
DDM) and the oxidation of cytochrome c (II) at 550 nm was
monitored. All assays were performed at 37 ◦C. The total protein
was determined using the method of Lowry [16].
High-resolution respirometry and oxygen kinetics
Oxygen consumption measurements were performed as described
previously [14], except that the cells were permeabilized with
50–75 μg/ml digitonin and 0.5 μM FCCP (carbonyl cyanide
p-trifluoromethoxyphenylhydrazone) was used to uncouple and
maximally stimulate respiration. The P50 (partial pressure
of oxygen at the half-maximal respiration rate) value was
measured in the presence of 0.5 μM FCCP and 10 mM succinate
essentially as described in [17]. All measurements were performed
independently three to six times for each cell line.
RESULTS
Cox4i1 and Cox6a1 isoforms account for the majority of Cox4 and
Cox6a transcripts expressed in HEK-293 cells under normal
conditions
Because two tissue-specific isoforms of subunits Cox4 and Cox6a
were described in humans, we measured the levels of COX4I1,
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COX4I2, COX6A1 and COX6A2 mRNAs in HEK-293 cells.
To quantify both isoforms using qRT-PCR, pre-amplification of
the cDNA was necessary. The transcript levels of all mRNAs
were normalized to the level of TBP mRNA. The relative
normalized level of COX4I1 mRNA was found to be ∼2×105
times higher than COX4I2, whereas the relative normalized level
of COX6A1 mRNA was ∼5×106 times higher than that of
COX6A2 (Figure 1A). This finding suggests that the vast majority
of Cox4 and Cox6a expressed and assembled within the CcO
complex in HEK-293 cells are represented by Cox4i1 and Cox6a1
tissue isoforms.
Subunits Cox4, Cox5a and Cox6a are depleted in HEK-293 cells by
the stable expression of shRNAmir
Owing to the considerably long half-life of the CcO complex [2]
and the relatively large amount of material required for subsequent
analyses, a stable vector-based RNAi (RNA interference)
approach was utilized to down-regulate the expression of Cox4,
Cox5a and Cox6a in HEK-293 cells. We designed and constructed
13, nine and 11 pCMV-GIN-ZEO derivatives encoding miR-30-
based shRNAs (shRNAmirs) targeting human COX4I1, COX5A
and COX6A1 mRNAs respectively. These plasmids were used to
generate stable KD in HEK-293 cells. Six out of the 33 produced
cell lines, which were found to have substantially lower levels of
the target proteins, were selected for further analyses (Figure 1B).
The residual levels of the target subunits in mitochondrial
preparations were quantified using denaturing Western blots.
Serial dilutions of protein isolated from the mitochondria of the
control line expressing non-silencing shRNA were loaded on
the same gels as the KD samples so that the steady-state levels
of the respective polypeptides in KD cells could be assessed as a
percentage of the control values (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/428/bj4280363add.htm). The
residual amount of the Cox4 polypeptide was found to be
45% in COX4I1 (sh1) KD and 55% in COX4I1 (sh14) KD
mitochondria. In the COX5A (sh5) KD and COX5A (sh7) KD
samples, the amount of Cox5a polypeptide was decreased to 35
and 20% respectively. The Cox6a1 polypeptide was decreased
to 25 and 35% in COX6A1 (sh11) KD and COX6A1 (sh12) KD
mitochondria respectively.
Relative normalized mRNA levels (2−Ct×100) of the major
COX4I1 and minor COX4I2 isoform were 33 and 24% in the
COX4I1 (sh1) KD sample, and 18 and 77% in the COX4I1 (sh14)
KD sample respectively. The relative normalized mRNA levels of
the major COX6A1 and minor COX6A2 isoform accounted for 13
and 21% in the COX6A1 (sh11) KD sample, and 12 and 105%
in the COX6A1 (sh12) KD sample respectively.
Steady-state levels of a subset of respiratory chain subunits as
well as several other mitochondrial proteins are not affected in
COX4-, COX5A- and COX6A-KD cells
The mitochondrial preparations used to quantify target subunits
were utilized for SDS/PAGE immunodetection to determine
the steady-state levels of selected CcO subunits, representative
respiratory chain subunits and several other mitochondrial
proteins (see Supplementary Figure S1).
Depletion of subunit Cox4 led to a reduction in the level of
Cox5a to 45% in COX4I1 (sh1) KD and 55% in COX4I1 (sh14)
KD samples compared with the control. The levels of Cox1 and
Cox2 were both 80 and 90% of the control values in COX4I1 (sh1)
and (sh14) KD samples respectively. Depletion of subunit Cox5a
resulted in a decrease in the levels of Cox4 and Cox2 to 35% in
COX5A (sh5) KD and 20% in COX5A (sh7) KD, whereas the level
of Cox1 remained unchanged. Down-regulation of subunit Cox6a
Figure 1 Levels of COX4 and COX6A mRNAs and the effects of shRNA KD
of COX4I1, COX5A and COX6A1 in HEK-293 cells
(A) mRNA levels of COX4 and COX6A isoforms in control and COX4 and COX6A1-KD HEK-293
cells, normalized to the level of TBP mRNA (2−Ct ). (B) The relationship between the residual
target subunit, content of CcO and its enzyme activity. The residual level of the target subunit was
determined by SDS/PAGE of mitochondrial protein samples (∼30 μg) and Western blotting.
The amount of CcO holoenzyme was determined by BN (5–15 % acrylamide gradient)-PAGE
of mitochondrial proteins (∼20 μg) solubilized using 1.1 % DDM (4.8 DDM/protein) followed
by Western blotting. Immunoreactive material was visualized by chemiluminescence. For the
loading control, the amount of target subunit was normalized to that of subunit SDHA of
complex II and to the outer membrane protein porin. The amount of CcO holoenzyme was
normalized to that of complex II. The final values are expressed relatively to control (NS) sample,
which was arbitrarily set at 100 %. The CcO activity was determined by measuring the rate
of cytochrome c oxidation (nmol/min per mg of mitochondrial protein) and normalized to the
activity of complex II (SQR) (CcO/SQR ratio), which was determined by measuring the rate of
2,6-dichloroindophenol reduction (nmol/min per mg of mitochondrial protein). For comparison
with the level of RNAi-target subunit and CcO content, the CcO/SQR ratio of the mean activity
values was, in turn, expressed relative to the CcO/SQR ratio value obtained in the control (NS)
sample, which was arbitrarily set at 100 %. NS, mitochondria from HEK-293 cells expressing
the non-silencing control shRNAmir.
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caused a reduction in the levels of subunits Cox1, Cox2, Cox4 and
Cox5a to 80% of the control values. The steady-state levels of
PDH-E2 (pyruvate dehydrogenase subunit E2), porin, cytochrome
c, the 70-kDa flavoprotein subunit of SDHA, the ATP synthase
subunit F1-β (ATPase F1-β), complex III core protein 2 and the
complex I subunit NDUFA9 [NADH dehydrogenase (ubiquinone)
1α subcomplex 9] were not changed compared with the control.
Depletion of subunits Cox4, Cox5a and Cox6a decreases
the quantity of CcO holoenzyme and increases an accumulation
of CcO subcomplexes
To study the impact of the depletion of subunits Cox4, Cox5a
and Cox6a on CcO holoenzyme levels, we performed 5–15%
BN-PAGE Western blot analyses. The same mitochondrial
fractions used for SDS/PAGE Western blots were solubilized in
DDM and analysed along with serial dilutions of control samples
(Figure 2A). The amount of CcO holoenzyme was diminished
to 65% of the control value in COX4I1 (sh1) KD and to 75%
of the control value in COX4I1 (sh14) KD samples. The COX5A
(sh7) and (sh5) KD samples showed a decrease in the amount
of the CcO holoenzyme to 20 and 60% of the control values
respectively. In COX6A1 (sh11) KD and COX6A1 (sh12) KD
samples, CcO holoenzyme was reduced to 25 and 30% of the
control values respectively.
To investigate the assembly pattern of CcO, we performed BN-
PAGE as well as two-dimensional BN-SDS/PAGE, in which we
utilized 8–16% polyacrylamide gradients followed by Western
blot analysis of the selected subunits. The BN anti-Cox1 immuno-
blots revealed the presence of several distinct bands in KD mito-
chondria, which were denoted a–e (Figure 2B). The holoenzyme
band a was, in fact, found to be composed of two bands (a1 and a2)
[18]. COX6A1-KD mitochondria showed a reduction in the levels
of both bands a1 and a2 to 20% of the control values (Figures 2B
and 2C). In contrast, the decrease in band a1 in COX4- and COX5A-
KD samples, which was comparable with that for COX6A1-KD
mitochondria, was accompanied by a more profound reduction
in the amount of band a2 (Figures 2B and 2C). In addition to
band a, anti-Cox1 immunoblotting detected three faster migrating
bands (b, x and c) in all samples with approximate molecular
masses of 180, 155 and 110 kDa respectively. Band b, which was
barely discernible between control, COX4-KD and COX5A-KD
mitochondria, was increased in COX6A-KD samples (Figure 2B).
This band probably represents the previously identified assembly
intermediate S3 (Figure 2D) [2]. Band x, which was almost
undetectable in controls and slightly increased in COX6A-KD
mitochondria, was markedly increased in the COX5A (sh7)
KD sample. Despite its high apparent molecular mass, this band
was detectable only with the anti-Cox1 antibody. Band c, which
was detected in all samples, was increased in COX4- and COX5A-
KD mitochondria. This band was detected with antibodies against
Cox1, Cox4 and Cox5a in COX6A1-KD samples, but only
with the anti-Cox1 antibody in COX4- and COX5A-KD samples
(Figure 2D). Finally, bands d and e, with approximate molecular
masses of 100 and 85 kDa respectively, were found only in
COX4- and COX5A-KD samples. These bands were increased
in the severely CcO-deficient COX5A (sh7) KD sample and were
detected exclusively with the anti-Cox1 antibody.
Whereas CcO activity is significantly decreased, activities
of respiratory chain complexes I, II and III are not affected
in COX5A- and COX6A1-KD cells
To assess residual CcO activity in mitochondrial preparations,
we determined CcO activity and normalized it to the activity of
SQR (succinate:coenzyme Q10 reductase, complex II) (Figure 1B).
The same mitochondrial preparations used in the electrophoretic
analyses were utilized in these assays. The relative CcO/SQR ratio
values obtained for mitochondria from the COX4I1 (sh1) (97%)
and COX4I1 (sh14) (103%) KD cells were comparable with
that obtained for control cells. In COX5A (sh5) KD and COX5A
(sh7) KD mitochondria, the relative normalized CcO/SQR ratio
accounted for 72 and 57% of the control values respectively.
The mitochondrial preparations from COX6A1 (sh11) KD and
COX6A1 (sh12) KD cells revealed a decrease in the CcO/SQR
ratio to 51 and 73% of the control values respectively. The
activities of the remaining respiratory chain complexes were
found to be unchanged in all of the KD samples investigated
(results not shown).
Isolated CcO deficiency due to COX5A and COX6A1 KD affects the
organization of respiratory supercomplexes in HEK-293 cells
To study the impact of COX5A and COX6A1 KD on the
composition of respiratory chain supercomplexes, mitochondrial
fractions were solubilized with digitonin (digitonin/protein ratio
of 6) and analysed by BN-SDS/PAGE and BN/BN-PAGE Western
blotting. Both approaches showed that COX5A and COX6A1 KD
significantly decreased the levels of the dimeric form of the CcO
holoenzyme (Figure 3). Furthermore, BN/BN-PAGE Western
blots revealed markedly reduced levels of supercomplexes III2IV2
and I1III2IV2, which apparently contained the dimeric form of
the CcO holoenzyme (Figure 3B). In contrast, the amount of the
major mammalian supercomplex I1III2IV1 was normal or slightly
increased (Figure 3B). The appearance of the faint spot
corresponding to undissociated IV2 below the spot corresponding
to III2 of the III–IV-containing supercomplex substantiates the
presence of the III2IV2, rather than the III2IV1 supercomplex
in the samples (Figure 3B, long exposure). The two spots
migrating above complex I probably represent undissociated
supercomplexes (e.g. I1III2IV1 and I1IV1) [19].
In all samples, including the controls, BN/BN-PAGE
immunoblots revealed additional spots that migrated at the level of
supercomplexes in the first dimension, but had apparent molecular
masses lower than that of the CcO holoenzyme (Figure 3B). These
spots were most apparent in COX5A-KD mitochondria, which
exhibited the most severe CcO holoenzyme defect and the highest
accumulation of incomplete CcO assemblies (Figure 2B). Indeed,
these spots might represent CcO assembly intermediates already
in the form of respiratory supercomplexes.
Normal normoxic respiration is accompanied by increased P50
values in COX5A- and COX6A1-KD cells
To further characterize mitochondrial respiratory function
in COX5A (sh7) KD and COX6A1 (sh11) KD cells, we
performed high-resolution respirometry using the Oroboros
Oxygraph. The only difference observed in this assay was
diminished oxygen consumption (∼80% of control) after
the addition of ascorbate/TMPD (N,N,N ′,N ′-tetramethyl-p-
phenylenediamine) substrates in COX5A (sh7) KD cells (Figure
4A). Therefore we analysed the respiratory response of the cells
to low oxygen. The digitonin-permeabilized cells were treated
with FCCP to uncouple and maximally stimulate respiration
(state 3u) and were then treated with succinate. The oxygen
kinetics were quantified by determining the P50. The average
P50 value was 0.072 +− 0.02 (S.D.) kPa (n = 6) in control (non-
silencing) cells, 0.163 +− 0.01 kPa (n = 5) in COX5A (sh7) KD
cells and 0.105 +− 0.01 kPa (n = 3) in COX6A1 (sh11) KD samples(Figure 4B). Thus the P50 value was elevated more than 2-fold in
COX5A (sh7) KD and ∼1.5-fold in COX6A1 (sh11) KD cells.
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Figure 2 Levels of CcO holoenzyme and the assembly pattern of CcO in COX4-, COX5A- and COX6A1-KD mitochondria
(A) Equal amounts (∼20 μg) of mitochondrial protein prepared by solubilization using 1.1 % DDM (4.8 DDM/protein) and serial dilutions of non-silencing control samples (NS) were resolved
by BN (5–15 % acrylamide gradient)-PAGE and subjected to Western blot analysis with an anti-Cox1 antibody. (B) Mitochondrial proteins (∼25 μg) prepared by solubilization using 1.1 % DDM
(4.8 DDM/protein) were resolved by BN (8–16 % acrylamide gradient)-PAGE and subjected to Western blot analysis with an anti-Cox1 antibody. Both short (upper panel) and long (lower panel)
exposures are shown. Equal loading was verified using antibodies against the complex II subunit SDHA and the complex III subunit Core 2 (A, B). (C) The same protein samples as in (B) were
fractionated using BN (7–10 % acrylamide gradient)-PAGE and subjected to Western blot analysis with an anti-Cox1 antibody. The amount of protein loaded per lane was normalized to the signal of
the holoenzyme band a1. (D) The same protein samples as in (B) (∼35 μg) were resolved by two-dimensional BN (8–16 acrylamide gradient)-SDS (13 % acrylamide) or 13 % BN-SDS/PAGE and
subjected to Western blot analysis with a cocktail of antibodies specific for subunits Cox1, Cox2, Cox4 and Cox5a. The migration direction of the first, native (BN-PAGE), and the second, denaturing
(SDS/PAGE), dimension are marked with grey arrows. The positions of bands a–e and the molecular mass (MW) of complex II (123 kDa), the SDHA–SDHB (succinate dehydrogenase complex
subunit B) subcomplex (97 kDa) and SDHA (70 kDa) are indicated. Both short and long Cox1-specific exposures are shown. Immunoreactive material was visualized by chemiluminescence (A–D).
Overexpression of the Cox6a2 isoform complements the
quantitative CcO holoenzyme defect of COX6A1-KD cells
Despite the substantial decrease in CcO holoenzyme levels, the
levels of heart/muscle-specific COX6A2 mRNA remained low in
Cox6a1-depleted CcO-deficient cells (Figure 1A). Therefore we
tested whether the Cox6a2 isoform can substitute for subunit
Cox6a1 during CcO assembly in HEK-293 cells. To obtain
optimal accumulation of the subunit polypeptide, the cells were
transfected twice consecutively, leading to transgene expression
for a total of 4 days. Both untagged and FLAG-tagged forms were
used to transfect wild-type and COX6A1-KD cells. This analysis
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Figure 3 Supramolecular organization of CcO in COX5A- and COX6A1-KD cells
(A) Digitonin-solubilized (6 digitonin/protein) mitochondrial proteins were separated by two dimensional BN (5–12 % acrylamide gradient)-SDS (10 % acrylamide)/PAGE (∼45 μg) and subjected
to Western blot analysis with antibodies specific for the complex III subunit Core 1 and the complex IV subunit Cox1. IVDim and IIIDim indicate complex IV and III homodimers respectively, and IVSub
indicates CcO subcomplexes. NS, non-silencing control samples. The migration direction of the first, native (BN-PAGE), and the second, denaturing (SDS-PAGE), dimension are indicated with grey
arrows. (B) The same protein preparations as in (A) (∼45 μg) were fractionated using two-dimensional BN (4–13 % acrylamide gradient)/BN (4–15 % acrylamide gradient)-PAGE and subjected
to Western blot analysis with a cocktail of antibodies specific for the complex I subunit NDUFB6, the complex III subunit Core 1 and the complex IV subunit Cox1. The migration direction of the
first (dig) and the second (DDM) dimension are indicated with grey arrows. Complexes from the first BN-PAGE that retained their masses after two-dimensional BN-PAGE are found on a diagonal.
Supercomplexes that dissociated into individual complexes were detected below the diagonal. The small arrows indicate supramolecular assemblies of respiratory complexes that did not dissociate
in the second dimension. Asterisks indicate undissociated supercomplexes of higher molecular masses than complex I. Arrowheads denote spots migrating in the first dimension at the level of
supercomplexes, but with apparent molecular masses (MW) lower than that of the CcO holoenzyme. Immunoreactive material was visualized by chemiluminescence (A and B).
was simplified by the fact that both COX6A1 shRNAmirs used to
prepare the KD cells targeted the 3′-UTR (untranslated region) of
COX6A1 mRNA, which was not present in our Cox6a2 expression
constructs.
The ectopic expression of the Cox6a2 isoform in COX6A1
(sh11) KD cells led to the restoration of wild-type CcO
levels. The total pool of CcO in these cells consisted of
the Cox6a2-containing enzyme as well as residual Cox6a1-
containing molecules (∼25%) (Figure 5B). Therefore both
untagged (Figures 5A and 5B) and FLAG-tagged (Figures 5A and
5C) Cox6a2 polypeptides could substitute for the Cox6a1 isoform
during CcO assembly in HEK-293 cells. From these experiments,
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Figure 4 High-resolution respirometry in permeabilized (digitonin-treated) uncoupled (FCCP-treated) COX5A- and COX6A1-KD cells
(A) Respiration at environmental normoxic levels of oxygen. The mean rate of oxygen consumption (pmol of O2/s per mg of protein) in KD cells was expressed relative to the non-silencing control
(NS) mean value, which was arbitrarily set at 100 %. GM, relative respiration after addition of glutamate and malate (rotenone-sensitive); GMS, relative respiration after addition of glutamate,
malate and succinate (antimycin A-sensitive); S, relative respiration after addition of succinate (antimycin A-sensitive); aT, relative respiration after addition of ascorbate and TMPD (sodium
azide-sensitive). (B) Mean P50 values in cells supplied by succinate. Results in (A) and (B) are means+S.D. (C) The relationship of P50 and protein-specific oxygen flux. P50 values from
individual measurements were plotted as a function of protein-specific oxygen flux (Jmax)., Control sample (NS);H17009, COX5A (sh7) KD cells;, COX6A1 (sh11) KD cells. *P<0.05; **P<0.01;
***P<0.001.
it was also apparent that ectopic expression of Cox6a2 in wild-type
HEK-293 cells increased the amount of CcO holoenzyme (band
a1) as well as the level of band a2. In all transfected samples,
including controls, an increase in the amount of the assembly
intermediate S3 (band b) was observed, probably as a result of the
transfection treatment (Figures 5A and 5B).
The consequences of increased CcO content after ectopic
expression of the Cox6a2 isoform in COX6A1-KD cells were
analysed by spectrophotometric measurement of CcO activity.
CcO activity in Cox6a2–FLAG expressing cells, which was
normalized to the activity of the control enzyme (SQR), did
not change significantly compared with either untreated wild-
type cells or wild-type cells transfected with the control vector
(1.26–1.29). In COX6A1-KD cells, ectopic expression of the
Cox6a2–FLAG isoform led to a ∼1.5-fold increase in CcO/SQR
activity ratio compared with transfection with the control vector
(CcO/SQR ratio was 0.75 and 0.49 respectively) (Figure 5D).
Subunit Cox7a2 enters the CcO assembly after Cox7b,
but before Cox6a2
To elucidate the entry points of subunits Cox7a2 and Cox7b
with respect to the formation of the assembly intermediate
S3, which shows increased accumulation in COX6A1-KD cells,
we transfected COX6A1-KD cells with expression constructs
containing Cox7a2- and Cox7b-coding sequences fused to a
C-terminal FLAG epitope. To obtain optimal accumulation
of the subunit polypeptides, the cells were transfected twice
consecutively, leading to transgene expression for a total of 4
days. Subsequently, isolated mitochondria were resolved by BN
(7–10% acrylamide gradient)-PAGE and subjected to Western
blot analysis using antibodies specific to Cox1 and the FLAG
epitope. No changes in the amount of the CcO holoenzyme or S3
intermediate were observed in COX6A1-KD mitochondria upon
expression of these polypeptides (Figure 5C).
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Figure 5 Expression of FLAG-tagged versions of Cox6a2, Cox7a2 and Cox7b in wild-type and COX6A1-KD HEK-293 cells
(A and B) Equal amounts (∼20–50 μg) of mitochondrial protein were solubilized using 1.1 % DDM (4.8 DDM/protein) and resolved by BN (7–10 % acrylamide gradient)-PAGE and
subjected to Western blot analysis with antibodies specific to Cox1 (A), Cox2, Cox6c and Cox6a1 (B). (C) Equal amounts of mitochondrial protein solubilized using 1.1 % DDM (4.8
DDM/protein) were resolved by BN (7–10 % acrylamide gradient)-PAGE and subjected to Western blot analysis with antibodies specific to the Cox1 subunit (∼20 μg of protein loaded
per lane) and FLAG epitope (∼60 μg of protein loaded per lane). Both short and long exposures are shown. (A–C) Equal loading was verified using an antibody against the complex II
subunit SDHA. Positions of the various assembly forms of complex IV (a and b) and holoenzyme of complex II (C II) as well as specificity of the antibodies (in the right hand margin)
are indicated. Immunoreactive material was visualized by chemiluminescence. (D) CcO activity was determined by measuring the rate of cytochrome c oxidation (nmol/min per mg of
mitochondrial protein) and normalized to the activity of complex II (SQR) (CcO/SQR ratio), which was determined by measuring the rate of 2,6-dichloroindophenol reduction (nmol/min
per mg of mitochondrial protein). NS, mitochondria from stable HEK-293 cells expressing the non-silencing control shRNAmir; wt, mitochondria from wild-type HEK-293 cells; wt -
COX6A2, mitochondria from wild-type HEK-293 cells transiently transfected with a construct encoding the Cox6a2 subunit; wt - COX6A2-FLAG, mitochondria from wild-type HEK-293 cells
transiently transfected with a construct encoding the FLAG epitope-tagged Cox6a2 subunit; wt - COX7A2-FLAG, mitochondria from wild-type HEK-293 cells transiently transfected with a
construct encoding the FLAG epitope-tagged Cox7a2 subunit; wt - COX7B-FLAG, mitochondria from wild-type HEK-293 cells transiently transfected with a construct encoding the FLAG
epitope-tagged Cox7b subunit; wt - pmaxFP-Red-N, mitochondria from wild-type cells transiently transfected with control plasmid pmaxFP-Red-N encoding a fluorescent marker; COX6A1
c© The Authors Journal compilation c© 2010 Biochemical Society
Assembly and function of nuclear-encoded cytochome c oxidase subunits 4, 5a, 6a, 7a and 7b 371
In contrast with the anti-Cox1 immunoblot, which detected
the S3 intermediate in all of the analysed samples (Figure 5C,
long exposure of band b), the FLAG-specific antibody cross-
reacted with this assembly intermediate only in mitochondria
from cells expressing Cox7b–FLAG. The fact that Cox1-specific,
but not FLAG-specific, antibodies detected S3 in the samples
expressing Cox7a2–FLAG indicated that, unlike Cox7b, Cox7a2
is incorporated after the formation of the assembly intermediate
S3 (Figure 5C).
Mitochondrial preparations from cells transfected with the
Cox6a2–FLAG construct were also analysed for the presence of
expressed subunits in the late assembly forms of CcO. Despite the
high cross-reactivity of both bands a1 and a2 with the anti-Cox1
antibody in these samples, the FLAG-specific antibody detected
band a2 only in Cox7a2–FLAG- and Cox7b–FLAG-expressing
samples (Figure 5C). Furthermore, when endogenous Cox6a1
was probed, only a1 was detected in samples, whereas both bands
a1 and a2 were confirmed with antibodies specific to Cox1, Cox2
or Cox6c (Figures 5A and 5B). These results indicate that subunit
Cox6a is incorporated after the formation of band a2, probably
as the last structural subunit incorporated into the human CcO
complex.
DISCUSSION
CcO is a crucial cellular enzyme with a central role in oxidative
metabolism [2,20]. The significant interest in the biogenesis of
CcO stems from its clinical importance. Defective CcO biogenesis
is frequently related to severe mitochondrial diseases that often
involve tissues with a high energy demand [2,21,22].
It was demonstrated previously in various non-human
eukaryotic models that KD of Cox4 or Cox5a affects CcO
holoenzyme content [23–26]. Deficiency of subunit Cox6a was
described to cause severe CcO deficiency in Drosophila [27] and
mice [28]. However, the yeast Cox6a homologue is dispensable
for assembly of the yeast CcO complex [29]. In the present
study, we have demonstrated that the impact of stable down-
regulation of Cox4i1, Cox5a and Cox6a1 in cultured human cells
on the content of CcO corresponds to similar studies in higher
eukaryotes. Furthermore, our results provide detailed KD-specific
patterns of CcO assembly intermediates and indicate several novel
aspects of the sequential incorporation of subunits during the
assembly process, including identification of a novel assembly
intermediate in human CcO assembly.
Overall, the accumulation of CcO subcomplexes seen in our KD
cells reflected the proposed entry of individual subunits into the
assembly. The effects of COX6A KD on CcO subcomplex pattern
was manifested mainly by the marked increase in the assembly
intermediate S3. Unlike COX4- and COX5A-KD mitochondria, in
which the reduction in the holoenzyme band a1 was accompanied
by a more pronounced decrease in band a2, Cox6a-deficient
mitochondria retained significantly higher levels of the latter
species. These results indicate that band a2 represents another rate-
limiting step in human CcO assembly. Both Cox6a and Cox6b
subunits, which are thought to be responsible for dimerization
of CcO, are the first to dissociate from the bovine complex under
various destabilizing conditions [30,31]. Thus it appears plausible
that the elevated levels of the assembly intermediate S3 in COX6A-
KD cells could stem from compromised binding of Cox6b,
which might be contingent upon the concomitant assembly of
Cox6a. KD of both early-assembled subunits Cox4 and Cox5a
resulted in accumulation of four subcomplexes consisting merely
of subunit Cox1. The absence of Cox1–Cox4/Cox5a heterodimers
confirmed further the interdependence of the assembly of Cox4
and Cox5a [11,32]. Together with the lack of accumulation of
higher-molecular-mass intermediates, our findings suggest that
the assembly of the Cox4–Cox5a heterodimer with Cox1 is
necessary for the subsequent association of Cox2, and thus for the
rest of the assembly to proceed. The Cox1-containing subcomplex
x of ∼155 kDa, which apparently does not contain any of the CcO
subunits that we tested, was found to be particularly increased in
COX5A-KD mitochondria. The composition and migration of this
subcomplex suggests that it might represent an off-path complex
that is not relevant to the normal route of assembly. However, the
other samples, including controls, contained small amounts of this
subcomplex as well. A similar situation in terms of discrepancy
between subunit composition and the apparent molecular mass
was observed in the case of the 110 kDa subcomplex c from
COX4- and COX5A-KD mitochondria. These results strongly
suggest that individual CcO subunits as well as CcO subcomplexes
associate during the assembly with several non-subunit proteins,
as reported for yeast Cox1 [33]. The expression of FLAG-tagged
versions of Cox7a2, Cox7b and Cox6a2 in both wild-type and
Cox6a1-deficient backgrounds allowed us to elucidate for the
first time the very late events in human CcO assembly. We
identified the particular entry points of these three subunits and
demonstrated the significance of the CcO holoenzyme bands a1
and a2. According to our results, band a1 probably represents
the 13-subunit CcO holoenzyme (S4). In contrast, band a2 lacks
subunit Cox6a, which appears to be added as the last assembled
structural subunit. Band a2 (S4*) is formed by the addition of
Cox7a2 and probably Cox6b1 [18] to the assembly intermediate
S3. Finally, subunit Cox7b was found to join the assembling
complex during or at the end of the formation of the assembly
intermediate S3 (Scheme 1).
The amount of CcO holoenzyme in COX5A (sh7) KD and
both COX6A1-KD samples corresponded to the residual content
of the targeted subunits. On the basis of our assertion that the
Cox6a subunit completes the assembly of the CcO holoenzyme,
the amount of fully assembled CcO seems to be strictly contingent
upon the amount of the residual Cox6a. Furthermore, transient
overexpression of subunit Cox6a in wild-type HEK-293 cells
increased the content of CcO holoenzyme. Lower levels of
S3 intermediate and a shift in the a1/a2 ratio towards a1 in
COX5A (sh7) KD samples suggest changes in the kinetics of CcO
assembly in terms of the increased utilization of intermediates
subsequent to the integration of Cox5a, thereby increasing the
level of complete CcO complex to the level of Cox5a. A similar
reduction in the levels of RNAi-target subunits in COX5A (sh5)
KD and COX6A1 (sh12) KD cells resulted in a milder reduction of
Figure 5 Continued
(sh11) - COX6A2, mitochondria from stable COX6A1 (sh11) KD cells transiently transfected with a construct encoding the Cox6a2 subunit; COX6A1 (sh11) or (sh12) - COX6A2-FLAG, mitochondria
from stable COX6A1 (sh11) or (sh12) KD cells transiently transfected with a construct encoding the FLAG epitope-tagged Cox6a2 subunit; COX6A1 (sh11) - COX7A2-FLAG, mitochondria from stable
COX6A1 (sh11) KD cells transiently transfected with a construct encoding the FLAG epitope-tagged Cox7a2 subunit; COX6A1 (sh11) - COX7B-FLAG, mitochondria from stable COX6A1 (sh11) KD
cells transiently transfected with a construct encoding the FLAG epitope-tagged Cox7b subunit; COX6A1 (sh11) - pmaxFP-Red-N, mitochondria from stable COX6A1 (sh11) KD cells transiently
transfected with control plasmid pmaxFP-Red-N encoding a fluorescent marker; NS - pmaxFP-Red-N, mitochondria from NS cells transiently transfected with control plasmid pmaxFP-Red-N
encoding a fluorescent marker.
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Scheme 1 Proposed model of the mammalian CcO assembly pathway
Prosthetic groups and assembly factors are indicated. Arabic numerals denote CcO subunits within subcomplexes. S2 and S3 indicate previously identified assembly intermediates. S4 represents
the 13-subunit CcO holoenzyme, and S4* indicates the late assembly intermediate that immediately precedes the formation of the holoenzyme (see the text for details).
CcO holoenzyme levels in Cox5a-deficient cells. This observation
suggests the existence of different threshold values for the
availability of various CcO subunits during enzyme assembly.
The diminished content of CcO holoenzyme in our KD cells
resulted in a milder reduction in specific CcO activity. Indeed, the
relatively mild Cox4 reduction in COX4I1-KD cells resulted in
virtually normal CcO activity. These observations are in line with
the well-established high excess capacity of CcO [20,34].
Diaz et al. [35] demonstrated that the total loss of CcO leads
to complex I deficiency in a mouse COX10-knockout model.
Furthermore, RNAi KD of Cox4 in murine cultured cells resulted
in decreased stability and activity of complex I [24]. A similar
effect of COX4- and COX5A-KD on complex I was described
in Caenorhabditis elegans, where the content of complex I was
normal, but its enzymatic activity was reduced significantly
[23]. In contrast, the CcO deficiency in our COX4-, COX5A-
and COX6A-KD cells did not lead to any significant changes
in the amount and/or activity of other complexes of oxidative
phosphorylation system, including complex I. Similarly, normal
levels and activity of complex I were also found in murine COX5B-
KD cells with severe CcO deficiency [36]. Further work is needed
to establish the potential role of fully assembled CcO in complex
I biogenesis.
High-resolution respirometry in our CcO-deficient cellular
model showed significantly increased P50 values. This may
indicate either a change in mitochondrial capacity or decreased
affinity for oxygen (=1/P50) of the residual CcO [20]. The lack of
a significant decrease in maximal (state 3u) normoxic respiration
in our KD cells argues against the possibility that P50 is increased
due to lower mitochondrial capacity. The second possibility,
which involves a decrease in oxygen affinity in active states
when the demand for oxygen is highest, is paradoxical from a
functional point of view [20]. However, if the increase in P50
is accompanied by a greater increase in maximum flux (Jmax),
the Jmax/P50 ratio still increases and indicates elevated apparent
catalytic efficiency with activation by ADP [20]. When plotted
as a function of the specific oxygen flux normalized to protein
content, the P50 values in both our KD cell lines increased without
a corresponding increase in oxygen flux (Figure 4C). Therefore
the increase in P50 in our KD cells is most likely to be due to
decreased affinity of CcO for oxygen, i.e. an increased apparent
Km for oxygen. Marked CcO deficiency with almost unchanged
normoxic cellular respiratory rates accompanied by increased P50
values were also found in fibroblasts from patients with Leigh
syndrome owing to Surf1 deficiency [17]. In addition to reduced
holoenzyme levels, Surf1-deficient fibroblasts were characterized
by increased accumulation of CcO subcomplexes. It was
hypothesized that, under conditions of high oxygen pressure, the
accumulated subcomplexes could restore near normal respiration,
and contribute to the increased P50 value [17,37]. However, it
was repeatedly demonstrated that subcomplexes found in Surf1-
deficient fibroblasts are devoid of the catalytic core subunit
Cox2 [11,38]. Similar subcomplexes, i.e. devoid of Cox2, also
accumulate in COX5A-KD mitochondria. Cox2 is known to
mediate electrostatic binding of cytochrome c and represents the
initial entry site for electrons. The subcomplexes in COX6A1-KD
cells are represented mainly by incomplete CcO assemblies that
lack only few peripheral nuclear-encoded subunits. Exposure of
isolated monomeric bovine CcO to hydrostatic pressure results
in a mixture of 13-, 11- and nine-subunit CcO complexes [31].
Analysis of separated forms showed that both the 13-subunit
complex as well as the 11-subunit form devoid of subunits Cox6a
and Cox6b retained 85–90% of electron transport activity of the
untreated enzyme. The nine-subunit form that lacks two additional
subunits (Cox3 and Cox7a) had only 40–45% activity of intact
enzyme. The authors were not able to determine the loss of which
of the two subunits led to such marked reduction in enzyme
activity [31]. Nevertheless, the results of other studies suggest that
the loss of Cox3 is likely to be responsible for the majority of CcO
inactivation observed [39,40]. Both of the major intermediates
found in our Cox6a-deficient cells (a2 and S3) are thus likely
to be capable of electron transfer, unlike the subcomplexes from
COX5A-KD cells. Indeed, the capacity of CcO in COX5A-KD
cells as measured by oxygen consumption after ascorbate/TMPD
was significantly decreased, and the P50 value was significantly
increased when compared with both control and COX6A1-KD
samples. Therefore it appears likely that the presence of the high-
molecular-mass CcO subcomplexes in COX6A-KD cells might
contribute to cellular respiration at low oxygen levels and lead
to higher apparent CcO excess capacity. In contrast, uncoupled
respiration did not change at normoxic levels of oxygen after
natural substrates, and spectrophotometric measurement indicated
a decrease of specific CcO activity to the same extent in both cell
lines.
Nonetheless, the decreased oxygen affinity of CcO in both
KD cell lines appears paradoxical, as there apparently seems to
be no rational reason for the decreased catalytic competence of
the residual CcO enzyme. Furthermore, the substantial reduction
in CcO content was accompanied by less diminished specific
activity of CcO in COX5A- and COX6A1-KD cells, suggesting
compensatory catalytic stimulation of the residual CcO. Taken
together, we assume that decreased oxygen affinity of CcO in our
KD cells results from quantitative changes in the CcO pool which,
when reduced, undergoes normal flux at high oxygen pressure, but
is significantly more sensitive to decreased oxygen levels. Such
an assumption is in line with the oxygen dependence of CcO
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flux control demonstrated previously [41]. In this study, a lower
experimental concentration of oxygen was related to a steeper
initial slope of the cyanide titration curve for maximal succinate
oxidation rate. Moreover, a lower concentration of CcO inhibitor
was necessary to cause complete inhibition of respiration [41].
Both COX5A- and COX6A-KD mitochondria showed, in
addition to a reduction in the CcO monomer, an even more
pronounced reduction of the dimeric form of CcO. Indeed,
the pattern of respiratory supercomplexes showed that species
containing the dimeric form of the CcO complex (III2IV2 and
I1III2IV2) are significantly reduced in KD cells. In contrast,
supercomplexes containing monomeric CcO were unaltered or
even slightly increased. A similar effect was shown recently to
stem from a CcO defect induced by KD of the human CcO-
specific copper metallochaperone Cox17 [42]. The majority of
mammalian CcO is thought to exist in a dimeric form within
the inner mitochondrial membrane [43]. Indeed, it appears that
dimerization of CcO plays a crucial structural and functional role,
conferring maximal structural stability on the complex [31].
In yeast, it was shown that complex IV associates with
complex III already in the form of incomplete subcomplexes,
and that some of the late assembled subunits are probably added
directly to the III/IV supercomplex [44]. An example of such a
subunit is Cox13, the yeast homologue of human Cox6a [45].
Indeed, BN/BN-PAGE immunoblots for both control and down-
regulated cells revealed additional spots that migrate at the level
of supercomplexes in the first dimension, but with an apparent
molecular mass lower than that of the CcO holoenzyme. Although
we cannot, in principle, exclude the removal of some of the
peripheral subunits because of detergent treatment, these spots
might represent incomplete CcO assemblies that are already
present in supercomplexes. Further analyses are required to
confirm this hypothesis.
Despite remarkable conservation of secondary structure in
Cox6a isoforms, mature Cox6a1 and Cox6a2 subunits (non-
muscle and heart/muscle isoform) were found to share lower
intra-species (approx. 60%) than inter-species (80–88%) amino
acid sequence identity in humans, rats and cows, suggesting
that the COX6A1 and COX6A2 genes arose before mammalian
radiation [46]. The tissue-specific pattern of these isoforms is
established during tissue differentiation [47–49]. A switch from
COX6A1 to COX6A2 isoforms was described to occur during
mammalian postnatal development in skeletal muscle and heart
as well as during differentiation of myogenic cells in vitro, and
is assumed to be essential for normal function of tissues with
high aerobic metabolic demands [48,49]. In the heart of mice
lacking the COX6A2 gene, the content of the CcO holoenzyme
was virtually equal to the level of Cox6a1 isoform in wild-type
control, which accounted for 20% of the total Cox6a content.
Thus the content of CcO comprising Cox6a1 appeared to be
unchanged; in other words, without apparent compensation by
induction of the expression of subunit Cox6a1 in the knockout
heart [28]. HEK-293 cells used in this study are derived from
embryonic kidney tissue, which is specific by almost exclusive
(both prenatal and postnatal) expression of the COX6A1 isoform
[47–49]. Indeed, the vast majority of the COX6A transcripts
in HEK-293 cells is represented by the COX6A1 isoform. The
COX6A1 RNAi constructs were designed to target the 3′-UTR of
the COX6A1 transcript, which is lacking in the COX6A2 isoform.
Indeed, similar to the results from COX6A2-knockout heart, the
decrease in the major isoform in our COX6A1-KD cells was not
accompanied by up-regulation of the minor isoform (COX6A2).
However, ectopic expression of Cox6a2 in COX6A1-KD cells
tends to complement the CcO defect. It therefore appears that
the mechanisms responsible for maintenance of tissue-specific
patterns of COX6A isoforms cannot react in response to actual
cellular state. In contrast, it is also possible that the pronounced
biochemical defect still did not provoke sufficient physiological
impairment, which would otherwise trigger the expression of the
minor subunit.
In conclusion, our results indicate that, whereas nuclear-
encoded CcO subunits Cox4 and Cox5a are required for the
assembly of the functional CcO complex, the Cox6a subunit is
required for the overall stability of the holoenzyme. Consequently,
the heterogeneous CcO population of Cox6a-deficient cells
exhibits higher residual respiration at low oxygen levels than
the various CcO forms found in COX5A-KD cells. The fact
that the ectopic expression of heart/muscle-specific isoform of
Cox6a can complement the CcO defect in COX6A1-KD cells
is in sharp contrast with unaltered levels of this isoform in
our CcO-deficient model, and suggests the existence of a fixed
differentiation programme regarding human Cox6a isoforms. The
description of a novel assembly intermediate at the very last
step of CcO assembly suggests additional regulatory level of the
process. The normal amount and function of complex I in all
of our CcO-deficient cell lines suggest that even relatively small
residual amounts of CcO can maintain normal biogenesis of this
respiratory complex in human cells.
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Figure S1 Steady-state levels of selected respiratory chain subunits and several mitochondrial proteins in COX4-, COX5A- and COX6A1-KD cells
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[NADH dehydrogenase (ubiquinone) 1α subcomplex 9].
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5.2. Characterization of the biochemical properties of OXA1L, the 
human homologue of the yeast mitochondrial Oxa1 translocase, 
and study of its role for CcO biogenesis (specific aim 1b)  
 
 
Stiburek L, Fornuskova D, Wenchich L, Pejznochova M, Hansikova H and Zeman J 
 
Knockdown of human Oxa1l impairs the biogenesis of F1Fo-ATP synthase and 
NADH:ubiquinone oxidoreductase. 
 
J Mol Biol 2007; 374: 506-516. 
 
 
We addressed the role of human Oxa1l in the biogenesis of oxidative 
phosphorylation system.   
To study the molecular role and biochemical properties of human OXA1L gene 
product, we employed expression cloning and propagation of plasmid constructs in 
bacteria, rabbit OXA1L antibody design and preparation, immunocytochemistry, 
confocal microscopy, co-immunoprecipitation as well as subcellular and 
submitochondrial fractionation and localization. To estimate functionality and integrity 
of OXPHOS in context of Oxa1l deficiency, we prepared stable human HEK-293 
knockdown lines using human microRNA-adopted design evoking RNA interference. 
The obtained material was analyzed with use of isolation of crude mitochondrial 
fraction by cellular fractionation and differential centrifugation, FACS analysis, 
spectrophotometric measurements of specific enzyme activities, high-resolution 
respirometry and blue-native (BN), denaturing (SDS) and two-dimensional (BN/SDS) 
PAGE with downstream immunoblot detections using monoclonal or polyclonal 
antibodies against various mitochondrial proteins. 
The Oxa1 protein is a member of the evolutionarily conserved Oxa1/Alb3/YidC 
protein family, which is involved in the biogenesis of membrane proteins in 
mitochondria, chloroplasts and bacteria. The predicted human homologue, Oxa1l, was 
originally identified by partial functional complementation of the respiratory growth 
defect of the yeast oxa1 mutant. Here we demonstrate that both the endogenous human 
Oxa1l, with an apparent molecular mass of 42 kDa, and the Oxa1l-FLAG chimeric 
protein localize exclusively to mitochondria in HEK-293 cells. Furthermore, human 
Oxa1l was found to be an integral membrane protein, and, using two-dimensional blue 
native/denaturing PAGE, the majority of the protein was identified as part of a 
600-700 kDa complex. The stable short hairpin (sh) RNA-mediated knockdown of 
62 
Oxa1l in HEK-293 cells resulted in markedly decreased steady-state levels and ATP 
hydrolytic activity of the ATP synthase and moderately reduced levels and activity of 
NADH:ubiquinone oxidoreductase (complex I). However, no significant accumulation 
of corresponding sub-complexes could be detected on blue native immunoblots. 
Intriguingly, the achieved depletion of Oxa1l protein did not adversely affect the 
assembly or activity of cytochrome c oxidase or complex III. Taken together, our results 
indicate that human Oxa1l represents a mitochondrial integral membrane protein 
required for the correct biogenesis of ATP synthase and complex I. 
I contributed to this study by assisting in research design, by cloning of pCMV-
GIN-ZEO plasmid derivatives coding for candidate shRNAs to achieve the most 
efficient knockdown and by performing the part of electrophoretic and immunoblot 
analyses. 
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oxa1mutant. Here we demonstrate that both the endogenous human Oxa1l,
with an apparent molecular mass of 42 kDa, and the Oxa1l-FLAG chimeric
protein localize exclusively to mitochondria in HEK293 cells. Furthermore,
human Oxa1l was found to be an integral membrane protein, and, using
two-dimensional blue native/denaturing PAGE, the majority of the protein
was identified as part of a 600–700 kDa complex. The stable short hairpin (sh)
RNA-mediated knockdown of Oxa1l in HEK293 cells resulted in markedly
decreased steady-state levels and ATP hydrolytic activity of the F1Fo-ATP
synthase and moderately reduced levels and activity of NADH:ubiquinone
oxidoreductase (complex I). However, no significant accumulation of
corresponding sub-complexes could be detected on blue native immuno-
blots. Intriguingly, the achieved depletion of Oxa1l protein did not adversely
affect the assembly or activity of cytochrome c oxidase or the cytochrome bc1
complex. Taken together, our results indicate that human Oxa1l represents a
mitochondrial integral membrane protein required for the correct biogenesis
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lsevier Ltd. All rights reservethase (complex V) embedded within the inner mem-
brane of the organelle. The biogenesis of OXPHOS is
complicated by its sub-cellular location, dual genetic
origin, the large number of constituent subunits and
prosthetic groups, and the high hydrophobicity of
some of the membrane subunits. Consequently, a
number of specific gene products have evolved to
accommodate such complex requirements. One of
them is the Oxa1 protein, a founding member of the
evolutionarily conserved Oxa1/Alb3/YidC protein
family, which is involved in the biogenesis of
membrane proteins in mitochondria, chloroplasts
and bacteria.1,2 The best characterized member of
this family, Saccharomyces cerevisiae Oxa1, is an
intrinsic protein of the inner mitochondrial mem-
brane that mediates the insertion of mitochondrial
translation products as well as of conservatively
sorted nuclear gene products into the inner mem-
brane from the mitochondrial matrix.1,3,4 Although
the yeast Oxa1 was shown to represent a ratherd.
Figure 1. Overexpressed human Oxa1l–FLAG chi-
meric protein is targeted exclusively to mitochondria in
HEK293 cells. (b) HEK293 cells were transiently trans-
fected with the OXA1L–FLAG expression construct,
stained with MitoTracker Red, and (a) subsequently
labeled with a monoclonal M2 anti-FLAG antibody and
with an anti-mouse Alexa Fluor 488 antibody. The
fluorescence signal was recorded with a Nikon Eclipse
TE2000 microscope, and deconvolved using the Huygens
Professional Software (SVI). (c) Superimposition of (a) and
(b) shows complete overlap of the two staining patterns.
507Involvement of Human Oxa1l in OXPHOS Biogenesisgeneral export machinery of the inner membrane,
the co-translational membrane insertion of the
mitochondrially encoded Cox2 precursor appears
to exhibit the strictest dependency on its function.5–7
The other substrates of Oxa1, including Oxa1 itself,
can be inserted independently of its function, albeit
with significantly reduced efficiencies.8,9 Very re-
cently, a novel post-translational role in the biogen-
esis of OXPHOS was demonstrated for yeast Oxa1.
The protein was shown to stably interact in a post-
translational manner with the ATP synthase subunit
c, mediating its assembly into the ATP synthase
complex.10 Yeast oxa1 cells are respiratory-deficient,
with undetectable cytochrome c oxidase (CcO or
complex IV) activity and markedly reduced levels of
the F1Fo-ATP synthase and cytochrome bc1 complex
(complex III).3,4 Schizosaccharomyces pombe contains
two distinct Oxa1 orthologues, both of which are
able to complement the respiratory defect of yeast
Oxa1-null cells. The double inactivation of these
genes is lethal to this petite-negative yeast.11 The
depletion of Oxa1 in Neurospora crassa results in a
slow-growth phenotype accompanied by reduced
subunit levels of CcO and NADH:ubiquinone
oxidoreductase (complex I). The N. crassa, Oxa1
was shown to form a 170–180 kDa homo-oligomeric
complex, most likely containing four Oxa1 mono-
mers.12 Mitochondrial Oxa1 homologues possess a
hydrophobic core domain composed of five trans-
membrane helices, and a C-terminal matrix domain
that was shown in yeast to bind mitochondrial
ribosome, thereby mediating co-translational mem-
brane recruitment of nascent mitochondrial transla-
tion products.13,14
The predicted humanOxa1 orthologue, referred to
as Oxa1l, shares 33% sequence identity with the
corresponding yeast polypeptide. The human
OXA1L cDNAwas originally cloned by partial func-
tional complementation of the respiratory growth
defect of the yeast oxa1-79 mutant.15 It contains an
open reading frame predicted to encode a protein of
435 amino acids. It was suggested that the ten exons
ofOXA1Lmight form an open reading frame able to
encode a precursor protein of 495 amino acids,16 and
more recently the cDNA containing those additional
180 bpwas cloned.17 However, this extended version
was shown to exhibit an even lower capacity to
complement the respiratory growth defect of yeast
oxa1 cells than the original sequence.18 The human
OXA1L mRNA was found to be enriched in mito-
chondria-boundpolysomes isolated fromHeLa cells,
and its 3′ untranslated region was shown to be func-
tionally important when expressed in yeast cells.18
Here we address the role of human Oxa1l in the
biogenesis of OXPHOS. We demonstrate here that
human Oxa1l is a mitochondrial integral membrane
protein that exists as part of a 600–700 kDa complex
in mitochondria of human embryonic kidney 293
(HEK293) cells. We further show that the stable short
hairpin RNA (shRNA)-mediated knockdown of
human Oxa1l in HEK293 cells leads to markedly
decreased protein levels and ATP hydrolytic activity
of the F1Fo-ATP synthase and moderately reducedlevels and activity of NADH:ubiquinone oxido-
reductase. Intriguingly, the activity and content of
cytochrome c oxidase and the cytochrome bc1 com-
plex were unaffected or even increased in Oxa1l
knockdown cells. Hence, these results indicate that
human Oxa1l represents a mitochondrial integral
membrane protein which is required for the correct
biogenesis of the F1Fo-ATP synthase and NADH:
ubiquinone oxidoreductase.Results
Human Oxa1l localizes to mitochondria in
HEK293 cells
The predicted human Oxa1l precursor (Q15070)
has a calculated molecular mass of 48.5 kDa and
possesses a characteristic N-terminal mitochondrial
targeting sequence. Both Mitopred and MitoProt II
predict a significant score for location of the protein
within mitochondria. To demonstrate the mitochon-
drial targeting of Oxa1l, a chimeric construct con-
508 Involvement of Human Oxa1l in OXPHOS Biogenesistaining the OXA1L coding sequence tagged with a
C-terminal FLAG epitope was transiently expressed
in HEK293 cells. As shown in Figure 1, labeling of
the cells with an anti-FLAG monoclonal antibody
and with the mitochondria-selective dye Mito-
Tracker Red followed by confocal microscopy
revealed a characteristic mitochondrial staining
pattern, as well as a complete overlap of the two
signals. To analyze the sub-cellular location of the
endogenous human Oxa1l, we prepared samples of
whole cell lysates, isolated mitochondria and cyto-
plasmic fractions from HEK293 cells. Immunoblot
analysis using an antibody to human Oxa1l showed
that the protein, with an apparent molecular mass of
approximately 42 kDa, is clearly more enriched in
isolated mitochondria than in whole cell lysates, and
is absent from the cytoplasmic fraction (Figure 2(a)).
Antibodies to Cox1 (mitochondria), eIF2α (cyto-
plasm) and mtHSP70 (mitochondria and cytoplasm)
were used as compartment markers. These results
suggest that human Oxa1l localizes exclusively to
mitochondria in HEK293 cells.
Human Oxa1l is an integral membrane protein
Human Oxa1l is predicted to be a transmembrane
protein. We have determined its solubility by
fractionation of sonically disrupted mitochondria
into soluble matrix proteins and membrane vesicles.
Immunoblot analysis of the two fractions revealed
that Oxa1l is found exclusively in the membrane
fraction (Figure 2(b)). To find out whether Oxa1l is a
peripheral or integral membrane protein, its sus-resulting samples (5 μg of protein) were, together with the
immunoblots that were subsequently decorated with antibo
(integral protein). s, supernatant; p, pellet. (c) Mitochondria
dodecyl maltoside and fractionated (50 μg of protein) usin
6%–16% polyacrylamide gradient in the first dimension. The
Oxa1l and ATPase F1-α. Under the conditions employed, an a
of approximately 600 kDa and the F1-ATPase sub-complex of
of Oxa1l antibody that was also achieved using the Oxa1l prceptibility to alkaline carbonate extraction was
assessed. Mitochondria were extracted with sodium
carbonate (pH 11.5), and the supernatant and pellet
fractions were subjected to immunoblot analysis.
Oxa1l was found exclusively in the pellet fraction,
indicating that it is an integral membrane protein
(Figure 2(b)).
Human Oxa1l exists as part of a 600–700 kDa
complex in the mitochondria of HEK293 cells
The fact that both S. cerevisiae and N. crassa Oxa1
proteins were reported to be part of an oligomeric
assembly prompted us to assess this property in the
human protein. Mitochondria isolated fromHEK293
cells were solubilized with 1.3% (w/v) dodecyl mal-
toside and fractionated using two-dimensional
blue native/denaturing PAGE, on a 6%–16% (w/v)
polyacrylamide gradient in the first dimension.
Probing of the resulting immunoblots with the
antibody to Oxa1l and with the corresponding pre-
immune serum revealed that Oxa1l is specifically
present in one major, high molecular mass complex,
and in several minor, faster migrating assemblies.
As shown in Figure 2(c), simultaneous detection
with the antibody to Oxa1l and with an antibody to
ATPase F1-α revealed that the major Oxa1l-contain-
ing complex has an estimated molecular mass of
approximately 600–700 kDa. Since the yeast Oxa1
was recently shown to physically interact with
components of ATP synthase holoenzyme, we
have asked whether the human Oxa1l complex
also contains some of the ATP synthase subunits.Figure 2. Human Oxa1l is a
mitochondrial integral membrane
protein that exists as part of a
600–700 kDa complex. (a) Equal
amounts of protein (20 μg) from
isolated mitochondria, cytoplasmic
fraction and whole cell lysate from
the HEK293 cells were fractionated
using SDS–10% PAGE, and the
resulting immunoblots were deco-
rated with an antibody to Oxa1l.
Antibodies to Cox1 (mitochondria),
eIF2α (cytoplasm) and mtHSP70
(mitochondria and cytoplasm) were
used as compartment markers. (b)
Mitochondria isolated fromHEK293
cells were either sonically dis-
rupted or extracted with sodium
carbonate (pH 11.5) and centrifuged
at 100,000g for 30 min, and the
resulting fractions were processed
for SDS–PAGE. The aliquots of
whole mitochondria lysate, used to prepare denaturing
dies to Oxa1l, mtHSP70 (peripheral protein) and Cox1
isolated from HEK293 cells were solubilized with 1.3%
g two-dimensional blue native/denaturing PAGE, on a
resulting immunoblot was decorated with antibodies to
ntibody to F1-α recognized the ATP synthase holoenzyme
371 kDa. The small arrow indicates a non-specific binding
eimmune serum alone.
Figure 3. Oxa1l is substantially depleted in HEK293 cells by the stable expression of shRNAmir. (a) Equal amounts of
protein (10 μg) from mitochondria isolated from G418-resistant cells stably transfected with one of the OXA1L-targeted
shRNA constructs (shRNA 1, 2 and 3) and from cells expressing the negative control shRNA were fractionated using
SDS–10% PAGE. The resulting immunoblot was decorated with antibodies to Oxa1l, SDHA and porin. (b) The results of
densitometric quantification (Quantity One; Bio-Rad) of three independent experiments from (a) are presented in the
histogram. **, pb0.01 (c) Flow cytometric analysis of GFP expression in HEK293 cells stably transfected with the OXA1L-
targeted shRNA construct (shRNA 2) or with the negative control shRNA construct. The analysis of untransfected
parental HEK293 cells is included as a negative control.
†http://codex.cshl.org
509Involvement of Human Oxa1l in OXPHOS BiogenesisHEK293 cells were transiently transfected with the
OXA1L–FLAG expression construct and solubilized
with 1% (v/v) Triton X-100 and the fusion protein
was then immunoprecipitated from the lysate using
an ANTI-FLAG® M2 affinity agarose resin. The
immunoprecipitate was fractionated using SDS–
PAGE and the resulting immunoblots were probed
with available antibodies against the ATP synthase
subunits and against various respiratory chain
subunits. However, despite high efficiency of
Oxa1l–FLAG protein precipitation we could not
detect any OXPHOS subunits in the immunopreci-
pitate using available antibodies (data not shown).
These results suggest that a substantial fraction of
human Oxa1l exists in the mitochondria of HEK293
cells as part of an approximately 600–700 kDa
assembly that do not appear to contain any of the
mitochondrial OXPHOS complexes.
Stable knockdown of Oxa1l in HEK293 cells
To uncover the functional involvement of human
Oxa1l in the biogenesis of OXPHOS, we down-
regulated its expression in HEK293 cells using RNA
interference (RNAi). Given the considerable half-life
of the OXPHOS complexes, a stable vector-basedapproach was utilized that incorporates the RNA
polymerase II-driven expression of short hairpin
RNAs embedded within the context of a mamma-
lian miR-30 microRNA primary transcript. This
method was shown to provide high-level knock-
down even in polyclonal cell populations of single-
copy integrants.19 Sequences of eight different miR-
30–based shRNAs (shRNAmirs) targeted to the
coding sequence of human OXA1L were down-
loaded from the publicly accessible RNAi Codex
database†, synthesized, cloned into the lentiviral
pCMV-GIN-Zeo vector, and functionally validated
by their transient co-expression with the OXA1L-
FLAG construct (data not shown). The three shRNA
constructs that proved to be effective were selected
(shRNA 1, mp_id 433861; shRNA 2, mp_id 19616
and shRNA 3, mp_id 19615), and together with the
negative control (non-silencing) shRNA construct
and the empty vector were used to establish G418-
resistant stably expressing cells. The fact that the
expression of shRNAmir in the pCMV-GIN-Zeo
vector is transcriptionally coupled with that of green
fluorescent protein (GFP) permitted an estimation of
510 Involvement of Human Oxa1l in OXPHOS BiogenesisshRNA expression levels in stable cells. Flow cyto-
metric analysis revealed that practically all the cells
were GFP positive, without marked differences in
expression levels (Figure 3(c)). The extent of
endogenous Oxa1l protein depletion was then
determined by immunoblot analysis of mitochon-
drial fractions isolated from pooled colonies of
stable cells (Figure 3(a)). The cells carrying the
OXA1L-targeted constructs expressing shRNA 1,
shRNA 2 and shRNA 3 showed substantial reduc-
tions in Oxa1l protein levels to approximately 12%,
20% and 16% of control values, respectively (Figure
3(b)). No significant differences in the Oxa1l protein
levels were observed between cells carrying the
negative control shRNA construct and cells carrying
the empty vector (data not shown). Given the
substantial reduction in Oxa1l protein levels, pooled
colonies were used for subsequent analysis, obviat-
ing the need for additional sub-cloning.
Knockdown of human Oxa1l leads to markedly
diminished protein content and ATP hydrolytic
activity of the F1Fo-ATP synthase and
moderately reduced content and activity of
NADH:ubiquinone oxidoreductase (complex I)
We initially determined the steady-state levels of
several mitochondrial proteins, mainly OXPHOS
subunits, in our cellular Oxa1l knockdown model.
Since we did not detect significant alterations in the
content of mitochondria (porin, 70 kDa flavoproteinsubunit of succinate:ubiquinone oxidoreductase
(SDHA)), the whole-cell lysates, normalized to the
immunoblot signal of α-tubulin, were used for
denaturing immunoblots. The steady-state levels of
SDHA, core protein 2, porin, mtHSP70 and pyruvate
dehydrogenase (PDH)-E2 were found to be similar
to those in negative controls, whereas the levels of
Cox1, Cox2 and Cox5a were either unaffected or
slightly increased to approximately 120%–130% of
control values. In contrast, the steady-state levels of
ATP synthase subunits F1-α, F1-β, OSCP and
subunit d were reduced to approximately 25%–
50%. In addition, the levels of complex I subunits
NDUFB6 and NDUFA9 were decreased to approxi-
mately 50%–60% of control values in Oxa1l-depleted
cells (Figure 4(a), or data not shown).
To determine the holoenzyme content and assem-
bly state of each of the OXPHOS complexes, blue
native immunoblots of dodecyl maltoside-solubi-
lized mitochondria were prepared. Consistent with
denaturing analysis, native immunoblots showed
unaffected levels of respiratory complexes II and III,
whereas the content of cytochrome c oxidase
holoenzyme was increased to approximately 130%
of control values (Figure 4(b)). On the contrary, the
levels of F1Fo-ATP synthase holoenzyme were
reduced to approximately 25%–50%, whereas the
holoenzyme content of complex I was decreased to
approximately 50%–60% of control values in the
mitochondria of Oxa1l-depleted cells (Figure 4(b)).
However, no significant accumulation of either theFigure 4. Depletion of Oxa1l in
HEK293 cells results in decreased
steady-state levels of the F1Fo-ATP
synthase and NADH:ubiquinone
oxidoreductase holoenzyme and
subunits. (a) Equal amounts of pro-
tein (10 μg) from whole cell lysates
prepared from G418-resistant cells
stably transfected with one of the
OXA1L-targeted shRNA constructs
(shRNA 1, 2 and 3) and from cells
carrying the negative control shRNA
construct were fractionated using
SDS–PAGE. The resulting immuno-
blots were decoratedwith antibodies
to α-tubulin, SDHA, F1-β, subunit d,
OSCP, Cox1, Cox2, porin, PDH-E2,
NDUFA9 and NDUFB6. (b) Isolated
mitochondria were solubilized with
1.3% dodecyl maltoside and fractio-
nated using blue native PAGE on
6%–15% polyacrylamide gradient.
The amount of protein loaded per
lane (∼5 μg) was normalized to the
immunoblot signals of porin and
SDHA. The resulting immunoblots
were decorated with antibodies to
NDUFA9 (complex I), subunit d
(complex V), Cox1 (complex IV)
and core protein 2 (complex III).
The immunoblots shown are repre-
sentative of at least three indepen-
dent experiments.
511Involvement of Human Oxa1l in OXPHOS BiogenesisATP synthase or complex I sub-complexes could be
detected on blue native immunoblots using avail-
able antibodies (data not shown).
To confirm and extend the above results, enzy-
matic activities of respiratory chain complexes, as
well as the aurovertin-sensitive ATP hydrolytic
activity, were determined. The activities of succi-
nate:ubiquinone oxidoreductase (SDH), cytochrome
c reductase and citrate synthase (CS) were found to
be at control levels (data not shown), whereas the
activity of CcO, normalized to that of CS, was either
unaffected or insignificantly increased to approxi-
mately 110%–120% of control values. In contrast, the
aurovertin-sensitive ATP hydrolytic activity was
substantially decreased to approximately 30%–60%
of control values in the mitochondria of Oxa1l-
depleted cells (Figure 5(a)). In line with the
moderately reduced protein content, the activity of
complex I, normalized to that of CS, was diminished
to approximately 70%–80% of control values. The
values of aurovertin-sensitive ATPase activity cor-
related with the relative residual content of ATP
synthase holoenzyme, consistent with the fact that
no significant accumulation of F1 sub-complex(es)
could be detected on blue native immunoblots.
To further confirm the results of CcO activity and
content determination, high-resolution polaro-
graphic measurements of ascorbate/N,N,N′,N′-tet-
ramethyl-p-phenylenediamine dihydrochloride
(TMPD)-fuelled, sodium azide-sensitive oxygen
consumption were carried out with digitonin-
permeabilized cells. The measurements showed
significantly increased ascorbate/TMPD-fuelled
respiration in Oxa1l-depleted cells to approximately
150%–160% of control values, indicating increased
activity and/or content of the membrane-embedded
CcO complex in these cells (Figure 5(b)).Discussion
This study represents the first characterization of a
mammalian member of the evolutionarily con-measured in digitonin-permeabilized cells in the presence of FC
as mean±S.D. *, pb0.05; **, pb0.01.served Oxa1/Alb3/YidC family of proteins. The
evidence presented herein indicates that human
Oxa1l is a mitochondrial integral membrane protein
that exists as part of a 600–700 kDa complex in the
mitochondria of HEK293 cells. We further demon-
strate here that the shRNA-mediated depletion of
human Oxa1l leads to compromised biogenesis of
the F1Fo-ATP synthase and, to a lesser extent,
NADH:ubiquinone oxidoreductase.
The mitochondrial membrane localization of
human Oxa1l is supported by several lines of
evidence. First, the protein possesses a characteristic
N-terminal mitochondrial targeting sequence and a
hydrophobic core region composed of five predicted
transmembrane helices. Second, the sub-cellular
fractionation of HEK293 cells together with subse-
quent immunoblotting using an antibody to Oxa1l
revealed that the protein, with an apparent mole-
cular mass of approximately 42 kDa, is highly
enriched in isolated mitochondria and absent from
the cytoplasmic fraction. Third, immunofluores-
cence labeling of HEK293 cells transfected with the
OXA1l–FLAG expression construct, followed by
confocal microscopy, showed an exclusive mito-
chondrial targeting of the overexpressed Oxa1l-
FLAG chimeric protein. Finally, the human Oxa1l
was found exclusively in the pellet fraction of
sonically disrupted mitochondria, and could not be
extracted from the mitochondrial membrane by
alkaline carbonate treatment. Similarly, the yeast
Oxa1 was shown to be a mitochondrial integral
membrane protein, spanning the inner membrane
with five transmembrane helices.20,21
Both S. cerevisiae andN. crassaOxa1 were reported
to be part of an oligomeric assembly.8,12,22 Here we
demonstrate that the majority of human Oxa1l exists
in the mitochondria of HEK293 cells as part of a
600–700 kDa complex of unknown composition. In
contrast to yeast Oxa1,10 no ATP synthase subunits
to which we have antibodies were found to co-
purify with the human Oxa1l–FLAG protein
expressed in HEK293 cells. Similarly, we could not
detect any respiratory chain subunits in the Oxa1l–Figure 5. Depletion of Oxa1l in
HEK293 cells leads to diminished
aurovertin-sensitive ATP hydrolytic
activity and increased ascorbate/
TMPD-fuelled, sodium azide-sensi-
tive oxygen consumption. (a) Aur-
overtin-sensitive ATP hydrolytic
activity was measured using an
ATP-regenerating system in mito-
chondria isolated from G418-resis-
tant cells stably transfected with
one of the OXA1L-targeted shRNA
constructs (shRNA 1 and 2) and
from cells carrying the negative
control shRNA construct. (b) Ascor-
bate/TMPD-fuelled, sodium azide-
sensitive oxygen consumption was
CP using an OROBOROS oxygraph. Values are expressed
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from N. crassa was shown to be composed exclu-
sively of Oxa1 monomers,12 it is possible that also
the human complex might be similarly organized.
However, given the higher estimated molecular
mass of the human complex, it seems likely that
some other protein(s) might be involved.
To investigate the functional involvement of
human Oxa1l in the biogenesis of OXPHOS, we
down-regulated its expression in HEK293 cells by
the stable expression of shRNAmir. The depletion of
Oxa1l achieved was specific, since a qualitatively
identical loss-of-function phenotype was induced
using three different shRNA species. The Oxa1l-
depleted cells showed largely normal mitochondrial
content, and both functionally and quantitatively
intact respiratory chain complexes II and III.
Intriguingly, the cytochrome oxidase activity and
content of CcO, as well as the ascorbate/TMPD-
fuelled, sodium azide-sensitive oxygen uptake, were
either unaffected or even increased when compared
to negative controls. On the contrary, markedly
reduced protein content and ATPase activity of the
F1Fo-ATP synthase and moderately reduced content
and activity of NADH:ubiquinone oxidoreductase
were found in Oxa1l-depleted cells, indicating
selectively compromised assembly or stability of
these two OXPHOS complexes. However, no sig-
nificant accumulation of sub-complexes containing
either the ATP synthase or complex I subunits could
be detected in the mitochondria of Oxa1l-depleted
cells.
The observed defect of ATP synthase and com-
plex I is consistent with the mitochondrial localiza-
tion and integral membrane nature of Oxa1l and,
to a certain extent, with the functional involvement
of fungal Oxa1 homologues. However, the inacti-
vation of OXA1 in yeast was shown to cause more
pleiotropic OXPHOS defects, characterized mainly
by the complete absence of CcO activity,4 pointing
to the essential requirement of Oxa1 in the bio-
genesis of CcO.23 In our opinion, there are at least
four reasons that might account for the observed
difference between the human cell line and fungi.
First, the human protein might have functionally
diverged from its fungal counterparts, most likely
in terms of an adapted substrate preference.
Since the yeast Oxa1 is strictly required for the
N-terminal export of Cox2 precursor, it is possible
that the complete absence of the N-terminal leader
peptide in nascent human Cox2 might be respon-
sible for the observed Oxa1-independent assembly
of human CcO. Second, another protein that pro-
vides a partially overlapping function (e.g. Cox18)
might be able to compensate, to a certain extent,
for the lack of Oxa1l in human mitochondria.
Third, Oxa1l may exhibit a tissue-specific loss-
of-function phenotype, similar to several other
factors involved in human OXPHOS biogenesis.24
Finally, the depletion of Oxa1l achieved might
not reach the threshold necessary to induce a de-
tectable defect of cytochrome c oxidase and cyto-
chrome bc1 complex, though the increased respi-ratory activity and content of CcO argues against
this alternative.
The fact that human Oxa1l is able to partially
restore the respiratory growth of yeast oxa1 cells
suggests that both proteins share at least basic
functional features. However, given the wide
exchangeability among the members of the Oxa1/
Alb3/YidC family,25 this cannot be extrapolated to a
precise endogenous role. In this context, it was
suggested that the potential homo-oligomerization
of Oxa1 proteins might be responsible for their
functional conservation, as interaction with other
components may be dispensable for basic (translo-
case) function.12
The slightly increased activity and content of
CcO in Oxa1l-depleted cells may likely represent a
part of an adaptive response to OXPHOS impair-
ment. This explanation appears conceivable, since
CcO was repeatedly shown to exhibit a low reserve
capacity and a large control coefficient over the
respiratory chain.26–28 Furthermore, CcO was
shown to be required for the assembly/stability of
complex I in mouse fibroblasts.29 Indeed, a similar
increase in the protein content of CcO was observed
in human fibroblasts with a selectively reduced
content of complex I holoenzyme.30 The observed
discrepancy between the cytochrome oxidase activ-
ity and ascorbate/TMPD-driven respiration was
reported31 and probably stems from different pre-
parations of the enzyme complex. Unlike the low-
concentration digitonin treatment (respirometry),
which preserves the inner membrane intact, the
lauryl maltoside solubilization (spectrofotometric
CcO assay) removes the enzyme complex from the
inner membrane, eventually leading to altered
enzyme function (e.g. due to abrogated allosteric
interactions).
Since we did not detect any significant accumula-
tion of ATP synthase or complex I sub-complexes in
Oxa1l-depleted mitochondria, it seems unlikely that
the holoenzyme reduction observed could stem
from a compromised stability of the complex. The
lack of significant accumulation of F1-ATPase also
suggests that the assembly defect of ATP synthase
cannot be attributed solely to selectively affected
accumulation of mitochondrially encoded subunits
a and A6L, since human ρ0 cells were shown to
contain high levels of F1-ATPase.
32 The F1-ATPase
was, however, repeatedly found to be more or less
stably associated with subunit c (oligomer) in ρ0
cells.33,34 In contrast to yeast and S. pombe, the bio-
genesis of mammalian (and N. crassa) ATP synthase
is likely to be further complicated by the fact that the
highly hydrophobic subunit c is encoded in the
nucleus and has to be imported from the cytoplasm
prior to its membrane insertion and assembly.
Nargang et al.12 have studied the N. crassa oxa1
mutant but the authors did not address the effects of
Oxa1 depletion on the ATP synthase in their paper.
Recently, it was reported that the ATP synthase
defect of yeast oxa1 cells probably stems directly
from the compromised assembly of subunit c into
the holoenzyme.10 Indeed, the expression level of
513Involvement of Human Oxa1l in OXPHOS Biogenesissubunit c was suggested to determine the content of
ATP synthase in mammalian tissues.35 It was shown
that in mouse and rat thermogenic brown fat, the
low expression level of subunit c mRNA correlates
with the low relative content of ATP synthase in
this tissue, irrespective of high mRNA levels of the
remaining ATP synthase subunits.36–38 Furthermore,
no accumulated ATP synthase sub-complexes could
be detected in brown adipose tissue.39 Therefore, we
speculate that the ATP synthase defect of human
Oxa1l-depleted cells could stem from the impaired
assembly and/or membrane integration of the
nuclear-encoded ATP synthase subunit c.
In conclusion, this study has revealed a possible
role for the human member of the Oxa1/Alb3/
YidC protein family in the biogenesis of OXPHOS
that differs to a certain extent from that demon-
strated for fungal Oxa1 homologues. The specific
RNAi phenotype suggests that Oxa1l is involved in
the biogenesis of ATP synthase and complex I in
human mitochondria, consistent with its mitochon-
drial localization and integral membrane proper-
ties. Future work will involve investigation of the
exact composition of the Oxa1l-containing high
molecular mass complex, as well as knockdown of
Oxa1l expression in another (primary) human cell
type.Materials and Methods
Cell culture, transfections and flow cytometry
Human embryonic kidney cells (HEK293, CRL-1573)
were obtained from ATCC (Rockville, MD) and grown
at 37 °C in a 5% (v/v) CO2 atmosphere in high-glucose
Dulbecco's modified Eagle's medium (PAA, Austria)
supplemented with 10% (v/v) fetal calf serum (PAA).
Cell transfections were carried out either with a Nucleo-
fector™ device (Amaxa, Cologne, Germany) using the
HEK293 cell-specific transfection kit (Amaxa) or with the
Lipofectamine 2000 reagent (Invitrogen, Paisley, UK). The
GFP fluorescence of stable G418-resistant HEK293 cells
was measured with a FACSCalibur flow cytometer and
analyzed using the Cell Quest 3.3 application (Becton
Dickinson, San Jose, CA).Immunofluorescence
HEK293 cells (1.5×105) grown on 70 mm2 glass
chamber slides (BD Falcon, Palo Alto, CA) were trans-
fected with an OXA1L–FLAG expression construct using
the Lipofectamine 2000 reagent. At 24 h after the
transfection, the cells were incubated with 200 nM
MitoTracker Red CMX Ros (Molecular Probes, Eugene,
OR) for 15 min, and then fixed and permeabilized with
phosphate-buffered saline, 4% (v/v) paraformaldehyde
and 0.1% (v/v) Triton X-100 solutions, respectively.
Subsequently, the cells were incubated in phosphate-
buffered saline, 10% (w/v) bovine serum albumin solu-
tion for 1 h at 37 °C to block non-specific binding.
Immunocytochemical detection was then performed with
a monoclonal M2 anti-FLAG antibody (1:1000) and with
an anti-mouse IgG1 Alexa Fluor® 488 antibody (1:500).Laser scanning confocal microscopy
xyz images sampled according to the Nyquist criterion
were acquired using a Nikon Eclipse TE2000 microscope
equipped with a C1si confocal scanning head and an
Apo TIRF 60× (N.A. 1.49) objective. The 488 nm and
543 nm laser lines and appropriate 515(±15) and 590(±15)
nm band pass filter sets were used for excitation and
fluorescence detection, respectively. Individual channel
images were acquired separately. Images were restored
using the measured point spread function (PSF) and
the classic maximum likelihood deconvolution algorithm
in Huygens Professional Software (SVI, Hilversum,
Netherlands).Plasmid construction
The nucleotide sequences of eight different miR-30–
based shRNAs (shRNAmirs) targeted to the coding
sequence of human OXA1L were downloaded from the
publicly accessible RNAi Codex database.40 The corre-
sponding 97-mer oligonucleotides were synthesized (Invi-
trogen) and used as template sequences for PCR
amplification to produce clonable double-stranded pro-
ducts. The corresponding XhoI/EcoRI restriction frag-
ments were inserted downstream of the CMV-GFP-IRES-
Neo expression cassette of the lentiviral pCMV-GIN-Zeo
vector (Open Biosystems, Huntsville, AL). The negative
control (non-silencing) shRNAmir pCMV-GIN-Zeo deri-
vative was obtained from Open Biosystems. The full-
length human OXA1L coding sequence was amplified
from the IMAGE (integrated molecular analysis of
genomes and their expression) clone 40017377 and
inserted into the C-FLAG fusion mammalian expression
vector pCMV-Tag4 (Stratagene, La Jolla, CA). The fidelity
of all constructs was confirmed by automated DNA
sequencing.Validation of shRNAs and generation of stable
transfectants
To assess the efficiency of the shRNAmir constructs,
HEK293 cells were co-transfected using a Nucleofector™
device with either one of the eight OXA1L-targeted
shRNA constructs or the negative control (non-silencing)
shRNA construct and with the OXA1L–FLAG expres-
sion construct. At 48 h after the transfection, the cells
were lysed and the expression level of the Oxa1l-FLAG
fusion protein was examined by immunoblot analysis.
The three OXA1L-targeted constructs that contained
shRNA 1 (mp_d 433861, 5′-CAAGTTAGCAGGAGAC-
CAT-3′), shRNA 2 (mp_id 19616, 5′-CCTACAACCTG-
GAAAG GAT-3′) and shRNA 3 (mp_id 19615, 5′-
GAGACCATATTGAGTATTA-3′) (RNAi Codex) showed
the highest potential to interfere with the expression of
Oxa1l–FLAG protein in the transient assay. For the
generation of stable transfectants, HEK293 cells (106)
were transfected using a Nucleofector™ device with the
three functionally validated OXA1L-targeted shRNA
constructs, the negative control (non-silencing) shRNA
construct and with the empty vector. At 48 h after the
transfection the cells were split into culture medium
containing 720 μg/ml of G418 sulfate (Clontech,
Mountain View, CA) and antibiotic-resistant colonies
were selected over a period of three weeks. The cells
were further maintained in the presence of 720 μg/ml
G418.
514 Involvement of Human Oxa1l in OXPHOS BiogenesisPreparation of a polyclonal antibody to human Oxa1l
An Oxa1l-specific antiserum was generated by immu-
nizing chicken with a synthetic peptide (KLH-coupled)
corresponding to the C-terminal part of human Oxa1l
(CKPKSKYPWHDT). The polyclonal antibody to human
Oxa1l was affinity-purified from the total IgY with the
respective peptide-packed column. The specificity of the
produced antibody was tested by immunodetection of the
Oxa1l-FLAG fusion protein.
Immunoblot analysis
Protein sample preparations, electrophoresis and
immunoblot analysis were performed essentially as
described.24 Monoclonal antibodies against the mitochon-
drial outer membrane protein porin, CcO subunits Cox1,
Cox2 and Cox5a, the 70 kDa flavoprotein subunit of SDH
(SDHA), complex III subunit core protein 2, complex I
subunits NDUFA9 and NDUFB6, complex V subunits
F1-α, F1-β, subunit d and OSCP, and pyruvate dehydro-
genase (PDH) subunit E2 were obtained from Mitos-
ciences (Eugene, OR). The mouse monoclonal antibody to
mtHSP70 was from Alexis Biochemicals (San Diego, CA).
Polyclonal antibodies to α-tubulin and eIF2α were from
Cell Signaling Technology (Beverly, MA), and the mono-
clonal anti-FLAG antibody was from Sigma (Prague,
Czech Republic). Signal acquisition was performed using
either a VersaDoc 4000 imaging system (Bio-Rad Labora-
tories, Hercules, CA) or Kodak BioMax Light films
(Eastman Kodak Co., Rochester, NY). Digital images
were analyzed using the Quantity One application (Bio-
Rad Laboratories).
Immunoprecipitation of Oxa1l–FLAG protein
HEK293 cells (∼106) were transiently (48 h) transfected
with the Oxa1l–FLAG expression construct, lysed with a
buffer containing 1% Triton X-100, 150 mM NaCl, 1 mM
EDTA and 50 mM Tris–HCl (pH 7.4), and the lysate was
incubated for 6 h at 4 °C with previously washed 50 μl of
an ANTI-FLAG® M2 affinity agarose resin (flagipt-1;
Sigma, Prague, Czech Republic). Subsequently, the resin
was washed five times with a buffer containing 150 mM
NaCl, 50 mM Tris–HCl (pH 7.4), and the bound protein
was eluted by competition with 3× FLAG peptide. Finally,
the eluted immunoprecipitate was combined with SDS
sample buffer and resolved using SDS–PAGE.
Enzyme activity assays
The activities of enzyme complexes NADH:ubiquinone
oxidoreductase (complex I), succinate:ubiquinone oxidor-
eductase (SDH or complex II), cytochrome bc1 complex
(complex III), cytochrome c oxidase (complex IV) and
citrate synthase (CS) were measured spectrophotometri-
cally in whole cell extracts and isolated mitochondria
using standard methods.41 Aurovertin-sensitive ATP
hydrolytic activity was measured in isolated mitochondria
using an ATP-regenerating system as described.41,42
Polarographic measurements
The ascorbate/TMPD-fuelled sodium azide-sensitive
oxygen consumption of digitonin-permeabilized HEK293
cells was measured at 30 °C using an OROBOROSOxygraph (Anton Paar, Innsbruck, Austria) in a medium
containing 0.5 mM EGTA, 3 mMMgCl2, 60 mM potassium
lactobionate, 20 mM taurine, 10 mM KH2PO4, 110 mM
sucrose, 1 g/l BSA, 20 mM Hepes (pH 7.1). The
measurements were carried out in the presence of
30 μg/ml of digitonin, 2.5 μM antimycin A, 2 mM
ascorbate, 500 μM TMPD and 1.5 μM carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone (FCCP). Respira-
tion was inhibited by the addition of sodium azide to a
final concentration of 10 mM.
Sub-cellular and submitochondrial fractionation
HEK293 cells (107) were harvested, washed twice with
phosphate-buffered saline, resuspended in an isotonic
buffer containing 250 mM sucrose, 10 mM Tris–HCl (pH
7.4), 1 mM EDTA, 1% (w/v)Protease inhibitor cocktail
(Sigma), and disrupted on ice using a Dounce homo-
genizer. Unbroken cells and nuclei were removed from the
homogenate by centrifugation at 600g for 15min. The post-
nuclear supernatant was centrifuged at 10,000g for 25 min
to pellet the mitochondria. The resulting supernatant cor-
responding to the cytoplasmic fraction was collected, and
the mitochondrial pellet was washed once with the
isotonic buffer. For sonical disruption, isolated mitochon-
dria were adjusted to a protein concentration of 2.5 mg/
ml, sonicated and centrifuged at 100,000g for 30 min.
Alkaline sodium carbonate extraction of mitochondrial
membranes was performed essentially as described.43
Statistical analysis
A Student's t test was performed using Microsoft Excel.
Results are expressed as mean±S.D. A p value of less than
0.05 was considered as statistically significant, and
asterisks are used to denote significance as follows: *,
pb0.05; **, pb0.01.Acknowledgements
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Numerous studies have characterized the molecular mechanisms of point 
mutations in mitochondrial tRNA genes in vitro, but less was known how these 
mutations affect the amount and stability of OXPHOS complexes in human tissues. We 
have characterized the tissue- and gene-specific impact of 8363G>A, 8344A>G and 
3243A>G mutations affecting mt-tRNALys and mt-tRNALeu(UUR) on OXPHOS 
complexes in various tissues of patients carrying these mutations with clinical 
phenotypes of Leigh, MERRF and MELAS syndromes. 
We used spectrophotometric measurements of specific enzyme activities, high-
resolution respirometry and isolation of crude mitochondrial fraction by cellular 
fractionation and differential centrifugation to perform blue-native (BN) and two-
dimensional (BN/SDS) PAGE with downstream immunoblot detections using 
monoclonal antibodies against various mitochondrial proteins. 
In skeletal muscle mitochondria, both mutations that affect mt-tRNALys 
(8363G>A, 8344A>G) resulted in severe combined deficiency of complexes I and IV, 
compared to an isolated severe defect of complex I in the 3243A>G sample (mt-
tRNALeu(UUR)). Furthermore, we compared obtained patterns with those found in the 
heart, frontal cortex, and liver of 8363G>A and 3243A>G patients. In the frontal cortex 
mitochondria of both patients, the patterns of OXPHOS deficiencies differed 
substantially from those observed in other tissues, and this difference was particularly 
striking for ATP synthase. Surprisingly, in the frontal cortex of the 3243A>G patient, 
whose ATP synthase level was below the detection limit, the assembly of complex IV, 
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other than the availability of mtDNA-encoded subunits. 
I contributed to this study by designing the research, carrying out the part of one-
dimensional and two-dimensional electrophoretic and immunoblot analyses, and by 
writing the paper. 
Author's personal copy
The impact of mitochondrial tRNA mutations on the amount of ATP synthase
differs in the brain compared to other tissues
Daniela Fornuskova, Olga Brantova, Marketa Tesarova, Lukas Stiburek, Tomas Honzik,
Laszlo Wenchich, Evzenie Tietzeova, Hana Hansikova, Jiri Zeman ⁎
Department of Pediatrics and Center of Applied Genomics, First Faculty of Medicine, Charles University in Prague,
Ke Karlovu 2, Prague 2, 128 08, Czech Republic
Received 20 September 2007; received in revised form 1 February 2008; accepted 1 February 2008
Available online 15 February 2008
Abstract
The impact of point mutations in mitochondrial tRNA genes on the amount and stability of respiratory chain complexes and ATP synthase
(OXPHOS) has been broadly characterized in cultured skin fibroblasts, skeletal muscle samples, and mitochondrial cybrids. However, less is
known about how these mutations affect other tissues, especially the brain. We have compared OXPHOS protein deficiency patterns in skeletal
muscle mitochondria of patients with Leigh (8363GNA), MERRF (8344ANG), and MELAS (3243ANG) syndromes. Both mutations that affect
mt-tRNALys (8363GNA, 8344ANG) resulted in severe combined deficiency of complexes I and IV, compared to an isolated severe defect of
complex I in the 3243ANG sample (mt-tRNALeu(UUR)). Furthermore, we compared obtained patterns with those found in the heart, frontal cortex,
and liver of 8363GNA and 3243ANG patients. In the frontal cortex mitochondria of both patients, the patterns of OXPHOS deficiencies differed
substantially from those observed in other tissues, and this difference was particularly striking for ATP synthase. Surprisingly, in the frontal cortex
of the 3243ANG patient, whose ATP synthase level was below the detection limit, the assembly of complex IV, as inferred from 2D-PAGE
immunoblotting, appeared to be hindered by some factor other than the availability of mtDNA-encoded subunits.
© 2008 Elsevier B.V. All rights reserved.
Keywords: Brain; COX — cytochrome c oxidase; Leigh syndrome; MELAS syndrome; MERRF syndrome; Tissue specificity
1. Introduction
The mammalian organism fully depends on the oxidative
phosphorylation system (OXPHOS) as the major energy (ATP)
producer of the cell. Disturbances of OXPHOS may be caused
by mutations in either mitochondrial DNA (mtDNA) or
nuclear DNA, and environmental factors have also been
shown to have important effects on OXPHOS. In human
mitochondria, a small circular DNA molecule (16 659 bp)
codes for 13 polypeptides that form, together with nuclear-
encoded subunits, five inner-membrane OXPHOS complexes.
For the translation of these 11 mRNAs (nine monocistronic
and two bicistronic), mitochondria contain a separate transla-
tional system made of protein components, encoded exclu-
sively by nuclear genes and RNA components encoded by the
mitochondrial genome (two ribosomal RNA (rRNA) genes
and 22 transfer RNA (tRNA) genes). Mitochondrial translation
is precisely controlled to meet tissue-specific demands for
mtDNA-encoded structural subunits of the OXPHOS com-
plexes [1]. Although the basal components of the mito-
chondrial expression system are known, the mechanism of
regulation of the system in response to the metabolic needs of
the cell is poorly understood [2,3].
Since the late 1980s, large-scale deletions and point muta-
tions in mtDNA (approximately 120 in tRNAs and 11 in rRNAs)
have been identified to cause disorders of mitochondrial protein
synthesis, which is associated with defects of mitochondrial
bioenergetics in tissues that most depend on OXPHOS. Despite
numerous clinical studies on patients with mt-tRNA mutations,
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which usually involve morphological and functional character-
ization of OXPHOS insufficiency in skin fibroblast cultures or
skeletal muscle, little is known regarding tissue specificity of
OXPHOS deficiencies.
The aim of this study was to determine the steady-state levels
of OXPHOS protein complexes in the mitochondria of various
tissues (skeletal muscle, heart, frontal cortex and liver) of pa-
tients with mt-tRNA mutations. We chose (i) a patient with an
8363GNA mutation in mt-tRNALys, who died of Leigh syn-
drome; (ii) a patient with an 8344ANG mutation in the same
tRNA, who suffers from MERRF syndrome (myoclonic epi-
lepsy with ragged-red fibers); and (iii) a patient with a 3243ANG
mutation in mt-tRNALeu(UUR), who died of MELAS syndrome
(mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes). In the skeletal muscle of these patients, the mu-
tations manifested themselves as described in previous studies
[4–11]; however, these results disclose new aspects of OXPHOS
deficiencies in the brain, particularly in the case of ATP syn-
thase. Furthermore, the 3243ANG frontal cortex mitochondria
showed a marked loss of the complex IV holoenzyme, accom-
panied by accumulation of assembly intermediates, which might
be caused by the virtual absence of complex V in this sample. A
similar phenomenon was described in yeast ATP synthase mu-
tants [12–15].
2. Patients, materials and methods
2.1. Ethics
This study was carried out in accordance with the Declaration of Helsinki of
the World Medical Association, and was approved by the Committee of Medical
Ethics of the Faculty of Medicine and General Faculty Hospital. Informed
parental consent, in accordance with the guidelines of the Faculty of Medicine,
Charles University, was obtained for all biopsies and autopsies.
2.2. Case reports
2.2.1. Patient 1, with an 8363GNA mtDNA mutation
The boy was born at term with a birth weight of 2590 g (5th percentile) and a
length of 48 cm. The early postnatal adaptation was uneventful, but a failure to
thrive and progressive hypotony developed beginning in infancy, and he was
wheelchair-dependent from the age of 8 years. Psychological investigations
revealed moderate mental retardation, which later became severe. At the age of
8 he had his first epileptic paroxysm, and at the age of 11, an acute stroke-like
encephalopathy developed, resulting in generalized weakness and respiratory
failure requiring ventilatory support. The liver function was unaffected and
aminotransferases were always within the reference range. The EEG pattern was
abnormal; an EMG demonstrated peripheral neuropathy, echocardiography
showed hypertrophic cardiomyopathy, and MRI revealed bilateral necrotic basal
ganglia lesions typical of Leigh syndrome. The boy died at the age of twelve.
Metabolic analyses revealed hyperlactacidemia (2.5–5.5 mmol/l, controls
b2.1 mmol/l) with an increased lactate/pyruvate ratio (L/P 28).
2.2.2. Patient 2, with a 3243ANG mtDNA mutation
The girl was born at term with a birth weight of 3140 g and a length of 50 cm.
Her early postnatal adaptation was uneventful, but a failure to thrive and growth
retardation were observed beginning in infancy. At the age of 16 years, her weight
and height were 30 kg and 140 cm (b3rd percentile). Cardiac evaluation revealed
dilated cardiomyopathy and Wolf–Parkinson–White syndrome. At the age of
18 years, blurred vision, emesis and tiredness developed, and subsequently,
seizures and coma. An MRI study showed symmetrical lesions within the basal
ganglia, compatible with Leigh syndrome, in addition to several hypodensities in
the subcortical regions of the frontal and occipital parts of the brain, which are
consistent with a diagnosis of acute ischemia. Metabolic analyses revealed
metabolic acidosis (BE-10 to -25 mmol/l, controls±2 mmol/l), as well as
increased levels of lactate in the blood (4–10 mmol/l, controls b2.1 mmol/l),
cerebrospinal fluid (12 mmol/l, controls b2.1 mmol/l), and urine (4976 mM/mol
creatinine, controls b60 mM/mol creatinine). Despite intensive treatment, the
girl died of progressive encephalomyopathy and respiratory failure due
to acquired infection during the terminal phase of the disease, at the age of
18 years.
2.2.3. Patient 3, with an 8344ANG mtDNA mutation
The boy was born at term with a birth weight of 3500 g and length of
51 cm, with normal postnatal adaptation. Beginning at the age of 11 years, he
developed progressive muscle weakness and paresthesia. Now, at the age of 15,
he has generalized muscle hypotrophy and hyporeflexia. No mental deteriora-
tion has been observed. An EMG disclosed diffuse myopathic abnormalities
and normal nerve conduction velocities. The EEG and cardiac evaluation were
normal. Metabolic analyses revealed an increased level of lactate in the blood
(5.6–7.88 mmol/l, controls b2.1 mmol/l) and lactate in the urine (5148 mM/mol
creatinine, controls b60 mM/mol creatinine).
2.3. Tissues
All studied tissues were obtained from three patients harbouring one of two
mutations in mt-tRNALys (8363GNA and 8344ANG) or one mutation in mt-
tRNALeu(UUR) (3243ANG), as well as from age-related controls. Open muscle
biopsies from the tibialis anterior muscle were frozen at -80 °C. Post-mortem
tissue specimens obtained at autopsy of 8363GNA and 3243ANG patients, and
controls were frozen less than 2 h after death. The studies were performed in
available stored material from the muscle (tibialis anterior), heart, liver, and
brain (frontal cortex).
2.4. mtDNA analysis
Total genomic DNA was isolated by phenol extraction from available tis-
sues. The DNA sample from the muscle biopsy of patient 1 was used for the
sequencing of the whole mtDNA molecule on an AbiPrism 3100 Avant Genetic
Analyser (Applied Biosystems).
To determine the amount of mtDNA containing the mutation, PCR/RFLP
analysis was performed. PCR products (8279–8485) were radioactively labelled
with [α-32P]dCTP in the final cycle of PCR, and run on a non-denaturing 10%
(w/v) polyacrylamide gel after complete digestion with TspRI (New England
BioLabs). The mutation abolishes one of two TspRI restriction sites on the
fragment. The proportions of wild-type to mutant mtDNAwere measured using
a PhosphorImager and ImageQuant software (Molecular Dynamics). The levels
of heteroplasmy of the 3243ANG and 8344ANG mutations were determined as
described elsewhere [16].
2.5. Electrophoresis
BN-PAGE (Blue-Native PAGE) [17] was used for the separation of mito-
chondrial membrane protein complexes on polyacrylamide 6–15% (w/v) gra-
dient gels using a MiniProtean® 3 System (Bio-Rad Laboratories). 5–50 μg of
protein, which was prepared as described previously [18], was loaded in each
lane. Two-dimensional BN/SDS/PAGE [17] was performed as described pre-
viously [18]. The protein content was measured by the Bio-Rad Protein Assay
(Bio-Rad Laboratories), using BSA as a standard.
2.6. Immunoblot analysis
Proteins were electroblotted from the gels onto Immobilon™-P PVDF
membranes (Millipore) using semi-dry transfer for 90min at a constant current of
0.8 mA/cm2. Membranes were air-dried overnight, rinsed twice with 100% (v/v)
methanol, and blocked in TBS and 10% (w/v) non-fat dried milk for 1–2 h.
Primary detection of BN/PAGE-blots was performed with mouse monoclonal
antibodies raised against the complex I subunit NDUFA9 (2 μg/ml), ATP syn-
thase subunit alpha (2-3 μg/ml), complex III subunit Core 2 (0.5 μg/ml), complex
IV subunit COX2 (0.5–1 μg/ml), and complex II subunit 70 kDa protein (1 μg/
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ml) (Mitosciences), at indicated dilutions. Primary detection of two-dimensional
BN/SDS/PAGE-blots for the COX assembly was performed according to
Stiburek et al. [18]. Blots were incubated with primary antibodies in TBS, 0.3%
(v/v) Tween 20, and 2% non-fat dried milk for 2 h. Secondary detection was
carried out with a goat anti-mouse IgG-horseradish peroxidase conjugate
(1:1000–1:4000) (Sigma–Aldrich) in TBS, 0.1% Tween 20, and 2% non-fat
dried milk, for 1 h. The immunoblots were developed with SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce). The immunoblot-images of
chemiluminescence signals were captured using the VersaDoc Imaging System,
Model 4000 (Bio-Rad Laboratories), and analysed by the Quantity One
application (Bio-Rad Laboratories). All blotting experiments were repeated
with independently isolated mitochondrial samples. Duplicate experiments
yielded consistent results.
2.7. Spectrophotometric assays
The activities of respiratory chain complexes in isolatedmusclemitochondria
were measured spectrophotometrically by standard methods at 37 °C. NADH:
coenzyme Q10 reductase (NQR, complex I), succinate:coenzyme Q10 reductase
(SQR, complex II), succinate:cytochrome c reductase (SCCR, complex II+III),
NADH:cytochrome c reductase (NCCR, complex I+ III), coenzyme Q10:cyto-
chrome c reductase (QCCR, complex III), and cytochrome c oxidase (COX,
complex IV) were measured according to Rustin et al. [19], and citrate synthase
(CS) according to [20]. Total protein amount was determined by the method of
Lowry [21].
2.8. High resolution oxygraphy in muscle fibers
Muscle fibers were separated mechanically according to [22], and oxygen
consumption by saponin-skinned muscle fibers was determined using multiple
substrate inhibitor titrations as described previously [23].
3. Results
3.1. Heteroplasmy of mt-tRNA mutations in investigated tissues
Analyses of heteroplasmy by radioactive PCR-RFLP showed
80 – 97% heteroplasmy of mt-tRNA mutations in the tissues of
all patients (Table 1). Despite the narrow range of the mutation
load found in patient tissues, the severity of the clinical/func-
tional phenotype did not correlate with the level of heteroplasmy.
3.2. Steady-state levels of OXPHOS complexes in 8363GNA,
8344ANG and 3243ANG skeletal muscle
To investigate the impact of mtDNAmutations on the system
of oxidative phosphorylation, immunoblots of mitochondrial
fractions resolved by BN-PAGE were prepared. Dilutions of
samples from control mitochondria were loaded on the same gels
in order to express the residual steady-state levels of OXPHOS
complexes in the patient tissues as a percentage of control
values.
In the 8363GNA skeletal muscle sample obtained at autopsy,
profoundly decreased levels of complex I (5% of control) and
IV (b10% of control) were detected. The sample also revealed a
diminished amount of complex V holoenzyme (35% of control),
along with accumulated sub-complexes, most likely V⁎ (F1-
ATPase with several c-subunits) and F1-ATPase (Fig. 1A). The
same sub-complexes were also detected in a bioptic muscle
sample from the 8363GNA patient using BN-PAGE with Coo-
massie staining, followed by the second denaturing electropho-
retic dimension with silver staining (Fig. 2).
A very similar pattern, although less severe, was found in the
8344ANG skeletal muscle sample. The amount of complex I was
reduced to approximately 25% of control, the level of complex
IV holoenzyme was b15% of control, and the holoenzyme level
of complex V was decreased to 60% of the control value. Im-
munodetection of complex V further showed sub-complexes
similar to those observed in the 8363GNA sample (Figs. 1A, 2A).
In 3243ANG skeletal muscle, relative levels of OXPHOS
holoenzymes were normal, except for a decrease in the content
of complex I to 30% of control and complex IV to 60% of
control (Fig. 1A).
3.3. Steady-state levels ofOXPHOS complexes in other 8363GNA
and 3243ANG tissues
Only the 8363GNA and 3243ANG samples of heart, frontal
cortex, and liver tissue were available for comparison of the
Table 1
Summary of clinical consequences, mtDNA mutation loads and character of OXPHOS deficiencies in investigated tissues of the patiens
Skeletal muscle 8363GNA 3243ANG 8344ANG
Clinical phenotype Myopathy (+++) Myopathy (++) Myopathy (++)
Heteroplasmy 80% 90% 89%
OXPHOS protein deficiencies⁎ I and IV (↓↓↓), V (↓↓), Vsub I (↓↓) I and IV (↓↓↓), V (↓), Vsub
ADP-stimulated respiration after pyruvate/glutamate/succinate ↓↓ /↓↓ /↑↑ nd ↓ /N/↑↑↑
Heart 8363GNA 3243ANG 8344ANG
Clinical phenotype CardiomyopathyH(++) CardiomyopathyD(++) –
Heteroplasmy 89% 89% nd
OXPHOS protein deficiencies I and IV and V (↓↓↓), Vsub I (↓↓↓) nd
Frontal cortex 8363GNA 3243ANG 8344ANG
Clinical phenotype Encephalopathy (++) Encephalopathy (++) –
Heteroplasmy 87% 89% nd
OXPHOS protein deficiencies V (↓↓↓), I and IV (↓↓) V (↓↓↓), I and IV (↓↓↓), IVsub nd
Liver 8363GNA 3243ANG 8344ANG
Clinical phenotype – – –
Heteroplasmy 97% 87% nd
OXPHOS protein deficiencies I (↓↓) N nd
–, absent; ++, moderate; +++, severe; ↓↓↓, b30% of control; ↓↓, 30 – 50% of control/mean control value; ↓, N50% of control/mean control value; ↑↑, 160% of mean
control value; ↑↑↑, N200% of mean control value; N, normal; nd, not done; sub-assembly intermediates of indexed complex were present; D- dilated; H- hypertrophic.
⁎ relative steady-state protein levels (Western blot) correlated with activities of respiratory chain complexes (spectrophotometry), (Fig. 3).
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impact of mtDNA mutations on the system of oxidative phos-
phorylation in skeletal muscle and other tissues (Table 1).
The 8363GNA heart sample showed the same considerable
reduction in complexes I (5% of control) and IV (b10% of
control) content as skeletal muscle, but despite the greater re-
duction of complex V holoenzyme (15% of control), there was a
significantly lower accumulation of F1-ATPase. The 3243ANG
heart sample had a pronounced reduction of complex I (20% of
control), similar to skeletal muscle (Fig. 1B).
In the 8363GNA frontal cortex, the assembly of complexes I
and IV were less affected than in the above-mentioned tissues.
The amount of complex I was decreased to 40% of control, and
Fig. 1. Analysis of the assembly ofOXPHOS complexes by immunoblotting ofBN-PAGE.BN-PAGE of laurylmaltoside-solubilisedmitochondria isolated from autoptic
(8363GNA, 3243ANG) and bioptic (8344ANG) muscle (A) and from autoptic (8363GNA, 3243ANG) heart (B), frontal cortex (C) and liver (D) was electroblotted onto
PVDFmembranes and probedwith monoclonal antibodies that detect the native forms of the OXPHOS complexes. Three aliquots of control mitochondria corresponding
to the indicated dilutions of control samples were loaded on the same gels. The migration of holoenzymes (I–V) and molecular mass standards (kDa) are indicated; the
actual position of sub-complex V⁎ and/or F1 of complex V (⁎) in skeletal muscle (A) and heart (B) is directly below complex III (around 370–470 kDa).
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the holoenzyme level of complex IV was reduced to 50% of
control. Conversely, complex V (b20% of control) appeared to
be the most severely affected member of the OXPHOS system.
The decrease was more substantial than in skeletal muscle;
nevertheless, no detectable sub-complexes could be found. The
3243ANG frontal cortex sample showed a dramatic reduction of
complex V to below the detection limits of the method, and of
complex I to 10% of the control value. Probing of the immu-
noblots with an anti-COX2 antibody showed a reduction of
complex IV to 20% of control, as well as the presence of a high
Fig. 2. Complex V (V) subassemblies V⁎ and F1-ATPase (F1), compatible with
those described previously for T8993G mitochondria, ρ0 cells, or where mito-
chondrial translation has been inhibited. Long exposure of complex V immuno-
detection with the monoclonal antibody against the ATP-alpha subunit from
Fig. 1A (A). Coomassie staining of BN-PAGE (above) and silver staining of
two-dimensional BN/SDS/PAGE (below) of the 8363GNA sample obtained
from skeletal muscle (bioptic sample) (B).
Fig. 3. Relative steady-state protein levels and activities of respiratory chain
complexes normalized to complex II (II) or citrate synthase (CS) in isolated
muscle mitochondria. The ratios of specific activities are expressed as the
percentage of the mean of the control values (reference ranges are shown).
Fractions by the x-axis indicate which ratios are concerned; I— complex I, III—
complex III, IV— complex IV, (wb)— the ratio of holoenzyme levels obtained
from a Western blot, (act.) — the ratio of specific activities obtained using
spectrophotometry.
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molecular weight sub-complex (Fig. 1C). Due to the unex-
pected OXPHOS deficiency pattern observed in brain tissue,
particularly in the 3243ANG patient, the immunoblotting was
also performed on the frontal cortex sample from another
3243ANG patient. In the only available sample with a 65% level
of heteroplasmy, the immunoblotting analysis revealed normal
levels of OXPHOS complexes in comparison to control (data
not shown).
Despite the highest level of heteroplasmy (Table 1), the
8363GNA liver sample only showed an isolated deficiency of
complex I (40% of control) (Fig. 1D). Steady-state levels of
OXPHOS complexes in the 3243ANG liver mitochondria were
comparable to control (data not shown).
3.4. Activities of respiratory chain complexes in 8363GNA,
8344ANG and 3243ANG skeletal muscle
To characterize the impact of the 8363GNA, 8344ANG and
3243ANG mutations on the function of respiratory chain com-
plexes, the specific activities of the respective enzymes and
citrate synthase (CS, control enzyme) were measured spectro-
photometrically. The values expressed as relative ratios of the
activities of complexes I, III and IV normalized to complex II
(II, SQR) or CS were compared to the relative ratios of steady-
state protein levels normalized to complex II (Fig. 3). Consistent
with immunoblotting results, the spectrophotometry revealed
lower activity ratios for complex I (I/II and I/CS) in the isolated
muscle mitochondria of all three patients, and a severe deficiency
of complex IV in 8363GNA and 8344ANG isolated muscle mi-
tochondria. The COX/SQR (IV/II) and COX/CS (IV/CS) activity
ratios in the 3243ANG patient were just below the control range.
3.5. Oxygraphic analysis in 8363GNA and 8344ANG skeletal
muscle fibers
The functional consequences of the 8363GNA mutation in
comparison to the 8344ANG mutation were analysed by high-
resolution oxygraphy of the patients' skeletal muscle fibers per-
meabilized by a low concentration saponin treatment (Table 2).
In both samples, a decrease of ADP-stimulated oxygen con-
sumption compared to control fibers was observed using pyru-
vate as a substrate, and an increase was found after succinate
addition. A pronounced reduction in ADP-stimulated respira-
tion was found after pyruvate (33% of the mean control value)
as well as after glutamate (32% of the mean control value)
additions in 8363GNA muscle fibers. Indeed, ADP-stimulated
respiration after succinate treatment increased to 158% of
the mean control value. In 8344ANG muscle fibers, ADP-
stimulated respiration after pyruvate addition was 70% of the
mean control value, but after glutamate, it was within the
reference range. Similarly to 8363GNA muscle fibers, the ADP-
stimulated respiration after succinate addition increased to
222% of the mean control value in the 8344ANG sample. The
absolute oxygen consumption after ascorbate+TMPD treat-
ment was, in both samples, within control levels; however,
normalization of the data to the level of respiration after
succinate addition revealed decreased ratios after treatment with
all of the substrates (Table 2).
3.6. Mitochondrial content in skeletal muscles with mt-tRNALys
mutations
In isolated muscle mitochondria, Western blotting showed
an increased level of complex II holoenzyme, which is entirely
encoded by nuclear DNA, up to 150% and 160% of control
in 8363GNA and 8344ANG patient samples, respectively
(Fig. 1A). After normalization, this leads to artificially de-
creased amounts of complex III in the skeletal muscle mito-
chondria of both patients (Fig. 3, Complex III). Accordingly,
the II/CS activity ratio remained on the upper border of
Table 2
Oxygen consumption by saponin-permeabilized skeletal muscle fibers with
8363GNA and 8344ANG mutations
8363GNA 8344ANG Controls (n=9)
Mitochondrial respiration (nmol O2 min
−1 per mg of wet weight)
Pyruvate/malate 6.9 14.7 16–26
Glutamate/malate 5.1 16.5 10–22
Succinate 21.4 30.0 9–18
Ascorbate/TMPD 66.0 57.0 43–83
Value normalized to respiration after succinate addition
Pyruvate/malate 0.32 0.49 0.96–1.85
Glutamate/malate 0.24 0.55 0.83–1.72
Ascorbate/TMPD 3.08 1.90 3.50–5.98
Polarographic measurements were performed as multiple substrate-inhibitor
titration in the presence of 1 mM ADP with subsequent additions of pyruvate
(10 mM)/malate (5 mM) or glutamate (10 mM)/malate (5 mM); succinate
(10 mM); ascorbate (2 mM)/TMPD (500 μM).
Fig. 4. Subunit composition of complex IV subassemblies in skeletal muscle
obtained from the 8363GNA patient (bioptic sample). Two-dimensional BN/
SDS/PAGE of lauryl maltoside-solubilised mitochondria isolated from the
skeletal muscle of a control or the 8363GNA patient, obtained at biopsy, were
electroblotted onto PVDF membranes and probed with monoclonal antibodies
specific for the subunits COX1, COX2, COX4 and COX5A. The positions of
the holoenzyme (S4) and subassemblies (S1–S3) are indicated, along with the
migration of the molecular mass standard (kDa).
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the reference range (Fig. 3, Complex II), indicating a higher
mitochondrial membrane content (altered mitochondrial
morphology).
In tissue homogenates, the specific activity of CS was in-
creased to 380% and 285% of the mean control value in the
8363GNA and 8344ANG patient samples, respectively. His-
tochemistry revealed increased amounts of SDH product in
8363GNA skeletal muscle and ragged-red fibers in 8344ANG
skeletal muscle.
Based on the above-mentioned observations and on the
increased ADP-stimulated oxygen consumption after succinate
treatment (antimycin A-sensitive) of patients' skeletal muscle
fibers (Section 3.5), a proliferation of mitochondria with altered
morphology could be expected as a result of cellular energetic
imbalance.
3.7. Immunoblots of two-dimensional native/denaturing gels
Immunoblotting of BN/SDS/PAGE (native in the first di-
mension and denaturing in the second dimension) with COX1,
COX2, COX4 and COX5A antibodies was used to analyze the
assembly of complex IV in 8363GNA skeletal muscle, and to
confirm the alignment of the high molecular weight band iden-
tified in the 3243ANG frontal cortex after immunoblotting of
BN/PAGE with COX2 antibody.
In 8363GNA skeletal muscle, the level of free S1 sub-com-
plex was found to be below the detection limit of the method
(Fig. 4). This probably reflects the limiting character of the
COX1 subunit in the holoenzyme assembly.
In 3243ANG frontal cortex, significantly increased levels of
all known complex IV assembly intermediates were observed,
including free apoCOX1 (S1 sub-complex), apoCOX2, and
apoCOX5A (Fig. 5). The high molecular weight band just below
the COX holoenzyme, which was detected with anti-COX2
antibody (Fig. 1C), very likely represents the S3 assembly
intermediate (Fig. 5). Long exposure of the same immunoblot
also revealed the band representing free apoCOX2 subunit (data
not shown). This finding further supports the assumption that
the final reduction in the content of COX holoenzyme in the
3243ANG frontal cortexmitochondria is not caused solely by the
limiting character of mtDNA-encoded subunits of COX (trans-
lational defect, Fig. 4).
4. Discussion
This paper has presented a detailed analysis disclosing the
tissue-specific impact of the 8363GNA mtDNA mutation on the
amount, stability, and function of the OXPHOS complexes in a
patient who died of Leigh syndrome. Furthermore, these data
were compared with that from two other mtDNA mutations; the
first one in the same tRNA (8344ANG) and the other one in mt-
tRNALeu(UUR) (3243ANG), both of which are at least twice as
common as the total number of other mtDNA point mutations
known to cause disorders affecting the central nervous system
[24,25]. Although just one patient with a comparable level of
heteroplasmy was available per studied mutation, the observed
data demonstrate intriguing tissue-specific patterns of OXPHOS
protein deficiencies, with the most unexpected findings in the
3243ANG frontal cortex.
In the skeletal muscle of patient 1, the lowest level of
heteroplasmy but the most severe OXPHOS defect suggests a
more profound impact of the 8363GNA mutation on the trans-
lational system than that of the 8344ANG mutation. Concerning
the 3243ANG mutation, the relatively proportional levels of
heteroplasmy in 8344ANG and 3243ANG skeletal muscles, the
more significant decrease in the content of complex I, the severe
decrease in the amount of complex IV, and the slightly lower
level of complex V in patient 2 all indicate a less pronounced
impact of the 3243ANGmutation onmitochondrial translation in
this tissue. However, the different nuclear backgrounds [26–30],
distributions of heteroplasmy levels in cells and mitochondria
[25,31,32], and environmental factors [33,34] which have been
shown to influence expression of mitochondrial respiratory in-
sufficiency, prevent the reduction of these results to any simple
quantitative trait.
The frequency of UUR (Leu) codons in mitochondrially-
translated subunits of OXPHOS implies decreased steady-state
levels of complex I subunits, namely ND6, ND3, ND2 and ND5
(14–9 UURs) in 3243ANG mitochondria. In 8363GNA and
8344ANG mitochondria, the distribution of AAR (Lys) codons
anticipates diminished levels of ND5, ND2, ND4 and COX1
(21–10 AARs). Moreover, all these subunits contain two X/Lys/
Lys/X motifs, or one X/Lys/Lys/X and one Lys/X/Lys motif
(http://www.mitomap.org), which are apparently strong stalling
points for the ribosome. The particular abundance and distri-
bution of codons in mitochondrially-translated subunits of res-
piratory chain complexes appears to be a plausible explanation
for the isolated defect of complex I in the patient with a mutation
in mt-tRNALeu(UUR), along with the combined deficiency of
complexes I and IV in patients with mutations in mt-tRNALys.
Fig. 5. Subunit composition of complex IV subassemblies in the frontal cortex
obtained at autopsy of the 3243ANG patient. Two-dimensional BN/SDS/PAGE
of lauryl maltoside-solubilised mitochondria isolated from the frontal cortex of a
control or the 3243ANG patient, obtained at autopsy, were electroblotted onto
PVDF membranes and probed with monoclonal antibodies specific for the
subunits COX1, COX2, COX4 and COX5A. The positions of holoenzyme (S4)
and subassemblies (S1–S3, apoCOX2) are indicated, along with the migration
of the molecular mass standard (kDa).
323D. Fornuskova et al. / Biochimica et Biophysica Acta 1782 (2008) 317–325
Author's personal copy
Furthermore, the complete absence of unassembled apoCOX1
(S1) in the skeletal muscle of the 8363GNA patient, as revealed
by BN/SDS/PAGE immunoblotting, conforms to the limiting
character of the COX1 subunit in holoenzyme assembly. On the
contrary, the OXPHOS deficiency patterns found in the frontal
cortex mitochondria of the 8363GNA and 3243ANG patients
could suggest, similarly to [18], a specific character for brain
OXPHOS. First, in both frontal cortex samples, the decrease in
the content of complex V was more profound than in that of
complexes I and IV. Second, despite such a pronounced defect of
complex V, no sub-complexes similar to those observed in
skeletal muscle and heart could be detected, even when the
immunoblot exposure was prolonged (data not shown). Unfor-
tunately, no 8344ANG frontal cortex specimen was available for
the analysis. However, a selectively decreased expression of
COX2 subunit was previously reported in frontal cortex and
cerebellum of a MERRF patient [35]. F1-ATPase, which was
observed in heart, was found along with a sub-complex denoted
V⁎ in skeletal muscle. The sub-complex V⁎ is likely composed
of F1-ATPase and several c-F0 subunits. These sub-complexes
were described previously in 8993TNG mitochondria [36,37],
ρ0 cells [37], and in cells with inhibited mitochondrial trans-
lation [38]. The observed steady-state levels of OXPHOS com-
plexes suggest that the brain ATP synthase is most sensitive to
disturbances of the mitochondrial translational system caused by
the studied mt-tRNAmutations. Such a tissue-specific impact of
mt-tRNA mutations with comparable tissue heteroplasmy is
likely to result from tissue-specific variations in the nature of
mitochondria. Indeed, it was shown that the brain, liver and
kidney OXPHOS system is mainly controlled at the phosphor-
ylation level by ATP synthase and a phosphate carrier, in contrast
to the muscle and heart, where it is essentially controlled at the
level of the respiratory chain [39]. On the other hand, instead
of diminished energy provisions, an insufficient discharge of
mitochondrial membrane potential leading to reactive oxygen
species (ROS) production was proposed as the underlying pa-
thogenic mechanism of ATP synthase deficiency [40]. Accord-
ingly, the complete lack of complex V from 3243ANG frontal
cortex may be, apart from the translational defect, responsible
for the unusual assembly pattern of COX in this sample. Indeed,
it was shown in yeast that (i) cells deficient in ATP synthase have
a severe reduction of COX holoenzyme [12–15] and (ii) no
decrease in COX synthesis is observed in uncoupled ATP syn-
thase mutants, where the maintenance of mitochondrial poten-
tial is severely compromised by a massive proton leak through
the F0 sector [41,42]. Although the COX1 subunit was shown to
be a key regulatory target for COX reduction in yeast cells [12],
some other mechanism is likely to be involved in the hindered
assembly of COX in the 3243ANG frontal cortex mitochon-
dria, since this sample had high accumulated levels of all
three mitochondrially encoded subunits, either free or partially
assembled.
Although it is necessary to analyze considerably more sam-
ples with high levels of heteroplasmy (such samples are difficult
to obtain), these data show new effects of mt-tRNA mutations
on the brain which differ substantially from those described for
skeletal muscle, heart, and liver tissues.
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5.4. Study of molecular and biochemical impact of mtDNA mutation 
in the ATP6 gene (9205ΔTA) on the biosynthesis of ATPase 
subunit a and its structural and functional consequences 
(specific aim 2b) 
 
 
Jesina P, Tesarova M, Fornuskova D, Vojtiskova A, Pecina P, Kaplanova V, 
Hansikova H, Zeman J and Houstek J 
 
Diminished synthesis of subunit a (ATP6) and altered function of ATP synthase and 
cytochrome c oxidase due to the mtDNA 2 bp microdeletion of TA at positions 9205 
and 9206. 
 
Biochem J 2004; 383: 561-571. 
 
 
In patient with combined deficiency of complexes IV and V, we identified and 
studied rare mtDNA mutation in the ATP6 gene – a 2bp microdeletion at positions 9205 
and 9206 (9205ΔTA). This mutation cancels the STOP codon of ATP6 gene and 
changes the cleavage site between the ATP6 and COX3 transcripts. 
To unravel the molecular basis of combined cytochrome c oxidase and ATP 
synthase deficiency in patient with fatal infantile encephalopathy, severe psychomotor 
delay, frontal lobe atrophy and lactic acidosis, we used mtDNA sequencing. The 
amount of mtDNA containing the microdeletion was determined by the PCR/RFLP 
analysis in available tissues of the patient and his relatives. The functionality and 
integrity of OXPHOS, especially of complexes IV and V, was studied using isolation of 
crude mitochondrial fraction by cellular fractionation and differential centrifugation, 
spectrophotometric measurements of specific enzyme activities, rate of ATP synthesis, 
quantitative real-time RT-PCR and Northern blot analyses, assay for biosynthesis of 
mitochondrial proteins, high-resolution respirometry, cytofluorimetric analysis of 
mitochondrial membrane potential, and blue-native (BN), denaturing (SDS) and two-
dimensional (BN/SDS) PAGE with downstream immunoblot detections using 
monoclonal or polyclonal antibodies against various mitochondrial proteins. 
The mutation was present at increasing load in a three-generation family (in blood: 
grandmother - 16%, mother - 82%, proband - >98%). In the affected boy with severe 
encephalopathy, a homoplasmic mutation was present in blood, fibroblasts and muscle. 
The fibroblasts from the patient showed normal aurovertin-sensitive ATPase hydrolytic 
activity, a 70 % decrease in ATP synthesis and an 85 % decrease in CcO activity. 
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ADP-stimulated respiration and the ADP-induced decrease in the mitochondrial 
membrane potential at state 4 were decreased by 50 %. The content of subunit a was 
decreased 10-fold compared with other ATP synthase subunits, and [35S] methionine 
labelling showed a 9-fold decrease in subunit a biosynthesis. The content of CcO 
subunits 1, 4 and 6c was decreased by 30–60 %. Northern Blot and quantitative real-
time reverse transcription–PCR analysis further demonstrated that the primary 
ATP6-COX3 transcript is cleaved to the ATP6 and COX3 mRNAs 2-3-fold less 
efficiently. Structural studies by blue-native and two-dimensional electrophoresis 
revealed an altered pattern of CcO assembly and instability of the ATP synthase 
complex, which dissociated into subcomplexes. The results indicate that the 9205ΔTA 
mutation prevents the synthesis of ATP synthase subunit a, and causes the formation of 
incomplete ATP synthase complexes that are capable of ATP hydrolysis but not ATP 
synthesis. The mutation also affects the biogenesis of CcO, which is present in a 
decreased amount in cells from affected individuals. 
I contributed to this study by identification of the 9205ΔTA mutation in 
mitochondrial genome of the patient and his relatives. 
 
 
Vojtiskova A, Jesina P, Kalous M, Kaplanova V, Houstek J, Tesarova M, Fornuskova 
D, Zeman J, Dubot A and Godinot C  
 
Mitochondrial membrane potential and ATP production in primary disorders of ATP 
synthase. 
 
Toxicol Mech Methods 2004; 14: 7-11. 
 
 
We summarize the functional consequences of primary ATP synthase defects 
resulting from 8993T>G, 9205ΔTA and 8527A>G mutations in the ATP6 gene at the 
level of mitochondrial ATP synthesis and maintenance as well as discharge of the 
mitochondrial membrane potential.  
Studies of fibroblasts with primary defects in mitochondrial ATP synthase due to 
heteroplasmic mtDNA mutations in the ATP6 gene, affecting protonophoric function or 
synthesis of subunit a, show that at high mutation loads, mitochondrial membrane 
potential ΔΨm at state 4 is normal, but ADP-induced discharge of ΔΨm is impaired and 
ATP synthesis at state 3-ADP is decreased. Increased ΔΨm and low ATP synthesis is 
also found when the ATP synthase content is diminished by altered biogenesis of the 
enzyme complex. Irrespective of the different pathogenic mechanisms, elevated ΔΨm in 
67 
primary ATP synthase disorders could increase mitochondrial production of reactive 
oxygen species and decrease energy provision. 
I contributed to this study by molecular analysis and preparation of cultured skin 
fibroblasts derived from patients. 
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Diminished synthesis of subunit a (ATP6) and altered function of ATP
synthase and cytochrome c oxidase due to the mtDNA 2 bp microdeletion
of TA at positions 9205 and 9206
Pavel JESˇINA*1, Marke´ta TESARˇOVA´†1, Daniela FORN ◦USKOVA´†, Alena VOJTI´SˇKOVA´*, Petr PECINA*, Vilma KAPLANOVA´*,
Hana HANSI´KOVA´†, Jirˇ´ı ZEMAN† and Josef HOUSˇTEˇK*2
*Department of Bioenergetics, Institute of Physiology and Centre for Integrated Genomics, Academy of Sciences of the Czech Republic, Vı´denˇska´ 1083, 142 20 Prague,
Czech Republic, and †Department of Pediatrics and Institute for Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University, 120 00 Prague, Czech Republic
Dysfunction of mitochondrial ATPase (F1Fo-ATP synthase) due
to missense mutations in ATP6 [mtDNA (mitochondrial DNA)-
encoded subunit a] is a frequent cause of severe mitochondrial
encephalomyopathies. We have investigated a rare mtDNA mu-
tation, i.e. a 2 bp deletion of TA at positions 9205 and 9206
(9205TA), which affects the STOP codon of the ATP6 gene and
the cleavage site between the RNAs for ATP6 and COX3 (cyto-
chrome c oxidase 3). The mutation was present at increasing load
in a three-generation family (in blood: 16%/82%/> 98%). In the
affected boy with severe encephalopathy, a homoplasmic mutation
was present in blood, fibroblasts and muscle. The fibroblasts from
the patient showed normal aurovertin-sensitive ATPase hydrolytic
activity, a 70% decrease in ATP synthesis and an 85% decrease in
COX activity. ADP-stimulated respiration and the ADP-induced
decrease in the mitochondrial membrane potential at state 4
were decreased by 50%. The content of subunit a was de-
creased 10-fold compared with other ATPase subunits, and [35S]-
methionine labelling showed a 9-fold decrease in subunit a
biosynthesis. The content of COX subunits 1, 4 and 6c was de-
creased by 30–60%. Northern Blot and quantitative real-time
reverse transcription–PCR analysis further demonstrated that the
primary ATP6–COX3 transcript is cleaved to the ATP6 and COX3
mRNAs 2–3-fold less efficiently. Structural studies by Blue-
Native and two-dimensional electrophoresis revealed an altered
pattern of COX assembly and instability of the ATPase complex,
which dissociated into subcomplexes. The results indicate that
the 9205TA mutation prevents the synthesis of ATPase subunit
a, and causes the formation of incomplete ATPase complexes
that are capable of ATP hydrolysis but not ATP synthesis. The
mutation also affects the biogenesis of COX, which is present in
a decreased amount in cells from affected individuals.
Key words: ATP6, ATP synthase, COX3, cytochrome c oxidase,
mitochondrial disease, mitochondrial DNA (mtDNA).
INTRODUCTION
The mammalian ATPase (F1Fo-ATP synthase) complex cataly-
ses the synthesis of ATP from ADP and Pi, the final step of
the OXPHOS (oxidative phosphorylation) pathway. The ATPase
complex consists of 16 different subunits [1], and is composed of
the globular F1 catalytic part connected by two stalks to the mem-
brane-embedded Fo moiety that translocates protons across the
mitochondrial inner membrane. Only two Fo subunits, subunit a
(ATP6) and A6L (ATP8), are encoded by mtDNA (mitochondrial
DNA) [2]. Both are essential for the biogenesis and assembly of
the ATPase complex [3].
Mutations in mtDNA represent a frequent cause of mitochon-
drial diseases. They can involve tRNAs, rRNAs or protein-en-
coding genes (for review see [4]) and are associated with a wide
variety of clinical pictures, ranging from isolated myopathy to
multisystem disorders, affecting primarily tissues with high en-
ergy demands, such as skeletal muscle, heart and nervous system.
Most pathogenic mtDNA mutations are in tRNAs. Mutations
in protein-encoding genes are much less frequent, with the ex-
ception of those associated with complex I or ATPase dysfunction.
All maternally inherited ATPase diseases are caused by mutations
in the ATP6 gene; no mutation has been reported in the ATP8
(A6L) gene. Mutations in the ATP6 gene disturb the function of the
ATPase proton channel, which consists of subunit a and multiple
copies of subunit c. The most frequent are heteroplasmic T8993G
[5] or less severe T8993C mutations [6], which result in replace-
ment of Leu156 by Arg or Pro in subunit a, and often present as a
NARP (neurogenic muscle weakness, ataxia, retinitis pigmentosa)
[5] or MILS (maternally inherited Leigh syndrome) [7] pheno-
type. Several other, less frequent, mutations of ATP6 at positions
9176 or 8851 have also been described (for review see [8]),
resulting in similar lesions in brain, particularly in the striatum
(familiar bilateral striatal necrosis). The T8993G mutation results
in a decrease in mitochondrial ATP production [9] without a signi-
ficant effect on ATP hydrolysis [7], and in structural changes in
the ATPase complex [10], which, however, could not be found
in some cases [11]. It has been observed that the ATPase deficiency
is associated with a decreased ability of cells from affected indi-
viduals to assemble correctly the ATPase complex, which shows
instability in BN-PAGE (Blue-Native PAGE) experiments
[10,12].
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DDM, dodecyl maltoside; FCCP, carbonyl cyanide 4-trifluoromethoxyphenylhydrazone; LRPPRC, leucine-rich pentatricopeptide repeat cassette; mtDNA,
mitochondrial DNA; OXPHOS, oxidative phosphorylation; m, mitochondrial membrane potential; RFLP, restriction fragment length polymorphism;
RT-PCR, reverse transcription–PCR; SDH, succinate dehydrogenase; TMPD, N,N,N′,N′-tetramethyl-p-phenylenediamine; TMRM, tetramethylrhodamine
methyl ester; WB, Western blot.
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In the present paper we have studied a very rare mtDNA
mutation in the ATP6 gene – a 2 bp microdeletion at positions
9205 and 9206 (9205TA). This mutation cancels the STOP
codon of ATP6 gene and changes the cleavage site between the
ATP6 and COX3 (cytochrome c oxidase subunit 3) transcripts.
It was originally discovered in a newborn with transient lactic
acidosis [13]. Recently we found a second case of a 9205TA
mutation that was present in a child with severe encephalopathy
and hyperlactacidaemia [14]. Here we present the results of
molecular and biochemical studies of ATPase and COX that focus
on the biosynthesis of ATPase subunit a and the structural and
functional consequences of the 9205TA mutation.
EXPERIMENTAL
Ethics
This study was carried out in accordance with the Declaration of
Helsinki of the World Medical Association, and was approved by
the Committees of Medical Ethics at all collaborating institutions.
Informed consent was obtained from the parents of the child.
Case report
The boy was born at term from a second, uncomplicated preg-
nancy, with birth weight 3450 g and length 52 cm. Failure to
thrive, spastic quadruparesis and microcephalia were observed
from the 3rd month of life, followed by practical arrest of any
psychomotor development. Metabolic investigations revealed in-
termittent hyperlactacidaemia (B-lactate, 0.95–3.4 mmol/l; con-
trols < 2.1 mmol/l), with increased levels of lactate and alanine
in the cerebrospinal fluid [lactate, 4.8 mmol/l (controls
< 1.8 mmol/l); alanine, 36 µmol/l (controls < 34 µmol/l)]. He
is 5 years old at present. Both parents are healthy, but an older
brother (from the first marriage of the mother) died due to a
respiratory failure at the age of 3 years. He presented with fatal
infantile encephalopathy, severe psychomotor delay, frontal lobe
atrophy and lactic acidosis.
Cell cultures and isolation of mitochondria
Fibroblast cultures were established from skin biopsies, and
cells were grown in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% (v/v) fetal calf serum (Sigma) at 37 ◦C in
5% CO2 in air. Cells were grown to approx. 90% confluence and
harvested using 0.05% (w/v) trypsin and 0.02% (w/v) EDTA.
Detached cells were diluted with an ice-cold culture medium,
sedimented by centrifugation and washed twice in PBS.
Mitochondria were isolated from fibroblasts by a hypo-osmotic
shock method [15]. The freshly harvested cells were disrupted in
10 mM Tris buffer (pH 7.4) and quickly homogenized in a Teflon/
glass homogenizer at 4 ◦C. Sucrose was added to a final concen-
tration of 0.25 M immediately after homogenization. The nuclei
were removed by centrifugation for 10 min at 4 ◦C and 600 g
and the mitochondrial fraction was isolated from the postnuclear
supernatant by centrifugation for 10 min at 4 ◦C and 10 000 g.
The mitochondrial pellet was washed and finally resuspended
in 0.25 M sucrose, 2 mM EGTA, 40 mM KCl and 20 mM Tris,
pH 7.4, and stored at − 70 ◦C.
Mitoplasts were prepared from fibroblasts as described pre-
viously [16]. In brief, trypsinized cells suspended in an STE
medium (0.25 M sucrose, 10 mM Tris, 1 mM EDTA, pH 7.4)
were treated with digitonin (0.4 mg/mg of protein; Fluka) on ice
for 15 min. The suspension was diluted 10-fold with STE and
centrifuged for 10 min at 4 ◦C and 12 000 g. The pellet was
washed by centrifugation and resuspended in STE to a final
concentration of 1–2 mg of protein/ml. Based on immunodetec-
tion and enzyme activity measurements, > 95% of the mitochon-
drial inner membrane proteins were recovered in this fraction.
Muscle mitochondria were isolated according to [17], but
without use of protease. Tissue samples were homogenized at 4 ◦C
in a KCl medium (100 mM KCl, 50 mM Tris, 2 mM EDTA,
10 mg/ml aprotinin, pH 7.5). The homogenate was centrifuged
for 10 min at 4 ◦C and 600 g, the supernatant was filtered through
a 100 µm nylon screen, and mitochondria were sedimented by
centrifugation for 10 min at 4 ◦C and 10 000 g. The mitochondrial
pellet was washed by centrifugation and resuspended to a final
protein concentration of 20–25 mg/ml.
DNA analysis and sequencing
Total genomic DNA from muscle and cultured fibroblasts was
isolated by phenol extraction. The entire mtDNA was amplified
in six overlapping fragments by PCR (7–3148, 2073–5719,
5645–8815, 8403–11 132, 11 005–14 684 and 13 863–136). Puri-
fied fragments were sequenced on the automatic sequencer
ALFExpress II (Amersham Biosciences) using cycle sequencing
with 41 Cy5-labelled internal sequencing primers.
Restriction analysis
To determine the amount of mtDNA containing the microdeletion,
the PCR/RFLP (restriction fragment length polymorphism)
analysis method was performed according to [18] using the mis-
matched (bold) primers 5′-CCT CTA CCT GCA CGA CAA TGC
A-3′ (forward) and 5′-CGT TAT GCA TTG GAA GTG AAA TCA
C-3′ (reverse), which introduce two novel NsiI restriction sites in
the case of the wild-type mtDNA and one NsiI restriction site
in the case of mutant mtDNA. PCR products were radioactively
labelled with [α-32P]dCTP in the final cycle of PCR and run on
a non-denaturing 13% (w/v) polyacrylamide gel after complete
digestion. The proportions of wild-type and mutant mtDNA were
measured using a PhosphorImager and ImageQuant software
(Molecular Dynamics).
Northern blot analysis
Total RNA was isolated from cultured fibroblasts by phenol/
guanidium thiocyanate/chloroform extraction [19]. Approx.
20 µg of total RNA per lane was separated through a 1.2% (w/v)
agarose/formaldehyde gel and transferred to a Hybond-N nylon
membrane (Amersham) in 20 × SSC (1 × SSC is 0.15 M NaCl/
0.015 M sodium citrate). The membrane was prehybridized for
2 h at 45 ◦C in 5 × SSC, Denhardt’s solution, 0.5% SDS and
100 µg/ml sonicated herring sperm. The membranes were hy-
bridized overnight at 45 ◦C with [α-32P]dCTP-labelled probes cor-
responding to regions of the genes ATP6 (8361–9060), COX3
(9269–9912), ND1 (3313–4252) and COX1 (6120–6960). The
radioactivity was detected by phosphor imaging (as above).
Quantitative RT-PCR (reverse transcription–PCR) analysis
Total RNA was isolated from cultured fibroblasts using RNA Blue
reagent (Top-Bio, Prague, Czech Republic). Following DNase I
treatment (Invitrogen), first-strand cDNA was synthesized from
1 µg RNA aliquots with 200 units SuperScript II reverse trans-
criptase using either 200 ng of random hexamer primers or 500 ng
of oligo(dT)12−18 (all Invitrogen) according to the manufacturer’s
instructions. Real-time quantitative RT-PCR was performed on a
LightCycler instrument (Roche Diagnostics) using a QuantiTect
SYBR Green PCR kit (Qiagen). PCR reactions were performed
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on cDNAs using primer pairs specific for the ATP6 gene transcript
(forward, 5′-CCT TAT GAG CGG GCA CAG T-3′; reverse, 5′-
CAG GGC TAT TGG AA-3′; nt 8846–8994), for the COX3 gene
transcript (forward, 5′-GCC CTC TCA GCC CTC CTA ATG-3′;
reverse, 5′-GTG GCC TTG GTA TGT GCT TTC TCG-3′; nt
9267–9416), for the ATP6–COX3 gene transcript (forward, 5′-
AAT CCA AGC CTA CGT TTT CAC ACT-3′; reverse, 5′-TAG
GCC GGA GGT CAT TAG G-3′; nt 9150–9299), for the CYTB
gene transcript (forward, 5′-GAC CTC CCC ACC CCA TCC A-3′;
reverse, 5′-AAA GGC GGT TGA GGC GTC TG-3′; nt 14 804–
14 935) and for the ND1 gene transcript (forward, 5′-CAA CCT
CAA CCT AGG CCT CCT-3′; reverse, 5′-ACG GCT AGG CTA
GAG GTG GC-3′; nt 3595–3644). The primer pair for ATP6–
COX3 was designed to flank the splice site of the ATP6–COX3
transcript. Amplified regions of the ATP6 or COX3 transcript were
present in both processed and unprocessed RNAs. All reactions
were run at an annealing temperature of 60 ◦C. The PCR mixture
contained 5 µl of 2 × SYBR Green PCR Master Mix, 2 µl of
100 × diluted reverse transcription product and 200 nM of each
primer in a total volume of 10 µl. All reactions were performed
in triplicate. For each primer pair, non-template controls were in-
cluded to check for the absence of contaminants and primer-
dimers that would interfere with quantification when SYBR Green
is used. The external standard curve was generated in parallel for
all reactions using serial dilutions of cDNA synthesized from con-
trol RNA. For each sample, the relative amounts of ATP6, COX3,
CYTB, ND1 and unprocessed ATP6–COX3 transcripts were
determined from the standard curves. Each sample was analysed
in two separate experiments.
Electrophoresis and WB (Western blot) analysis
BN-PAGE [20] was used for the separation of native mitochon-
drial OXPHOS complexes on 6–15% (w/v) polyacrylamide
gradient minigels (Mini Protean system; Bio-Rad) as described
previously [16]. Mitoplasts were pelleted by centrifugation for
10 min at 4 ◦C and 10 000 g, and solubilized using 1 g of DDM
(dodecyl maltoside)/g of protein for 20 min on ice in a buffer
containing 1.75 M aminocaproic acid, 2 mM EDTA and 75 mM
Bis-Tris (pH 7.0). Samples were centrifuged for 20 min at
20 000 g and Serva Blue G dye was added to collected super-
natants at a concentration of 0.1 g/g of detergent. Electrophoresis
was performed at 50 V for 30 min and then at 90 V.
SDS/PAGE [21] was performed on 10% (w/v) polyacrylamide
slab minigels, and analysis of [35S]methionine-labelled proteins
was performed on a 16 cm long 15–20% (w/v) gradient poly-
acrylamide slab gels (Protean system; Bio-Rad). The samples
were boiled for 3 min in sample lysis buffer [2% (v/v) mercapto-
ethanol, 4% (w/v) SDS, 10 mM Tris/HCl, 10% (v/v) glycerol].
For 2D (two-dimensional) analysis, strips of the first-dimension
BN-PAGE gel were incubated for 1 h in 1% (w/v) SDS and 1%
(v/v) mercaptoethanol and then subjected to SDS/PAGE (10%
polyacrylamide) for separation in the second dimension [21].
Gels were blotted on to Hybond C-extra nitrocellulose mem-
branes (Amersham) by semi-dry electrotransfer for 1 h at 0.8 mA/
cm2 and the membrane was blocked in PBS containing 0.2%
(v/v) Tween 20 (PBST). The membranes were used whole or
were cut according to molecular mass markers into portions con-
taining individual OXPHOS complexes or their subunits. Mem-
branes were incubated for 3 h with primary antibodies diluted
in PBS containing 2% (w/v) BSA (PBSTA). Previously char-
acterized polyclonal antibodies were used at the indicated titres:
those against the Foc subunit of ATPase (1:900) [22] and those
against the Foa (ATP6) subunit of ATPase (1:500) [23]. In ad-
dition, we used monoclonal antibodies against subunits COX1
(1:330; Molecular Probes A-6403), COX4 (1:670; Molecular
Probes A-6409), COX6c (1:200; Molecular Probes A-6401),
NADH39 (1:250; Molecular Probes A-11 140), SDH70 (succinate
dehydrogenase 70 kDa subunit; 1:2000; Molecular Probes A-
11 142) and subunit α of F1-ATPase (1:200 000; lot 20D6 [24]).
Incubation with peroxidase-labelled secondary antibodies in
PBSTA was performed for 1 h using either goat anti-mouse
IgG (1:1000; Sigma A8924) or goat anti-rabbit IgG (1:1000;
Sigma F0382). The chemiluminescence reaction with an ECL®
kit (Amersham) was detected on an LAS 1000 instrument (Fuji)
and the signal was quantified using Aida 2.11 Image Analyser
software.
Spectrophotometric assays
The activities of the mitochondrial enzymes NADH:CoQ re-
ductase (complex I), succinate:CoQ reductase (complex II), CoQ:
cytochrome c reductase (complex III), COX (complex IV),
NADH:cytochrome c reductase (complex I + III), succinate:cyto-
chrome c reductase (complex II + III) and CS (citrate synthase)
were measured spectrophotometrically by standard methods at
37 ◦C in muscle homogenate and isolated muscle mitochondria
[17,25–28] or in cultured fibroblasts [29].
ATPase hydrolytic activity was measured in a ATP-regenerat-
ing system as described in [30]. Mitochondria (8–22 µg of pro-
tein/ml) were incubated in a medium containing 40 mM Tris
(pH 7.4), 5 mM MgCl2, 10 mM KCl, 2 mM phosphoenolpyr-
uvate, 0.2 mM NADH, 1 µg/ml rotenone, 0.1% (w/v) BSA,
5 units of pyruvate kinase and 5 units of lactate dehydrogenase for
2 min. The reaction was started by the addition of 1 mM ATP and
the rate of NADH oxidation, equimolar to ATP hydrolysis, was
monitored as the decrease in absorbance at 340 nm. Sensitivity
to aurovertin was determined by parallel measurements in the
presence of 2 µM inhibitor.
High-resolution oxygraphy
Oxygen consumption by cultured fibroblasts was determined at
30 ◦C as described previously [29,31] using an Oxygraph-2k
(Oroboros, Innsbruck, Austria). Freshly harvested fibroblasts
were suspended in a KCl medium (80 mM KCl, 10 mM Tris/HCl,
3 mM MgCl2, 1 mM EDTA, 5 mM potassium phosphate, pH 7.4)
and cells were permeabilized by digitonin (0.1 mg of detergent/
mg of protein). Respiratory substrates and inhibitors were used at
the concentrations indicated. Oxygen consumption was expressed
in pmol of oxygen/s per mg of protein. COX activity was measured
with 5 mM ascorbate and 1 mM TMPD (N,N,N ′,N ′-tetramethyl-
p-phenylenediamine), and was corrected for substrate auto-
oxidation (determined as oxygen uptake insensitive to 0.33 mM
KCN).
Cytofluorimetric analysis of m (mitochondrial membrane
potential)
Cytofluorimetric measurements were performed on a FACSort
flow cytometer (Becton Dickinson) according to [32]. Fibroblasts
were suspended in a KCl medium containing 10 mM succinate to
a protein concentration of 1 mg/ml and permeabilized by 0.1 mg
of digitonin/mg of protein. Permeabilized fibroblasts were diluted
to 0.2 mg of protein/ml and incubated with 20 nM TMRM (tetra-
methylrhodamine methyl ester; Molecular Probes) for 15 min.
OXPHOS inhibitors and ADP at the concentrations indicated were
added 1 min before cytofluorimetric analysis. Approx. 10000
cells were used for each measurement. Data were acquired on
a logarithmic scale using CellQuest (Becton Dickinson) and
analysed with WinMDI 2.8 software (J. Trotter, TSRI, La Jolla,
CA, U.S.A.). Arithmetic mean values of fluorescence signal in
c© 2004 Biochemical Society
564 P. Jesˇina and others
Table 1 Respiratory chain enzyme and mitochondrial ATPase activities in isolated muscle mitochondria and cultured skin fibroblasts
SCCR, succinate:cytochrome c reductase; NCCR, NADH:cytochrome c reductase; SQR, succinate:CoQ reductase; QCCR, CoQ:cytochrome c reductase; NQR, NADH:CoQ reductase; ND, not
determined. Values for age-related controls are presented as means +− S.D. and as a control range (parentheses).
(A)
Activity (nmol/min per mg of protein)
Muscle homogenate Muscle mitochondria Fibroblasts (mitochondria*)
Enzyme Patient Controls (n = 20) Patient Controls (n = 20) Patient Controls (n = 30)
COX 122 125 +− 72 (53–197) 331 682 +− 395 (287–1077) 5.1 29 +− 11 (18–40)
CS 241 114 +− 29 (85–143) 284 419 +− 221 (200–640) 40.6 58 +− 12 (46–70)
COX/CS 0.50 1.04 +− 0.44 (0.60–1.48) 1.16 1.66 +− 0.57 (1.09–2.23) 0.12 0.51 +− 0.18 (0.33–0.69)
SCCR ND 98 127 +− 77 (50–206) ND
NCCR ND 76 99 +− 57 (42–156) 16.3 28 +− 14 (14–42)
SQR ND 43 64 +− 44 (20–108) 10.6 13 +− 8 (5–21)
QCCR ND 54 178 +− 79 (100–257) 14.1 17 +− 10 (7–27)
NQR ND 192 274 +− 80 (194–354) 33.8 23 +− 10 (15–50)
ATPase ND ND 320 +− 33.1* 254 +− 16.0*
(B)
Activity (nmol/min per mg of protein)
Patient Mother Grandmother Controls (n = 30)
Enzyme Expt 1 Expt 2
COX 7.9 2.4 16.9 34.4 29 +− 11
CS 45.5 33.8 50.6 52.2 58 +− 12
COX/CS 0.17 0.07 0.33 0.66 0.51 +− 0.18
arbitrary units were determined for each sample for subsequent
graphic presentation.
ATP synthesis
The rate of ATP synthesis was measured at 37 ◦C in 150 mM KCl,
25 mM Tris/HCl, 10 mM potassium phosphate, 2 mM EDTA and
1% (w/v) BSA, pH 7.2, using 0.5 mM ADP and 10 mM suc-
cinate or 10 mM pyruvate + 10 mM malate as substrate, as de-
scribed previously [33]. Protein concentration was 1 mg/ml. For
permeabilization of fibroblasts, 0.1 mg of digitonin/mg of protein
was used. The reaction was started by addition of fibroblasts
and performed for the indicated time intervals. Reaction mixture
aliquots of 200 µl were added to 200 µl of DMSO, and ATP
content was determined in DMSO-quenched samples by a luci-
ferase assay according to [34]. ATP production was expressed in
nmol of ATP/min per mg of protein.
Biosynthesis of mitochondrial proteins
Growth medium was removed from cultured fibroblasts, and the
cells were rinsed with methionine-free medium without serum
(Gibco medium 21013; 1 mM pyruvate, 2 mM glutamine and
30 mg/l cysteine) and incubated in the same medium containing
10% (v/v) dialysed fetal calf serum and 100 µg/ml emetine
for 10 min. The cells were labelled for 3 h with 300 µCi/ml
L-[35S]methionine, as described in [35]. The products were
separated by 15–20% (w/v) polyacrylamide gradient SDS/PAGE.
A small aliquot of the samples prepared for electrophoresis was
used to measure the total incorporation of radioactivity in the
mitochondrial fraction as trichloroacetic acid-precipitable counts.
The radioactivity of proteins was quantified in dried gels using
a BAS-5000 system (Fuji). Labelled proteins were identified
according to their molecular mass as reported previously in ex
vivo translation assays [35].
Protein determination
The protein content was measured by the Bradford or Micro BCA
protein kit assays (Bio-Rad), using BSA as a standard. Samples
were sonicated for 20 s prior to protein determination.
RESULTS
Activities of respiratory chain enzymes and mitochondrial ATPase
The activities of respiratory chain enzymes (Table 1A) in a muscle
homogenate from a patient with encephalopathy and lactic acid-
osis showed a decrease in the COX/CS ratio. In isolated muscle
mitochondria, both COX activity and the COX/CS ratio were at the
lower end of the control range, complex I activity was below
the control range and complex III activity was moderately de-
creased. In fibroblasts from the patient, we found a pronounced
decrease in COX activity to 15% of the control, CS was just below
the control range, and the activities of other respiratory chain
enzymes were normal. ATPase hydrolytic activity was determined
in isolated mitochondria from the patient’s fibroblasts. It was
measured as aurovertin-sensitive activity at a constant ATP con-
centration and was found to be normal.
When COX activity was measured in fibroblasts from the
patient’s asymptomatic mother and grandmother, decreased COX
activity and a COX/CS ratio near the lower limit of the reference
range were found in the mother, but not in the grandmother
(Table 1B).
mtDNA 9205TA mutation in the affected family
Sequencing of the patient’s mtDNA revealed a very rare mtDNA
mutation – a heteroplasmic 2 bp deletion TA at positions 9205 and
9206 (9205TA) in the ATP6–COX3 genes. Analysis of mutation
heteroplasmy in tissues of the affected boy by radioactive RFLP
(using NsiI restrictase; Table 2) showed practically homoplasmic
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Table 2 9205TA mutation load in family members
Sample Heteroplasmy (%)
mtDNA
Grandmother – blood DNA 16
Grandmother – fibroblast DNA 9
Mother – blood DNA 82
Mother – fibroblast DNA 92
Patient – blood DNA > 98
Patient – muscle DNA > 98
Patient – fibroblasts DNA > 98
cDNA
Patient – fibroblasts cDNA oligo(dT) > 98
Patient – fibroblasts cDNA oligo(dT) + random primers > 98
Figure 1 Oxygen consumption by digitonin-permeabilized skin fibroblasts
Measurements were performed using 0.45–0.62 mg of cell protein/ml and 0.1 mg of
digitonin/mg of protein. Subsequent additions of pyruvate (5 mM), malate (1.5 mM), succinate
(10 mM), ADP (0.5 mM), oligomycin (1 µM), FCCP (1 µM), antimycin A (0.2 µg/ml),
ascorbate (5 mM), TMPD (1 mM) and KCN (0.33 mM) are indicated. Oxygen consumption
is expressed as negative values of the first time derivative of changes in oxygen tension (pmol
of O2/s per mg of protein).
9205TA mtDNA mutation in fibroblasts, muscle and blood
(>98%). Analysis of blood DNA confirmed the presence of the
9205TA mutation at lower loads both in the mother (82%) and
in the grandmother (16%). Interestingly, a similar mutation load
was found in their fibroblasts (mother 92%; grandmother 9%),
in correspondence with the observed decrease in COX activity in
the mother’s fibroblasts (see above).
An equal mutation load in the patient’s fibroblasts was found
using RFLP of isolated DNA as well as of cDNA reverse-
transcribed from isolated RNA using either oligo(dT) or oligo
(dT) + random primers, indicating that the mutation is fully
retained in ATP6–COX3 RNA and poly(A) RNA (Table 2).
Oxygraphic analysis of cultured fibroblasts
The functional consequences of the 9205TA mutation were ana-
lysed by high-resolution oxygraphy of the patient’s fibroblasts that
had been permeabilized by a low concentration of digitonin. The
9205TA cells showed a pronounced decrease in ADP-stimulated
oxygen consumption using pyruvate, malate and succinate as
substrate, which contrasted with a normal rate of state 3 respiration
in the presence of the uncoupler FCCP (carbonyl cyanide 4-tri-
fluoromethoxyphenylhydrazone). We also observed a decrease in
COX activity determined with TMPD and ascorbate (Figure 1).
In 9205TA cells from the patient, ADP-stimulated respiration
Figure 2 Production of ATP by control and 9205TA fibroblasts
The rate of ATP synthesis was measured in the presence of 0.5 mM ADP in 9205TA () and
control (H17009) cultured skin fibroblasts treated with 0.1 mg of digitonin/mg of protein. Substrates
were 10 mM pyruvate + 10 mM malate (A) or 10 mM succinate (B). ATP was determined
in DMSO-quenched aliquots by a luciferase assay. Data represent means +− S.D. for three
experiments.
was 50–60%, FCCP-stimulated respiration was 100–110% and
COX activity was 40–50% of values in control cells. Although
well coupled, the mitochondria of 9205TA cells thus showed a
strongly impaired effect of ADP, indicating a decreased ability to
synthesize ATP.
Low ATP production in 9205TA cells
The ability of fibroblasts to synthesize ATP by the mitochondrial
OXPHOS pathway was measured directly in cells suspended in
mitochondrial medium, permeabilized by digitonin and supplied
with respiratory substrates and ADP, as in the oxygraphic exper-
iments. With either succinate or pyruvate + malate as substrate,
linear production of ATP was observed in control cells for 15 min,
corresponding to ATP production of 16.4 +− 1.8 and 45.4 +−
1.5 nmol/min per mg of protein respectively, in accordance with
the oxygraphic measurements. In 9205TA fibroblasts, a steadily
diminished ATP production was observed during the 15 min
interval with both types of substrate, giving values of 4.8 +− 0.7
and 13.7 +− 0.4 nmol/min per mg of protein respectively, which
are approx. 30% of control values (Figure 2).
Changes in m
m was analysed cytofluorimetrically in digitonin-permeabi-
lized fibroblasts using the membrane potential-sensitive cationic
probe TMRM. We found that the m of the patient’s fibroblasts
was practically normal at state 4 using succinate as a substrate,
but the effect of the addition of ADP on m was significantly
decreased in 9205TA cells (Figure 3). Whereas in control cells
the TMRM fluorescence was decreased by the addition of ADP
(state 3 ADP) to approx. 28% of the state 4 value, in the 9205TA
cells the TMRM fluorescence decreased to only 50%. The ob-
served 2-fold difference in TMRM fluorescence would cor-
respond to an even more pronounced difference in m values in
mV, because the accumulation of the fluorophore obeys the
Nernst equation and depends exponentially on m [36]. In both
types of cells, the effect of ADP was fully reversible by oligo-
mycin (Figure 3), atractyloside or aurovertin (results not shown),
indicating that the effect of ADP requires the transport of ADP
to the mitochondrial matrix as well as the catalytic activity of
ATPase. In accordance with the measurements of ATP production
and respirometry, these results suggest that ATP synthesis by
mitochondrial ATPase is strongly impaired in 9205TA cells
from the affected individual.
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Figure 3 Cytofluorimetric analysis of control and 9205TA fibroblasts
Cytofluorimetric analysis was performed in digitonin-treated fibroblasts (0.1 mg of digitonin/mg
of protein) and stained with 20 nM TMRM in a KCl medium containing 10 mM succinate.
(A) Typical reading of TMRM fluorescence at state 4 and effect of 1 µM FCCP is shown in
the upper panels. Lower panels show the effect of 0.1 mM ADP and its sensitivity to 1 µM
oligomycin (oligo). (B) TMRM fluorescence of state 3-ADP and effect of oligomycin is expressed
as percentage of the state 4 signal. The m-independent signal (after addition of FCCP) was
subtracted from all data. The data represent means +− S.D. for four independent experiments.
Altered composition and increased lability of ATPase and COX
In order to assess the cellular content of ATPase and COX sub-
units, we analysed the mitochondrial proteins of isolated fibro-
blasts by SDS/PAGE and WB. It is clearly apparent from
Figure 4(A) that 9205TA fibroblasts had a selectively dimi-
nished content of ATPase subunit a and a significantly decreased
content of COX subunits. In comparison with control cells,
9205TA mitochondria contained 11 +− 5.9% of Fo subunit a,
127 +− 13.0% of F1 α subunit, 85% of OSCP (oligomycin-
sensitivity-conferring protein), 108 +− 18.0% of Fo subunit c,
47 +− 2.8% of COX1 subunit, 69 +− 8.5% of COX4 subunit and
36 +− 21.2% of COX6c subunit (average values of four experi-
ments; data normalized to the content of the SDH 70 kDa subunit).
The same pattern was obtained when analysing complete cell
protein extracts (results not shown).
To resolve the native ATPase complex, we solubilized mito-
chondrial OXPHOS complexes from mitoplasts by DDM and
analysed them by BN-PAGE and WB using an antibody against
ATPase F1 α subunit. As shown in Figure 4(B), in 9205TA cells
we found a decreased content of the full-size ATPase and the
accumulation of an incomplete form of the ATPase with a mol-
ecular mass of approx. 390 kDa. A parallel WB analysis of com-
plex I using an antibody to the NADH39 subunit showed an
Figure 4 Electrophoretic analysis of OXPHOS complexes
(A) SDS/PAGE WB of ATPase, COX and SDH subunits was performed using aliquots of 7.5 µg of
protein of mitochondria from control and 9205TA cells. Detection was done with monoclonal
antibodies against subunits SDH70, F1α, OSCP (oligomycin-sensitivity-conferring protein),
COX1, COX4 and COX6c, and with polyclonal antibodies against ATPase subunits Foa and Foc.
(B) BN-PAGE WB with monoclonal antibody against F1α and NADH39 subunit was performed
using 15 µg aliquots of protein solubilized using 1 g of DDM/g of protein from mitoplasts of
control and 9205TA cells. The migration of molecular mass standards is indicated.
identical pattern in control and 9205TA cells – we observed only
intact complex with a molecular mass above 800 kDa (Figure 4B)
that was present in the same amounts in 9205TA and control
cells.
2D electrophoretic analysis of ATPase and COX
Detailed analysis of the different forms of ATPase present in
DDM-solubilized enzyme complexes was performed by 2D elec-
trophoresis, whereby proteins resolved by BN-PAGE in the first
dimension were separated by SDS/PAGE in the second dimension
and detected by WB. The ATPase complex with an apparent mol-
ecular mass of approx. 620 kDa was significantly decreased in
9205TA cells, but several other, smaller ATPase subcomplexes
were detected by F1 subunit α- and Fo subunit c-immunoreactive
signals (Figure 5A). In addition to the 390 kDa F1 subcomplex
containing the α subunit, which was present in the 9205TA cells
in increased amounts, a larger 460 kDa complex containing both
subunits α and c was also found in the 9205TA cells. Moreover,
an additional, subunit c-containing complex with a molecular
mass of approx. 120 kDa and a markedly increased amount of
free subunit α (approx. 60 kDa) were seen. However, none of the
above complexes showed a detectable reaction with an antibody
against subunit a in the 9205TA cells.
2D analysis of COX was performed using antibodies to COX1
and COX4 subunits (Figure 5B). A pronounced decrease in the
amount of COX was observed in the DDM solubilizate of
9205TA cells. In control cells, most of the COX was present as a
monomer, but a significant amount of COX dimers (approx. 420–
440 kDa) and small amounts of COX supercomplex (approx.
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Figure 5 2D electrophoretic analysis and immunodetection of OXPHOS
complexes
Aliquots (15 µg of protein) of DDM-solubilized mitoplasts from 9205TA and control
fibroblasts were separated in the first dimension by BN-PAGE and in the second dimension by
SDS/PAGE. WB analysis was performed with an antibody against the SDH70 subunit and with
antibodies (A) against ATPase subunits F1α, Foa and Foc, or (B) against complex I subunit
NADH39 and against COX subunits COX1 and COX4. The migration of molecular mass standards
is indicated.
670 kDa; probably COX-bc1 supercomplex) as well as some
monomeric COX4 subunits were clearly seen. In the 9205TA
cells the pattern was different. An additional band of molecular
mass approx. 100 kDa was present, and the relative content of the
free COX4 subunit was much higher (approx. 15-fold) than in
control cells.
WB analysis of complex I on 2D gels using a monoclonal anti-
body to the NADH39 subunit showed no difference between con-
trol and 9205TA cells. Only the full-size, assembled complex I
was found, and was present in similar amounts in both types of
cells. No assembly intermediates were detected. Similarly, no dif-
ference was found in the case of complex II using the anti-SDH70
antibody. Thus, unlike ATPase and COX, the biosynthesis and/or
stability of complex I were not affected by the 9205TA mutation.
Steady-state levels and processing of ATP6 and COX3 mRNAs
The 9205TA microdeletion is situated between the genes ATP6
and COX3, which are transcribed in one polycistronic transcript
that is subsequently cleaved stepwise and polyadenylated into
mature mRNA. Therefore we studied the steady-state levels and
processing of ATP6 and COX3 mRNAs. Northern blot analysis
using cDNA complementary to mtDNA sequences 8361–9060
and 9269–9912 as a probe was performed to determine whether
the mutation disturbs the RNA processing of ATP6 and COX3
transcripts (Figure 6A). The primary, unprocessed, and the
secondary ATP8–ATP6–COX3 transcripts occurred in both
9205TA cells and control cells in similar amounts. The steady-
state levels of processed COX3 and ATP8–ATP6 transcripts were
decreased in 9205TA cells. The relative values of the ATP8–
ATP6/ATP8–ATP6–COX3 and COX3/ATP8–ATP6–COX3 RNA
ratios revealed approx. 40% and 50% decreases respectively
in ATP8–ATP6 and COX3 RNA levels. In parallel, we also
determined the steady-state levels of the transcripts of two other
genes encoded by mtDNA, i.e. ND1 and COX1. We observed the
same content of the mature ND1 transcript (Figure 6B) in con-
trol and 9205TA cells. Similarly, there was no difference in the
content of COX1 transcripts (results not shown).
These Northern blot data were fully confirmed by quanti-
tative RT-PCR experiments (Figure 7). Using PCR products
Figure 6 Northern blot analysis of ATP6 and COX3 transcripts
Northern blot analysis of COX3, ATP8–ATP6 and ND1 transcripts was performed in control and
9205TA cells. The mRNA species representing (A) the primary mtDNA polycistron transcript,
partially processed ATP8–ATP6–COX3 transcripts and mature COX3 and ATP8–ATP6 transcripts
and (B) mature ND1 and ATP8–ATP6 transcripts are indicated.
corresponding to ATP6 (nt 8846–8994), COX3 (nt 9267–9416)
and the ATP6–COX3 cleavage site (nt 9150–9299), we found
that ATP6 as well as COX3 RNA levels were decreased 2–3-
fold relative to those of the uncleaved polycistronic ATP8–ATP6–
COX3 transcript. The decrease was also confirmed when relating
ATP6 and COX3 RNA levels to CYTB and ND1 expression (PCR
product of 14804–14935 for CYTB and 3595–3644 for ND1).
As also shown in Figure 7, similar results were obtained using
cDNA prepared by oligo(dT) or random primers, indicating that
polyadenylation is neither impaired nor affects transcript
processing.
Specific decrease in the biosynthesis of ATPase subunit a
To assess how the 9205TA mutation affects the biosynthesis
of subunit a and other mtDNA-encoded proteins, [35S]methionine
labelling of proteins in 9205TA cells was performed in the pres-
ence of emetine (an inhibitor of cytosolic proteosynthesis). The
extent of labelling (Figure 8) was comparable in 9205TA and
control cells, and the pattern of labelled proteins was also similar,
with two exceptions – markedly decreased labelling of a band
of approx. 22 kDa and increased labelling of a band of approx.
12 kDa. The first band was identified as ATPase subunit a, based
on WB analysis performed on the same gel with an antibody
against subunit a (Figure 8), in accordance with the size and
mobility of subunit a in this type of SDS/PAGE [37]. On the basis
of its size, the second band was identified as ATPase subunit 8
(A6L). The COX3 subunit was weakly labelled in both types of
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Figure 7 Quantitative real-time RT-PCR analysis of ATP6, COX3,
cytochrome b and ND1 transcripts
(A) Scheme of ATP6–COX3 RNA processing and PCR products analysed. For experiments,
cDNAs obtained from (B) total RNA (reverse transcription with random primers) or (C) mRNA
[reverse transcription with oligo(dT) primers] were used. The relative amount of uncleaved
ATP6–COX3 transcript and the amounts of all ATP6 or COX3 transcripts present either in
unprocessed form or in mature form were measured and correlated. The values were also
correlated to the expression of mitochondrial CYTB and ND1 as reference genes. Graphs depict
results obtained in 9205TA fibroblasts expressed as a percentage of the mean +− S.D. for three
controls.
cells, and no significant difference could be seen between the
9205TA and control cells. Three independent experiments gave
essentially the same result, and clearly showed, in accordance
with all WB data, that mutation of the ATP6 STOP codon greatly
decreases the synthesis of ATPase subunit a (to 12.7 +− 0.73% of
the control). In turn, up-regulation of ATP8 synthesis is apparent.
DISCUSSION
We present a detailed analysis of the impact of a maternally in-
herited 2 bp microdeletion TA at position 9205 and 9206 in the
mtDNA (9205TA) on the respiratory chain complexes, with
the aim of disclosing the pathogenic mechanism in a patient
with severe encephalomyopathy, spastic quadruparesis, micro-
cephalia and hyperlactacidaemia.
Biochemically, the patient presented with a pronounced select-
ive decrease in COX activity in his fibroblasts (15% of control),
while a lowered COX/CS ratio and a mild decrease in com-
Figure 8 Incorporation of [35S]methionine into proteins encoded by mtDNA
mtDNA-specific translation was performed in control and 9205TA fibroblasts in the presence
of emetine. Radioactive proteins were separated by SDS/PAGE on a 15–20 % (w/v) gradient
polyacrylamide gel and detected by phosphorimaging. On the left side, the WB from the same
SDS/PAGE run using an antibody against subunit Foa is shown. The migration of mtDNA-encoded
polypeptides and of molecular mass standards is indicated.
plex III activity were found in muscle. Sequencing of mtDNA
revealed a 2 bp microdeletion, which disrupts the STOP codon
of the ATP6 gene. This mutation has been described only once
previously, in a patient with seizures and repetitive bouts of
lactic acidaemia [13]. It was reported as being homoplasmic
(lymphocytes and fibroblasts), but was not detected in that
patient’s mother or grandmother. In our patient, the mutation was
also found to be homoplasmic (>98%) in all tissues tested. In
addition, the heteroplasmic mutation 9205TA was present in the
asymptomatic mother (82%) and grandmother (16%). Im-
portantly, a high mutation load in the mother’s fibroblasts was
also associated with a decrease in COX activity.
The mtDNA mutation 9205TA lies on the boundary of two
genes, ATP6 and COX3, and it is highly probable that it influences
the transcription and post-transcriptional modification of these
genes. Assuming that this is the main cause of the patient’s pheno-
type, insufficient energy provision is to be expected in the tissues,
particularly in brain (explaining the dominating encephalopathy).
Our measurements in the patient’s fibroblasts showed a 3-fold de-
crease in mitochondrial ATP production. In fact, the observed
decrease was even higher than that observed in cases of missense
mutations in the ATP6 gene (T9176G, T8993G and T8993C),
where higher values of residual mitochondrial ATP production
have been reported [10–12,38]. By analogy with these mutations,
we found completely normal ATPase hydrolytic activity. Thus it
appears that only a fraction of ATPase complexes can utilize m
to drive ATP synthesis in 9205TA cells. This view is further
supported by the normal m observed at state 4 and its decrease
by FCCP, while ADP (state 3-ADP) caused a much smaller
decrease in m in the patient. These data indicate that mitochon-
dria in 9205TA cells can be fully energized and that the mutation
does not enhance the passive H+ transport at state 4 via the Fo
proton channel of the ATPase complexes, which are known to
contribute to the proton conductivity of the mitochondrial inner
c© 2004 Biochemical Society
Functional consequences of mtDNA 9205TA microdeletion in the ATP6 gene 569
membrane [39]. When, however, ADP becomes available, the
discharge by ATP synthesis of m in 9205TA cells is signi-
ficantly decreased.
Our functional data support the view that the Fo part has an
altered function in the majority of ATPase complexes of the pa-
tient’s fibroblasts, due to the absence of subunit a (an essential
component of the ATPase proton channel) or an alteration of
its structure (for review, see [40]). The absence of the ATP6
STOP codon could interfere with synthesis of the subunit by
decreasing the translational efficacy of the ATP6 mRNA, resulting
in a low amount of subunit a being produced and in the form-
ation of ATPase complexes lacking subunit a and incapable of
synthesizing ATP. Another possibility might be production of sub-
unit a modified in the C-terminal part, as a poly(A) tail in the
absence of a regular STOP codon could cause extension of several
lysine residues at the C-terminus. Indeed, several amino acid
residues involved in H+ translocation are located in this part of
the protein [8].
To delineate the subunit composition and native structure of
ATPase, we employed electrophoretic/WB analysis using subunit-
specific antibodies, including a polyclonal antibody against sub-
unit a [23]. We have found that the content of subunit a is greatly
decreased (to 11% of control) in the patient’s fibroblasts, whereas
other ATPase subunits are unchanged. The antibody was raised
against 10 amino acids at the N-terminal part of human subunit
a, and most probably would react with a putative form of sub-
unit a elongated at the C-terminus. However, no larger forms of
subunit a could be detected by WB. A low content of subunit
a was confirmed by 9-fold decreased labelling of this subunit by
[35S]methionine, and the labelling pattern also did not indicate the
accumulation of a larger form of this subunit in 9205TA cells.
Under native electrophoretic conditions, we found in the
9205TA cells a decreased content of DDM-solubilized, normal-
sized F1Fo-ATPase, together with an increased content of an F1
subcomplex of 390 kDa. There was no apparent difference
between the mobility of the 620 kDa ATPase complex in the
9205TA and control samples; however, subunit a, present in
the ATPase in one copy, represents only 4% of the total ATPase
mass, and the expected difference in mobility of the whole, subunit
a-lacking complex is below the resolution of BN-PAGE.
Furthermore, we found yet another larger, F1-containing subcom-
plex of 460 kDa that consists of F1-ATPase and some Fo subunits,
including subunit c. This pattern closely resembles that in cells
with a T8993G mutation in the ATP6 gene [10,12], or in
cells with doxycycline-inhibited mitochondrial protein synthesis
[3]. Interestingly, these three different mechanisms that affect the
biosynthesis of subunit a gave a very similar picture at the level
of ATPase structure. In the case of the 9205TA mutation, the
ATPase complexes exert lability upon DDM extraction that is not
observed in those from control cells; however, even the subunit
a-lacking ATPase complexes maintain structural interactions
between the F1 and Fo parts of the enzyme, although these are
weaker. It appears that incomplete Fo is also able to ‘gate’ the F1 in
these complexes, as no H+ leak has been detected by measurement
of membrane potential.
In addition to changes in ATPase, we also found changes in the
structure and function of COX. The pronounced decrease in COX
activity observed in spectrophotometric assays was confirmed
by the oxidation of TMPD + ascorbate in 9205TA cells. The
remaining COX activity, however, did not limit the generation
of m, and it was also sufficient for substrate oxidation in the
uncoupled state. The functional consequences at the level of COX
resembled to some extent COX assembly defects due to SURF1
mutations [41]. The total amount of COX subunits detected by
WB was also decreased, indicating a 30–50% decrease in enzyme
content. Some of the COX complexes showed a normal size, but
some COX subunits detected by 2D/WB analysis were found to
be present in COX subcomplexes or as free subunits. The 2D pat-
tern resembled the pattern observed in cells with a 15 bp deletion
(948015) in COX3 [37] that show a failure to assemble the
holoenzyme complex and instability of the COX1–COX2 inter-
action [42].
When comparing the changes in ATPase and COX, it appears
that 9205TA cells contain approx. 10% of the control content
of normal ATPase complexes and 30–50% of that of normal
COX complexes. Both enzymes are present in mitochondria at
normal, physiological conditions in excess in most tissues, and
their threshold values are known to vary in individual cell types
[43]. With regard to the dominating encephalopathy in our patient,
it is interesting that the reserve capacity of COX appears to be
rather high in brain, while the reserve capacity of ATPase appears
to be much lower.
All of the data presented herein are in accordance with the
hypothesis that the mechanism by which the 9205TA mutation
affects mitochondrial function is associated with changes in the
transcription of the ATP6 and COX3 genes and their translational
competence and efficacy. Using two independent approaches, i.e.
Northern blot and quantitative real-time PCR analysis of cDNA,
we found that processing of the primary ATP8–ATP6–COX3
transcript is impaired in our patient. Both methods revealed a
2–3-fold decrease in the content of mature ATP6 and COX3 trans-
cripts, while the content of ND1 and COX1 transcripts was un-
affected. The same picture emerged when analysing polyadenyl-
ated forms of ATP6 and COX3 RNAs. These differences found in
the patient’s cells were also confirmed when relating the steady-
state levels of ATP6 and COX3 RNAs and mRNAs to the levels
of CYTB or ND1 transcripts.
The decrease in the amount of the mature ATP6 transcript
agreed well with the decreased synthesis and content of subunit a.
Interestingly, the labelling of subunit 8 was increased, indicating
up-regulated translation of the ATP8 gene, which precedes and
partially overlaps the ATP6 gene. The translation of the ATP8
and ATP6 mRNAs is well described in yeast, but the structure
of these genes and its regulation differs completely from that in
mammalian mitochondria, where the mechanism of ATP8 and
ATP6 biosynthesis is largely unknown. The question arises
whether increased labelling of subunit 8 could be caused by trans-
lation of ATP8 from an unspliced form of the ATP8–ATP6–
COX3 transcript, part of which is, according to our results, poly-
adenylated [cDNA synthesis with random primers and oligo(dT)
primer] and could be therefore subjected to translation.
Recently, Seneca and co-workers continued an analysis of the
fibroblasts from the first patient identified with the 9205TA
deletion [18,44]. They investigated the levels and fate of ATP6
and COX3 mRNAs and did not find any difference in primary
transcript processing in their patient, but some differences in the
deadenylation of mRNAs were present. In the second paper they
investigated the biochemical consequences of the mutation, and
the only difference they found was an accumulation of the F1-
ATPase intermediate and increased ATP8 labelling. Therefore
two patients with the same 9205TA homoplasmic mutation
differ dramatically, and this difference is difficult to understand.
There appears to be a good correlation between changes in mature
transcripts, pronounced biochemical consequences and severe
encephalopathy in our patient, compared with unchanged RNA
processing, insignificant biochemical changes and much weaker
clinical presentation in the Seneca study. On the other hand, both
patients harbour the same homoplasmic 9205TA mutation. Thus
in one case the mutation is pathogenic, and in the other it has
little effect. We have no explanation for this difference at the
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moment, but several aspects might be important. In both cases
numerous other changes in mtDNA sequence were found. In our
case all were identified as more or less frequent polymorphisms,
one of which was present in the ATP6 gene (A8860G) and one
in the COX3 gene (G9477A). In the Seneca case mtDNA
sequencing revealed 42 changes from the revised Cambridge Ref-
erence Sequence, including three rare polymorphisms (C9335T,
A11362G and A12822G) and two novel transitions (T15287C
and T15705C) in the CYTB gene. The two types of mtDNA also
belong to different haplogroups.
The question arises as to whether in the Seneca case the absence
of pathogenicity might be due to some compensatory mechanism
affecting the post-transcriptional processing and translation of the
ATP6 and COX3 mRNAs. Two revertants have been described in
human mtDNA, in cells carrying tRNA mutations. A suppressor
mutation at position 12300 was found, generating tRNALeu
(CUN), which compensated for the 3243 (MELAS; mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episodes) mu-
tation of tRNALeu (UUR) [45]. In the second case, a G5703A
mutation in tRNAAsn was functionally rescued without changes in
mtDNA upon cultivation in a galactose medium [46]. A com-
pensatory import of surrogate tRNA due to nuclear mutation
was proposed, but not shown. Moreover, a similar compensatory
import of RNAs or proteins is highly unlikely in 9205TA cells.
A possible compensatory mechanism could be connected with
factors that affect (and/or correct) the processing of mitochondrial
transcripts and their translation in 9205TA cells. Interestingly,
several nuclear-encoded factors have been described in yeast
(NCA2, NCA3, NAM1/MTF2, Aep3p) that are essential for
proper processing of mitochondrial RNAs, namely the ATP8–
ATP6 co-transcript (for references see [47]), but their mammalian
orthologues have not been found, possibly reflecting differences in
the structure of mitochondrial RNAs between yeast and mammals.
Another group of factors is represented by proteins mediat-
ing the mRNA–ribosome interaction. The search for mammalian
orthologues in this group was more successful. A LRPPRC
(leucine-rich pentatricopeptide repeat cassette) protein was identi-
fied using a functional genomics approach [48], and it was
shown that mutation in the LRPPRC gene causes the Leigh syn-
drome of French–Canadian type, which is a human mitochondrial
COX deficiency [49]. However, the divergence of the LRPPRC
protein sequence from that of the analogous yeast protein is very
large and, therefore, it has not yet been possible to identify other
mammalian proteins by a sequence similarity approach.
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Studies of fibroblasts with primary defects in mitochondrial
ATP synthase (ATPase) due to heteroplasmic mtDNA mutations
in the ATP6 gene, affecting protonophoric function or synthesis of
subunit a, show that at high mutation loads, mitochondrial mem-
brane potential m at state 4 is normal, but ADP-induced dis-
charge of m is impaired and ATP synthesis at state 3-ADP is
decreased. Increased m and low ATP synthesis is also found
when the ATPase content is diminished by altered biogenesis of the
enzyme complex. Irrespective of the different pathogenic mecha-
nisms, elevated m in primary ATPase disorders could increase
mitochondrial production of reactive oxygen species and decrease
energy provision.
Keywords ATP Synthase, ATP6, Flow Cytometry, Membrane
Potential, Mitochondrial diseases, mtDNA
Mitochondrial encephalomyopathies due to defects in mi-
tochondrial F0F1-adenosine 5′-triphosphate (ATP) synthase
(ATPase) are less common than disorders of the respiratory-
chain complexes, but they are usually very severe and can be
caused by mitochondrial DNA (mtDNA) mutations or by mu-
tations in nuclear genes. Mitochondrial ATPase is the key en-
zyme of cellular energy conversion. By means of a fascinat-
ing rotary motor mechanism (Kinosita et al. 1998; Stock et al.
2000), it couples the H+ gradient generated by the respiratory
Received 1 July 2003; accepted 10 July 2003.
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chain to the synthesis of ATP from adenosine 5′-diphosphate
(ADP) and phosphate. The ATPase complex comprises 16 dif-
ferent subunits (Walker and Collinson 1994). It is composed
of the globular F1 catalytic part, which is connected by two
stalks to the membrane-embedded F0 moiety; the latter translo-
cates protons across the inner mitochondrial membrane. Two
F0 subunits, subunit a (ATP6) and subunit A6L, are coded by
mtDNA (Anderson et al. 1981); all other subunits are nuclearly
encoded.
The most common cause of ATPase defects are missense het-
eroplasmic mtDNA mutations in the ATP6 gene, which affect
the protonophoric function of subunit a, an essential component,
together with multiple copies of subunit c of the ATPase pro-
ton channel (Hutcheon et al. 2001; Stock et al. 1999). Higher
prevalence show T8993G(C) mutations (Ciafaloni et al. 1993;
Holt et al. 1990; Puddu et al. 1993; Shoffner et al. 1992; Tatuch
et al. 1994) which change Leu156 to Arg or Pro. At a lower
mutation load, they manifest as neurogenic muscle weakness,
ataxia, and retinitis pigmentosa (NARP syndrome); at hetero-
plasmy exceeding 90% they present as maternally inherited
Leigh syndrome (severe and fatal encephalopathy). Less com-
mon are T9176G(C) mutations, which change Leu217 (Carrozzo
et al. 2001; Dionisi-Vici et al. 1998; Thyagarajan et al. 1995), or
a T8851G mutation (De Meirleir et al. 1995) that changes Trp109,
all manifesting also as striatal necrosis syndromes (Schon et al.
2001). Impairment of the ATPase H+ channel results often, but
not always, in decreased ATP production, whereas the ATPase
hydrolytic activity remains largely unchanged (Houstek et al.
1995; Tatuch and Robinson 1993). A different type of pathogenic
mechanism represents mtDNA 2bp microdeletion 9205delTA,
which was found in a newborn with transient lactic acidosis
(Seneca et al. 1996) and also in a child with encephalopathy
and severe psychomotor retardation (Fornuskova et al. 2003).
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A 9205delTA mutation removes the stop codon of the ATP6
gene and affects the cleavage site between the ATP6 and COXIII
transcripts. Most recently, a new mutation, in which A8527G
changes the ATPase 6 initiation codon AUG into GUG (Met >
Val), has been found in an adult patient with neuropathy, mental
retardation, myopathy, suprarenal peripheral insufficiency, and
retinopathy (Dubot et al. 2003).
ATPase defects due to nuclear genome mutations are very
rare and appear to be caused by diminished biosynthesis of the
ATPase complex. ATPase deficiency of possible nonmitochon-
drial origin was first described in a child with 3-methylglutaconic
aciduria and severe lactic acidosis (Holme et al. 1992). Ex-
tremely low ATPase activity and low, tightly coupled respiration
rates were observed in muscle mitochondria, but no mutation
was found in mtDNA genes encoding ATPase subunits. A nu-
clear origin of ATP synthase deficiency was demonstrated for
the first time in 1999 (Houstek et al. 1999) in a new type of
fatal mitochondrial disorder: a child with severe lactic acidosis,
cardiomegaly, and hepatomegaly died 2 days after birth. 70 to
80% decrease in ATPase activity and ATP production was as-
sociated with a corresponding selective decrease in the ATPase
complex, which had normal size and subunit composition. In-
creased biosynthesis of the β subunit with a very short half-life
contrasted with decreased biosynthesis of the assembled AT-
Pase and indicated assembly defect at the level of F1-ATPase.
Cybrid cells made of patient fibroblasts fully complemented the
ATPase defect and confirmed the nuclear origin of impaired
biogenesis of the enzyme complex (Houstek et al. 1999). Later
on several other selective ATPase defects of varying severity
have been found, including a fatal ATPase defect described in
Belgium (Van Coster et al. 2001); a milder case of ATPase defi-
ciency found in an Austrian patient (Mayr et al. 2002); and two
new families with ATPase deficiency of nuclear origin found
in the Czech Republic. In this article, we summarize our stud-
ies of the functional consequences of various types of primary
ATPase defects at the level of mitochondrial ATP synthesis
and maintenance and discharge of the mitochondrial membrane
potential.
MATERIALS AND METHODS
Cell Cultures
Human skin fibroblasts were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) medium with 10% fetal calf serum
at 37◦C in 5% carbondioxide in air to approximately 90% con-
fluence. Cells were harvested using 0.05% trypsin and 0.02%
ethylenediaminetetraacetic acid (EDTA). Previously established
fibroblast cultures with different heteroplasmic mtDNA muta-
tions in the ATP6 gene (Table 1), and fibroblast cultures with
selective ATPase deficiency of nuclear origin from three unre-
lated Czech families (Table 2) were used for the experiments.
Derived transmitochondrial cybrids were prepared as before by
the method of Tiranti and colleagues (1995).
TABLE 1
ATP production in fibroblasts with different mtDNA mutations
in the ATP6 gene
ATP
Mutation Mutation type Heteroplasmy productiona
T8993G Missense Leu → Arg 97% 35–54%
9205delTA Stop codon → Lys 86% 20–40%
A8527G Met → Val, change 97% 90–100%
of initiation codon
AUG → GUG
aAntimycin A–sensitive production using succinate or pyruvate +
malate as a substrate.
Cytofluorometric Analysis
Freshly harvested fibroblasts were resuspended in 80 mM
KCl; 10 mM Tris Cl pH 7.4; 3 mM MgCl4; 1 mM EDTA; 5 mM
KH2PO4; and 10 mM succinate at a protein concentration of
1 mg/mL. Cells were permeabilized by 0.1 mg digitonin per
mg protein (Sigma Chemical, St. Louis, MO) and stained with
20 nM tetramethylrhodamine methyl ester (TMRM; Molecular
Probes, Eugene, OR) for 15 min at room temperature. ADP, in-
hibitors, or both were added at indicated concentrations 1 min
before cytofluorometric measurements, which were performed
as described elsewhere (Floryk and Houstek 1999) on a FACSort
flow cytometer (Becton Dickinson, San Jose, CA) equipped with
an argon laser, 488 nm. The TMRM signal was analyzed in the
FL2 channel, equipped with a band pass filter 585 ± 21 nm; the
photomultiplier value of the detector was at 631 V in FL2. Data
were acquired in log scale using CellQuest (Becton Dickinson,
San Jose, CA) and analyzed with WinMDI 2.8 software (TSRI,
La Jolla, CA). Arithmetic mean values of the fluorescence sig-
nal in arbitrary units were determined for each sample for the
purpose of subsequent graphic representation.
ATP Production Measurements
The rate of ATP synthesis (Wanders et al. 1993) was mea-
sured in 150 mM KCl; 25 mM Tris/HCl; 10 mM KPi; 2 mM
EDTA; 1% BSA, pH 7.2; using 0.5 mM ADP and succinate,
ketglutarate + malate, or pyruvate + malate as a substrate, all
in 10 mM concentration. For permeabilization of fibroblasts and
cybrids, 0.1 and 0.03 mg digitonin per mg protein, respectively,
was used. ATP was determined in DMSO-quenched aliquots
according to Ouhabi and colleagues (1998) by a luciferase
assay.
Ethics
The described studies were carried out in accordance with
the Declaration of Helsinki of the World Medical Association
and were approved by the Committees of Medical Ethics at all
collaborating institutions. Informed consent was obtained from
investigated individuals or their parents.
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TABLE 2
ATP production in fibroblasts from three patients with selective deficiency of ATP synthase
Case I II III
Phenotype LA, CM, H LA, CM LA, CM, EM, dev. delay
Onset/survival Newborn/2 days Newborn/32 days Neonate/7 years
ATPase activity in fibroblasts 30% 20% 30%
(% of control)a
ATP production in fibroblasts 28–32% 32–47% 18–23%
(% of control)b
ATP production in cybrids 102–116% 220–380% 230%
(% of control)b
aOligomycin-sensitive ATPase activity.
bAntimycin A–sensitive production using succinate, ketoglutarate + malate, or glutamate + malate as a substrate.
CM, cardiomyopathy; EM, encephalomyopathy; H, hepatomegaly; LA, lactic acidosis.
Note: The data for Case I are from the work of Houstek and colleagues (1999); the data for Cases II and III are
from two new patients from unrelated families.
RESULTS AND DISCUSSION
The pathogenic mechanisms underlying different types of
ATPase defects and disorders seem to range from a dysfunction
of mutated subunit a, through insufficient or altered biosynthe-
sis of subunit a, to a diminished production of otherwise normal
ATPase complex. With the aim of assessing how these differ-
ent ATPase defects influence the mitochondrial energy provi-
sion, mitochondrial membrane potential m and ATP pro-
duction were studied. As summarized in Table 1, three types
of heteroplasmic mutations in the ATP6 gene, all present in
high mutation loads (86 to 97%), affected substrate-supported
ATP production to different extents. The most pronounced de-
crease in ATP synthesis was in 9205delTA cells; higher rates
were found in T8993G fibroblasts; the A8527G mutation was
without any effect. Flow cytometry using TMRM as a fluores-
cent probe further showed that these mutations have varying
influences on the m. Steady-state levels of m were de-
termined under state 4 conditions, when no ADP is available
and µH+ cannot be utilized for ATP synthesis. In all types
of fibroblasts, the state 4 m values were within the control
range, and the addition of an uncoupler, FCCP, similarly de-
creased the TMRM signal, indicating that none of the ATP6
mutations studied increases the passive H+ flow at state 4. The
addition of ADP (state 3-ADP) caused a significant decrease
of m in both the control and the A8527G cells, and this
ADP-dependent decrease was fully prevented by the ATPase
inhibitor oligomycin (Fig. 1). A much smaller, although fully
reversible, effect of ADP was seen in 9205delTA cells, and only
a minute effect was found in T8993G fibroblasts. Both types
of studies, thus, convincingly showed that near-homoplasmic
T8993G mutation largely, but not completely, prevented the
discharge of m and the synthesis of ATP by mitochondrial
ATPase.
It is interesting to note that the behavior of cells with
9205delTA is very similar, and alteration of the ATP6 stop codon
probably interferes with the synthesis of subunit a; or an elon-
gated form of subunit a could be produced, resulting in nonfunc-
tional ATP synthase. In the first case, some incomplete, subunit
a–lacking ATPase complexes would be formed. In the second
case, the subunit a would be modified in the C-terminal part,
where several AA residues that are involved in H+-translocation
are located (Schon et al. 2001). Both types of measurements also
clearly showed that A8527G mutation is without detectable ef-
fect on mitochondrial ATP synthesis and, very likely, the GUG
initiation codon, replacing the canonical AUG, is somehow op-
erative in human mitochondrial ATP6 mRNA translation, as is
the case of COXI and COXII in some vertebrates (Johansen et al.
1990; Pan et al. 1993).
A completely different pathogenic mechanism is associated
with primary ATPase defects of nuclear origin (Houstek et al.
1999), where the mitochondrial content of ATPase complex is
selectively reduced relative to the content of respiratory-chain
enzymes, while the subunit composition and the hydrolytic as
well as the synthetic function of the remaining ATPase com-
plexes are normal. This relative lack of ATPase was found to
cause an increase in membrane potential at state 4 (Houstek
et al. 1999), which is indicative of decreased passive H+ leak
and which resulted in a pronounced decrease in ATP production
(see Table 2 and Houstek et al. 1999). As is shown in Table 2,
a similarly pronounced decrease of ATP production was found
in two new patients from different families, in whom a 70–80%
decrease of mitochondrial ATPase was found. Their clinical pre-
sentations also included lactic acidosis and cardiomyopathy. In
one case the patient survived for several weeks; the other case
was milder and presented with lactic acidosis, cardiomyoptahy,
encephalopathy, and developmental delay. In order to find out the
genetic origin of these new ATPase defects, transmitochondrial
cybrids were prepared by fusing enucleated patient fibroblasts
with mtDNA-less (ρ0) 143B. TK− osteosarcoma cells. As shown
in Table 2, the ATP synthesis was fully restored in both types
of cybrids, indicating again that the underlying genetic defect is
not a mtDNA mutation.
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FIG. 1. Changes in the mitochondrial membrane potential m in fibroblasts with different ATP6 mutations. Cytofluorometric analysis of the mitochondrial
membrane potential by TMRM fluorescence was performed in a digitonin-permeabilized fibroblast supplied with 10 mM succinate. (A) The effect of 1 µM FCCP,
0.1 mM ADP, and ADP followed by 1 µM oligomycin (oligo) in control cells. (B) The ADP-induced decrease of TMRM fluorescence relative to the FCCP-induced
decrease was analyzed in cells with indicated mtDNA mutations.
All the known primary deficiencies of mitochondrial ATPase
can significantly affect the mitochondrial ATP production, irre-
spective of whether the cause is an insufficient amount of normal
enzyme or altered properties of ATPase complex that is present in
normal quantities. It is also quite clear that in all types of ATPase
defects, the production of ATP is only partly inhibited, even in
very severe cases. It is difficult to understand how only a partial
decline of energy provision (sometimes only 50% or less) can
have such serious and often fatal effects. All ATP synthesis data
are based on cell cultures, and the situations in the most com-
monly affected tissues, which have high energy demands, such
as brain, heart, and skeletal muscle, can be completely different.
On the other hand, inhibitor titration studies in muscle tissue
(Rossignol et al. 1999, 2003) show an especially high threshold
for ATPase, indicating that some 10% of the normal activity of
the enzyme is sufficient for more than 50% functionality of the
whole respiratory chain.
It is well established that along with energy shortage, other
metabolic consequences, in particular the production of reac-
tive oxygen species (ROS) and the induction of apoptosis and
tissue necrosis, are major components of the pathogenic mech-
anism in mitochondrial OXPHOS diseases (Lenaz et al. 2002;
Wallace 1999). An exponential increase in mitochondrial ROS
production has been demonstrated at levels of m above 140
mV (Korshunov et al. 1997; Liu 1999), whereas a decrease in
m via stimulation of ATP synthase activity, a low ATP/ADP
ratio, substrate limitation, or increased proton permeability due
to external or internal uncoupling lower the amount of ROS pro-
duced (Kadenbach 2003). The main conclusion we draw from
our cytofluorometric studies is that in ATPase disorders, higher
levels of m can be expected because a low amount of enzyme
or altered function of the F0 proton channel apparently limit the
physiological discharge of respiration-generated µH+. If this
is the case, increased and unbalanced ROS production, rather
than diminished energy provision, would be the key pathogenic
process in primary ATPase diseases.
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6     CONCLUSIONS 
 
• Whereas nDNA-encoded CcO subunits Cox4 and Cox5a are required for the 
assembly of the functional CcO complex, the Cox6a subunit is required for the 
overall stability of the holoenzyme. Consequently, the heterogeneous CcO 
population of Cox6a-deficient cells exhibits higher residual respiration at low 
oxygen levels than the various CcO forms found in COX5A-KD cells. The 
description of a novel assembly intermediate at the very last step of CcO 
assembly suggests additional regulatory level of the process. 
 
• The fact that the ectopic expression of heart/muscle-specific isoform of Cox6a 
can complement the CcO defect in COX6A1-KD cells is in sharp contrast with 
unaltered levels of this isoform in our CcO-deficient model, and suggests the 
existence of a fixed differentiation programme regarding human Cox6a 
isoforms. The normal amount and function of complex I in all of our CcO-
deficient cell lines suggest that even relatively small residual amounts of CcO 
can maintain normal biogenesis of this respiratory complex in human cells. 
 
• The RNAi knockdown of OXA1L in HEK-293 cells showed that the protein 
plays an important role in the biogenesis of ATP synthase and respiratory 
complex I. In sharp contrast to the yeast orthologue, the loss of human Oxa1l 
does not lead to any impairments of assembly of CcO or the complex III, 
suggesting functional divergence during evolution.  
 
• In skeletal muscle tissue, comparably high mutant loads (∼ 90%) of 3243A>G 
affecting mt-tRNALeu(UUR) and 8344A>G affecting mt-tRNALys  have been 
associated with severe defect of complex I, but only 8344A>G mutation also 
resulted in severe deficiency of complex IV. Similarly, 80% heteroplasmy of 
8363G>A mutation affecting mt-tRNALys resulted in combined severe 
deficiency of complexes I and IV. Virtually the same patterns of OXPHOS 
holoenzyme deficiencies were observed in heart mitochondrial samples. 
However, the patterns of OXPHOS deficiencies in frontal cortex mitochondria 
of 8363G>A and 3243A>G patients differed substantially from those of other 
tissues. This difference was particularly striking for ATP synthase. Although it 
is necessary to analyze considerably more samples with high levels of 
heteroplasmy (such samples are difficult to obtain), effects of mt-tRNA 
mutations on the brain OXPHOS are likely to be particularly different from 
those described for skeletal muscle, heart, and liver tissues. 
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• The mechanism by which the 9205ΔTA mutation affects mitochondrial function 
is associated with changes in the transcription of the ATP6 and COX3 genes and 
their translational competence and efficacy. The decrease in the amount of the 
mature ATP6 transcript agreed well with the decreased synthesis and content of 
subunit a. Interestingly, the labelling of subunit 8 was increased, indicating up-
regulated translation of the ATP8 gene, which precedes and partially overlaps 
the ATP6 gene. The translation of the ATP8 and ATP6 mRNAs is well described 
in yeast, but the structure of these genes and its regulation differs completely 
from that in mammalian mitochondria, where the mechanism of ATP8 and 
ATP6 biosynthesis is largely unknown. The question arises whether increased 
labelling of subunit 8 could be caused by translation of ATP8 from an unspliced 
form of the ATP8-ATP6-COX3 transcript, part of which is, according to our 
results, polyadenylated [cDNA synthesis with random primers and oligo(dT) 
primer] and could be therefore subjected to translation. 
 
• Based on the cytofluorometric studies in cultured skin fibroblasts from patients 
with complex V defects, higher physiological levels of ΔΨm can be expected 
because of low amount of enzyme or altered function of the Fo proton channel. 
Consequently, increased and unbalanced ROS production, rather than 
diminished energy provision, would be the key pathogenic process in primary 
ATP synthase diseases. 
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7     SUMMARY 
 
In this PhD thesis, we utilized molecular approaches to manipulating the gene 
expression in human HEK-293 cell line and rare autoptic/bioptic tissue materials or 
cultured skin fibroblasts from patients with mitochondrial disorders to deal with 
molecular, biochemical and functional aspects of OXPHOS deficiencies.  
We prepared stable HEK-293 cell lines with downregulated expression of selected 
structural CcO subunits (Cox4i1, Cox5a and Cox6a1) and OXA1L gene to study new 
aspects of the CcO assembly pathway. The obtained knockdown samples in 
combination with ectopic expression of C-end epitope-tagged Cox6a, Cox7a and Cox7b 
in wild-type HEK-293 cells and knockdown cell lines allowed us to elucidate early and 
very late events of CcO assembly and let us to propose new scheme of human CcO 
holoenzyme assembly pathway. Based on the study of OXA1L knockdown material, we 
showed that OXA1L is to a great extent expendable, unlike the loss of OXA1 in yeast, 
for CcO biogenesis. 
Due to unique collection of tissues from patients with comparably high 
heteroplasmy of mt-tRNA mutations resulting in MELAS, MERRF and Leigh 
syndromes, we found that in skeletal muscle of the patients, the impact of mt-tRNA 
mutations seems to be gene-specific, whereas tissue-specificity of OXPHOS deficiency 
patterns was found among different tissues of the patients. Furthermore, we clarified at 
molecular and biochemical level a mechanism by which very rare mutation 9205ΔTA 
affects mitochondrial function. The data on complex V deficient cultured skin 
fibroblasts contributes to the growing idea that insufficient supply of ATP to meet 
cellular needs is not necessarily the only factor decisive for pathogenic processes in 
primary ATPase diseases but also increased and/or unbalanced ROS production might 
be underlying.  
The data presented in this PhD thesis were published in 5 scientific journals and 
were reported at specialized national or international meetings. 
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